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Russell J. Cox. Thesis submitted for the degree of Ph.D. 1992. 
Biosynthetic Studies on the Fungal Metabolite Tenellin. 
Abstract. 
This thesis is divided into seven chapters plus appendices. The first chapter 
introduces tenellin (1), its origins, structure and biogenetic relationships to 
other metabolites. The second chapter concentrates on polyketides and through 
three representative examples explains their relationship to the fatty acids and 
current theories and evidence for a processive mechanism during their 
biosynthesis. An investigation carried out into the biosynthesis of the 
polyketide sidechain of tenellin (1) from sodium [1-13c, 2-2H3] and [2-13C, 2-
2H3] acetates and L-[S-methyl-13c2H3]-methionine is described. The possible 
intermediacy of singly methylated diketides and doubly methylated triketides 
carrying stable isotopic labels during the biosynthesis of tenellin (1) is also 
tested experimentally and discussed. 
In the third chapter possible intermediates to both the 2-pyridone moiety 
of tenellin (1) and the tropic acid (42) moiety of the tropane alkaloids are 
discussed and tested experimentally. 3-Amino-2-phenylpropionic acid (104) 
was synthesised and rejected as an intermediate to tenellin (1) and tropic acid 
(42). In the case of tenellin (1) a tetramic acid (139) was implicated as a possible 
intermediate by a biosynthetic feeding experiment. An alternative mechanism 
to account for 2-pyridone formation from a tetramic acid is put forward. 
In the fourth chapter the determination of the absolute configuration of 
tenellin (1) is described. The configuration of the chiral methyl bearing centre of 
tenellin (1) is compared to that of similar fungal polyketide derived molecules 
and the mode of reduction by various fungal PKS enoyl reductase systems is 
assessed. 
In the fifth chapter the syntheses and characterisations of the compounds 
labelled with 14c, 13c and 2H that were used in the biosynthetic studies on 
tenellin (1) and tropic acid (42) are described. Chapter six describes in detail the 
experimental procedures used in the syntheses of these compounds. Chapter 
seven consists of a description of the biological materials and methods used 
during this study. 
The appendices consist of abbreviations used in the text, and a list of 
lectures, seminars and colloquia arranged within the Department of Chemistry 
and attended by the author. 
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1.1 Pi&ments of the genus Beauveria and related compounds. 
The genus Beauveria is a group of entomogenous fungi first described by 
Vuillemin in 19121. The genus is responsible for red muscardine disease in 
insects. As the name suggests species of this genus are usually coloured, 
colours including reds, yellows and greens, and although colouration has 
been used as a criterion for distinguishing species, von Arx has recently 
outlined species classification along morphological lines2. The two most 
common species, B. bassiana (Bals.) Vuill. and B. tenella (Delacroix) Siem., 
have been isolated from diseased insects3 and also as contaminants of 
submerged cultures of Agaricus campestris (field mushroom) and Amanit~ 
muscaria (fly agaric) respectively4. B. bassiana has been shown to be 
virulent towards Melanoplus sanguinipes (migratory grasshopper) by 
virtue of the excretion of an extracellular protease which has been shown to 
hydrolyse insect cuticleS. The excretion of the hexadepsipeptide beauvericin 
(3)6,7,8 has been shown to be responsible for B. bassiana toxicity towards 
Artemia salina (brine shrimp), Calliphora erythrocephala (blowfly) and 
Aedes aegypti (mosquito)9. 
(L) 
0 ~\ 0 
-N 
Beauvericin (3), the toxic principal of B. bassiana. 
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Vining et al. have studied the effect of nutrition upon the production 
of pigments by two species of Beauveria (B. tenella and B. bassiana)3. They 
established that red colouration was due to the diquinonoid metabolite 
oosporein (4)10,11 and that under certain circumstances, namely when the 
culture media contained a high carbon/nitrogen ratio, yellow pigments 
could be produced and isolated12. These compounds were divided into two 
groups, tenellins and bassianins. Tenellin (1) produced mainly by B . 
. bassiana and the closely related bassianin (2) produced by B. tenella were 
purified and their structures elucidated by a combination of physical, 
chemical and biosynthetic experiments13. 
0 
HO 
HO 
HO 
OH 0 
HO 
(4). 
(1). 
(2). 
OH 
0 
The principal pigments of Beauveria bassiana, oosporein (4), tenellin (1) 
and bassianin (2). 
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1.2 The 2aPyridones and related metabolites. 
Tenellin (1) and bassianin (2) differ only by an extra trans ethylene group in 
the side chain of bassianin (2). They are characterised by the presence of a 2-
pyridone moiety substituted at the 3 position by a branched conjugated acyl 
side chain and at the 5 position by a para-hydroxy benzyl group14. 
These two metabolites belong to a small family of 2-pyridone 
containing fungal secondary metabolites which includes funiculosin (5) 
(Penicillium funiculosum)15, ilicicolin-H (6) (Cylindrocladium 
ilicicocola)16, leporin-A (7) (Aspergillus leporis)17, viridicatin (8a)18, 
viridicatol (Sb) (Penicillium viridicatum )19 and harzianopyridone (9) 
(Trichoderma harzianum)20 and the structurally related atpenins (lOa,b,c) 
(Penicillium sp. F0125 )21. 
(5) 
HO ) 
0 
(6) 
The fungal 2-pyridones funiculosin (5) and ilicicolin-H (6). 
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(Sb) R=OH. 
OH 0 OH 0 X 
CH30 
CH30 
(9) X X• 
Cl H atpenin-A4 (lOa) 
a a atpenin-As (lOb) 
H H atpenin-B (lOc) 
The fungal 2-pyridones, leporin-A (7), viridicatin (Sa), viridicatol (Sb), 
harzianopyridone (9) and atpenins A4 (lOa), As (lOb) and B (10c). 
The interesting 2-pyridone unit also occurs in the bacterial 
efrotomycin family of antibiotics22. The parent glycone efrotomycin (11a) 
(Streptomyces sp.) co-occurs with the aglycones aurodox (llb) (also known 
as goldinomycin or antibiotic X5108) (Streptomyces goldinensis), kirromycin 
(11c) (Streptomyces sp.) and heneicomycin (lld) (Streptomyces sp.). 
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R1 
CH3 
CH3 
H 
CH3 
H 
N 
R2 
OH 
OH 
OH 
H 
R3 
Disaccharide efrotomycin (11a) 
H aurodox (11b) 
H kirromycin (11c) 
H heneicomycin (11d) 
The bacterial 2-pyridone efrotomycin family. 
These metabolites belong to a larger family of metabolites elaborated by 
both fungal and bacterial systems which is made up of groups of molecules 
biosynthesised from a combination of amino-acid derived, and polyketide 
derived, moieties. The group also contains, the acyl tetramic acids, 
including erythroskyrine (12) (Penicillium islandicum Sopp.)23,24, 
fuligorubin-A (13) (Fuligo septica (L.) Wiggers)25,26, tenuazonic acid (14) 
(Alternaria tenuis auct.)27, lydicamycin (17) (Streptomyces lydicus)28, 
ikarugamycin (15) (Streptomyces phaeochromogenes var. 
ikaruganensis)29,30,3l and the structurally interesting pseurotin-A (16) 
(Pseudeurotium ovalis Stolk)32 amongst others; the cytochalasins (18)33 
synthesised by the imperfect fungus Zygosporium masonii (Hughes) in 
which phenylalanine and tryptophan provide the amino acid residues; the 
ochratoxins34 (19a,b,c) elaborated by members of the genera Aspergillus and 
Penicillium in which L-phenylalanine forms an amide link to an acetate 
and methionine derived bicyclic residue; and the more distantly related his-
amino acids in which modified amino acids are condensed together to form 
the six membered rings of mycelianamide (20) (Penicillium griseofulvum)35 
and cryptoechinulin-A (22) (Aspergillus spp.)36 and the seven membered 
rings of cyclopenin and cyclopenol (21a,b) (Penicillium cyclopium)37. 
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OH 
0 
H 
H 
(12) 
0 
, , 
HOY'""" 
0 
(13) 
OH 
OH 0 
(15) 
OH 
The acyl tetramic acids erythroskyrine (12), fuligorubin (13), 
tenuazonic acid (14), ikarugamycin (15) and pseurotin-A (16). 
-7-
OH 
The acyl tetramic acid lydicamycin (17). 
cytochalasin D (18a) 
OR 
0 OH 0 
N 
' H .. .. ,,, 
X 
X R 
Cl H ochratoxin-A (19a) 
H H ochratoxin-B (19b) 
Cl Et ochratoxin-c (19c) 
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R 
0 
H 
N 
0 
(20) 
R (22). 
H cyclopenin (21a) 
OH cyclopenol (21b) 
0 
H 
~X: 
,,, 
···' 
Mycelianamide (20), cryptoechinulin (22), cyclopenin (21a) and cyclopenol 
(21b). 
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1.3 The polyketides. 
The polyketides make up a large and diverse group of secondary metabolites 
elaborated across a range of prokaryotic and eukaryotic organisms as varied 
as the bacteria, fungi and slime moulds, algae and marine sponges and 
corals. Examples include leptomycins-A and B (23a,b) (Streptomyces 1287)38 
and cubensic acid (24) (Xylaria cubensis)39,40 the macrolide antibiotic 
erythromycin-A (26a) (Saccharopolyspora erythraea),41 6-methylsalicylic 
acid (25) (Penicillium patulum) an aromatic polyketide42, the phytotoxin (-)-
betaenone-B (27) (Phoma betae Fr.)43,44, the polyether monensin-A (28) 
(Streptomyces cinnamonensis)45 and the marine metabolite tedanolide (29) 
(Tedania ignis)46. Even a cursory glance at these molecules reveals the vast 
diversity of structures grouped under the innocuous title of the polyketides. 
0 
HO 
0 OH 
HO 
R 
OH 0 
R 
CH3 leptomycin-A (23a) 
CH2CHJ leptomycin-B (23b) 
OH OH OH 
(24) 
(25) 
Leptomycin-A and B (23a,b), cubensic acid (24) 
and 6-methylsalicylic acid (25). 
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0 
0 
.•• ,,OSug 
(26a) 
OH 
(29) 
0 
(27) 
Erythromycin-A (26a), (-) betaenone-B (27), monensin-A (28) 
and tedanolide (29). 
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The enormous structural differences displayed by these metabolites, 
however, belies the simplicity of their biogenesis. Feeding experiments with 
labelled carbon units of four or (usually) fewer carbon atoms have 
highlighted the underlying similarities between structures. For example the 
macrolide dehydrocurvularin (30)47 elaborated by the fungal plant pathogen 
Alternaria cinerariae is biosynthesised from eight acetate (77) units, 
condensed head to tail. 
0 
HO~ 
~ HO 
SR 
HO ~ 0 
HO 0 
"'HO 
RS 
0 
Fig 1.31. Dehydrocurvularin (30) is biosynthesised from eight acetate units 
in a stepwise manner via the diketide and tetrakedide shown. 
More sophisticated feeding experiments using doubly labelled di- and 
tetra-ketides (that is, structures corresponding to two and four acetate units 
respectively) activated to N-acetylcysteamine thiolesters have shown that 
dehydrocurvularin (30) is built up in a processive manner using acetate 
units, reminiscent of classical fatty acid biosynthesis (see chapter 2, section 
2.34). 
In fungi chain methylations can occur to increase complexity. For the 
biosynthesis of cubensic acid (24), eight methyl groups are provided by L-
methionine (90)40, in addition to eleven acetates arranged head to tail. 
-U-
0 ~H2 
HOJl.... 
. : 
11 X 8 X ctto,s~oH 
\ I 0 
0 OH OH OH OH 
HO 
Fig. 1.32. The biosynthesis of cubensic acid (24) from eleven units of acetate 
and eight L-methionine (90) donated methyl groups. 
In bacterial systems the incorporation of propionate (78) and butyrate 
(79) units as well as acetate (77) increases complexity. The erythromycin 
aglycone 6-deoxyerythronolide-B (26c)48 produced by a mutant of 
Saccharopolyspora erythraea arises from the condensation of seven 
propionate (78) units, whilst the polyether monensin-A (28), elaborated by 
Streptomyces cinnamonensis, is built of five acetate (77), seven propionate 
(78) and one butyrate (79) units49. 
0 
Fig. 1.33. 6-Deoxyerythronolide-B (6-dEB) (26c) is biosynthesised from 
seven units of propionate (78). 
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OH 
0 
5 X AoH ---... 
0 
7 X (:OH ... 
__..,. 
OH 
Fig. 1.34. Monensin-A (28) is biosynthesised from five units of acetate, seven 
units of propionate and one butyrate unit. 
Post assembly modification of polyketides occurs in a number of ways 
to further increase structural diversity. Double bonds can be epoxidised as in 
the case of verrucosidin (31) (Penicillium verrucosum. var cyclopium),SO a 
fungal octaketide bearing seven methionine donated methyl groups. 
OMe 
verrucosidin (31). 
Epoxidation of polyketide double bonds also introduces scope for 
further elaboration to form tetrahydropyran and tetrahydrofuran rings and 
more complex bicycles. Thus it has been proposed that the hydroxylated 
furan ring occuring in citreoviridin (33)51 (Fig. 1.35), a potent neurotoxin, 
produced by the fungus Penicillium citroviride derives from a di-epoxide of 
an acetate and methionine derived tetra-methylated nonaketide. Such a 
metabolite, citreomontanin (32), is already known as a product of 
Penicillium pedemontanum.S2,53. More complex ring systems can be formed 
- 14-
by increasing the number of epoxidised double bonds, citreoviridinol (34) 
also produced by Penicillium citroviride is envisaged to derive from 
further epoxidation and cyclisation of citreoviridin (33)54. 
0 
)l....SCoA 
acetylCoA 
"" 
0 
NH2 . : 
CH3 .._5~0H 
0 
L-methionine 
/ OMe 
(32) 
! OMe 
J 
OMe 
OMe 
OMe 
Fig. 1.35. Postulated biosynthesis of citreoviridin (33) 
and citreoviridinol (34). 
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0 
0 
Lactonisations between the terminal carboxyl group and a hydroxyl 
functionality further down the polyketide backbone can also occur, to form 
metabolites such as tylactone (37) produced by Streptomyces fradiae55, one of 
the clinically important macrolide family, as well as the pyrone moieties 
typical of the polyene pyrone family (31-36). 
Me 
HO~ 
OMe OMe O 
0 
I ,,, 
..• 
.. , 
110H 1 many steps. 
0 
ro 
.. 
tylactone (37) 
,,,,~NMe2 
HO 0 0 
.. ,,,0 Mek&H 
Me 0 OH Me 
tylosin (38) 
Fig. 1.36. Post assembly modification of the polyketide tylactone (37) leads to 
tylosin (38). 
Oxidations are also a common modification step, for example 
leptomycins-A and B (23a,b) from Streptomyces 1287 are oxidised at the 
terminal carbon of the starter acetate unit whilst the Penicillium spp. 
metabolite radiclonic acid (39)56,57 contains two oxidised methyl groups, one 
partially oxidised to an alcohol and the other fully to a carboxylic acid. 
Derivatisations of alcohol groups also occur, especially with sugars, the acyl 
tetramic acid a-lipomycin (40)58,59 elaborated by Streptomyces aureofaciens 
being a good example bearing a digitoxide residue. The oxidation and 
alcohol derivitisation steps leading from tylactone (37) to tylosin (38) are 
particularly well understood60. 
-16-
OH 
radiclonic acid (39) 
0 
HO 
a-lipomycin (40) 
A further dimension of structural complexity can be introduced by 
carbon skeletal rearrangements and carbon-carbon bond cleavages. These 
changes often split the intact acetate units incorporated during polyketide 
biosynthesis de novo and thus tend to obscure the biogenetic origin of a 
particular metabolite derived by such means. Asteltoxin (35)61 elaborated by 
the fungi Aspergillus stellatus and Emericella variecolor is a case in 
poin t62. The carbon skeleton of asteltoxin (35) is related to that of 
citreomontanin (32)53, being modified only by the unusual incorporation of 
a propionate (78) rather than an acetate (77) starter unit. Feeding 
experiments with 13c labelled acetates revealed the enrichment pattern 
shown in Fig. 1.37 and led to the conclusion that the carbon skeleton of 
asteltoxin (35) is derived from a linear tri-epoxide (Scheme 1.38) which has 
undergone a pinacol63 type rearrangement64. The labelled feeding 
experiments also highlighted dual routes to the starter unit, this unit being 
derived from either intact propionate or from a combination of acetate and 
methionine. Asteltoxin (35) belongs to the aurovertin family of metabolites 
in which dual routes to propionyl starter units are a characteristic feature 
(see chapter 2, section 2.4)65. 
-1'7-
I 
I 
I 
propionate 
OMe 
,/J intact acetate unit. 
[] C-2 of acetate. 
0 C-1 of acetate. 
• meth 1 from L-methionine. 
Fig. 1.37. The distribution of labels from acetate, propionate and 
L-methionine incorporated into asteltoxin (35) during biosynthesis. 
R R 
... 
R 
Scheme 1.38. Postulated mechanism of chain rearrangement in the 
biosynthesis of the bicyclic moiety of asteltoxin (35). 
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1.4 The Biosynthesis of tenellin (1). 
Vining et al. have elucidated the biosynthetic origin of all the skeletal atoms 
of tenellin (1) in a definative series of feeding experiments utilising acetates, 
L-methionine and phenylalanine isotopically enriched with the stable 
isotopes 13c and 15N66. 
HO 
M M 
· tenellin (1) 
ltt B. ~ns. 
0 
+ II + HO~ 
0 
L-phenylalanine (99) 
HO 
acetate (77) 
!l+ Cylindrocladium 
ilicicolin-H (6) 
ilicicola. 
M 
Fig. 1.401. Tenellin (1) and ilicicolin-H (6) are derived from 
L-phenylalanine (99), acetate (77) and L-methionine (90). 
-11.9 ~ 
They demonstrated66 that tenellin (1) arose by the coupling of an 
amino phenylpropanoid moiety derived intact from L-phenylalanine, to the 
terminal acetate residue of a typical polyketide chain made up from five 
intact acetate units coupled in a head-to-tail manner, with two methionine 
derived pendant methyl groups. The biosynthesis of ilicicolin-H (6), a 
structurally related metabolite, has also been investigated and the pyridone 
ring shown to be similarly derived67. 
Vining and his co-workers were unsurprised by the incorporation of 
acetate and methionine derived methyl groups into the sidechain which 
was wholly in accordance with the known course of polyketide biosynthesis 
in fungi. However the observation of the apparant rearrangement of 
phenylalanine during the biosynthesis of .the pyridone ring of tenellin 
spurred their interest in the origin of this novel group. They further 
demonstrated in an elegant doubly labelled feeding experiment that the 
labels of DL-[1,3-13c2]-phenylalanine came together and showed 13c_l3c 
coupling in the 13c nmr spectrum of tenellin (1) obtained from a broth of B. 
bassiana supplemented with this materia168. This experiment conclusively 
demonstrated the intramolecular nature of the rearrangement but left open 
the timing and mechanism of the process. 
Two possibilities (at least) may be entertained (Scheme 1.402) to 
account for these observations concerning the rearrangement of 
phenylalanine during the biosynthesis of tenellin (1). In pathway A it may 
be envisaged that the amino acid is subect to direct rearrangement by a 
mutase enzyme before condensation with the polyketide group, forming the 
six membered pyridone ring directly, with subsequent oxidations furnishing 
tenellin (1). Alternatively, in pathway B, suggested by Vining et al., 
condensation between L-phenylalanine (99) and the terminal residue of the 
polyketide chain leads to the five membered ring of an acyl tetramic acid. 
The six-membered pyridone ring of tenellin (1) could then be formed by a 
ring expansion of the tetramic acid. Both hypotheses are consistent with the 
observations of Vining et al. and both have biogenetic precedence. 
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0 
~ 
RSJ:.O - r I 
PathwayB 
OH 
L-phenylalanine (99) HO 
0 OH~I 
RS 0 
(104) 
(139) 
tenellin (1) 
0 
Scheme 1.402. The biosynthesis of the 2-pyridone moiety of 
tenellin (1) could occur by either of pathways A or B. 
Biosynthetic experiments with numerous members of the family of 
acyl tetramic acids lend significant support to pathway B. Members of the 
group are produced by. both fungi and bacteria. The fungal metabolite 
erythroskyrine24 (12) from Penicillium islandicum has been shown to arise 
from the condensation of L-valine (91) with the terminal residue of a 
decaketide chain69, whilst the bacterial malonomicin (41) produced by 
Streptomyces rimosus var. paramomcyinus arises from the uncommon a-
amino acid 2,3 diaminopropionic acid (DAP) coupled to an acetate derived 
side chain70. In the case of malonomicin (41), the amino acid serine (92) was 
also efficiently incorporated into the five membered ring, suggesting a direct 
pathway between serine and DAP. 
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Fig. 1.403. Biosynthesis of erythroskyrine (12) and malonomicin (41). 
Vining et al. suggested that the ring expansion required to form the 
six-membered pyridone ring of tenellin (1) from the five membered acyl 
tetramic acid analogue could procede via a quinonoid intermediate66, with 
ring expansion promoting re-aromatisation of the pendant phenyl ring (Fig. 
1.404). This mechanism is feasible in the cases of tenellin (1), bassianin (2), 
ilicicolin-H (6) and funiculosin (5) (which may derive ultimately from 
phenylalanine or tyrosine), but cannot be invoked to explain the 
biosynthesis of the structurally divergent 2-pyridones such as leporin-A (7) 
which lacks a para-hydroxyl moiety on the phenyl ring and the non-benzyl 
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substituted harzianopyridone (9) and atpenins (lOa,b,c). A unifying 
mechanism would be expected for all of these metabolites bearing in mind 
the close relationship between their producing organisms. These possible 
mechanisms are discussed in more detail in chapter 3. 
[0] 
~ 
HO 
Fig. 1.404. Vining's proposed mechanism for the ring expansion of 
an acyl tetramic acid to form the 2-pyridone moiety of 
tenellin (1) by B. bassiana 
Precedence for the possible operation of pathway A has been provided 
by Leete and co-workers who have shown that L-phenylalanine is subject to 
intramolecular rearrangement71 to (S)-tropic acid (42) during the 
biosynthesis of the tropane alkaloids atropine (43) and scopolamine (44) in 
the Solanaceous plant genus Datura (Fig. 1.405). Feeding experiments with 
labelled L-phenylalanines using D. innoxia and D. stramonium showed 
that the carboxyl group of phenylalanine migrates from C-2 to C-3 to form 
the branched carbon skeleton of tropic acid (42) (see chapter 3, section 3.21). 
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The observation of concomitant migration of hydrogen72,73 from the 3-
position of phenylalanine to the hydroxyl bearing carbon of tropic acid raises 
the possibility that the rearrangement occurs by a radical induced. 
mechanism mediated by a co-enzyme Bt2 dependent mutase activity. A 
good example of this relatively rare type of biological rearrangement occurs 
in the metabolism of (S)-methylmalonyl CoA (83a) to succinyl CoA (45a) 
(Fig. 1.406). 
0 0-~ 
L-phenylalanine (99) y: H' N 
Daturasp. 
~.,rT I 
V L atropine (43) 
o~o-.~o -~ 
: H' N 
(S)-tropic acid (42) 
~.ri'T I 
V L scopolamine (44) 
Scheme 1.405. (S) Tropic acid (42) and the biosynthetic origin 
of atropine (43) and scopolamine (44) from L-phenylalanine (99). 
0 0 0 
V methylmalonyl ~T HO SCoA HO CoA mutase. 
,,.c, .. cyseoA H~ l T H'' l 
H H 
0 
(S)-methylmalonyl CoA (83a) suCclnyl CoA (45a) 
Fig. 1.406. A 1-2 carboxyl shift mediated by co-enzyme Bt2, 
the conversion of (S)-methylmalonyl CoA (83a) to succinyl CoA (45a). 
-24-
Tenellin (1) can be placed confidently and firmly within the broader 
group of secondary metabolites derived jointly from a polyketide and an 
amino acid moiety. The polyketide side chain is typical of fungi, being 
derived from acetate and methionine rather than acetate and propionate as 
in the bacterial systems. 
Whilst the feeding experiments carried out on tenellin have 
elucidated the primary metabolites utilised in vivo to form its structural 
skeleton, no information has been obtained concerning intermediates or 
mechanisms of biosynthesis. As with tenellin (1), the biosynthesis of very 
many of the other polyketides remains shrouded in mystery at a level 
intermediate between primary precursors (acetate, propionate, methionine 
etc.) and the fully assembled metabolites. Tenellin (1) therefore offers an 
ideal system to study the biosynthesis of not only the interesting 2-pyridone 
systems, but also the polyketides in the wider sense and fungal polyketides 
more specifically. 
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2.1 Polyketides and the link to primary metabolism 
- fatty acid biosynthesis. 
Extensive biosynthetic and structural studies using a large variety of 
polyketides from many sources have indicated a close analogy between the 
biosynthesis of these molecules and the classic biosynthesis of the fatty 
acidsl. Both classes are made up of linear chains of acetate (and propionate 
and butyrate in the case of the bacterial and marine polyketides and fungi 
where propionate appears as a starter unit). 
As a class the fatty acids encompass the typical fully saturated 
compounds such as palmitic (46) and stearic (47) acids as well as the 
unsaturated examples such as oleic (48) and linoleic (49) acids. They are 
commonly found as triesters of glycerol and as such act as energy reserves 
for the cell. Phosphoglycerides in which one of the fatty acids is replaced by a 
phosphatidylcholine or related ester, make up the bulk of cell walls and 
membranes. Fatty acids also provide valuable starting materials for further 
metabolism. 
0 
(46) 
(47) 
(48) 
(49) 
(51) 
Palmitic acid (46), stearic acid (47), oleic acid (48), 
linoleic acid (49) and arachidonic acid (51). 
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The biosynthesis of fatty acids has been shown to occur on a highly 
cooperative set of enzymes or enzyme complex known as the fatty acid 
synthase (FAS)2. The exact nature of this FAS varies, and the types of FAS 
are classified with reference to the level of association between the 
constituent parts. In primitive systems there is a cluster of distinct enzymes 
each with a unique activity, this is termed a Type n FAS, and is typical of the 
plants and bacteria. In the more advanced cases a much higher level of 
association and cooperation is observed, for example the FAS in mammals 
consists of two identical multifunctional proteins, each containing all of the 
activities required for synthesising fatty acids, which must dimerise to form 
the active fomi of FAS. This highly integrated system is termed Type I FAS3. 
Between these extremes exist a variety of intermediate systems, each 
classified according to its own merits. Although the exact nature of the FAS 
complexes varies between organisms, the series of biochemical reactions 
leading to the fatty acids are identical4. 
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2.2 Fatty acid biosynthesis. 
The process (Scheme 2.202) starts when acetate (77), activated in vivo to the 
thiolester acetylcoenzyme-A (acetyl CoA) (77a), condenses with carbon 
dioxide to form malonyl CoA (82a). This important reaction is catalysed by 
acetyl-CoA carboxylase, a biotin dependent enzyme, and is essential for 
synthesis. Malonyl CoA (82a) provides the two carbon units used to build 
the even numbered chains typical of the fatty acids. The condensation 
occurs with retention of configuration at C-2 of malonateS. 
0 II H H 
,.,.....S~N~N 
0 
acetyl ACP (77b) 
Fig. 2.201. Acetyl CoA (77a) and acetyl ACP (77b). 
Malonyl CoA (82a) is transesterified onto an acyl carrier protein (ACP) 
where condensation occurs directly with the chain starter unit acetyl CoA 
(77a) to yield acetoacetyl ACP (85b). The enzyme which catalyses this step in 
E. coli, acetoacetyl-ACP synthase, has recently been discovered6. 
Concomitant decarboxylation, liberating the carbon dioxide originally added 
by acetyl CoA carboxylase, occurs during this condensation and it is this that 
provides the driving force for the reaction. This condensation has been 
shown to occur with inversion of configuration at C-2 of malonate7. 
The acyl carrier protein (ACP) now holds the growing chain during 
biosynthesis. The acyl group is bonded as a thiolester to a 
phosphopantetheine prosthetic group, similar to that of CoA, attached to 
the ACP. 
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0 
HO~ 
acetate (77) 
0 
HOJ...~ 
fatty adds TE ) 0 
ACP)lR 
acylACP 
o/ 
ACP~R 
butyryl ACP (79b) 'ER ~ 
0 0 
KS • II II ~~,._--~~~ ACP~R 
(82b) acetoacetyl ACP (85b) 
Chain 
Cycles. 
,u ../ (R)-hydroxybutyryl ACP (86b) 
o D~ 
ACP~R 
crotonyl ACP (87b) 
CoA = co-enzyme A, ACP = acyl carrier protein. 
I<S = P..keto acyl synthase, KR = P..keto reductase. 
DH = dehydratase, ER = enoyl reductase. 
TE = thiolesterase. 
Scheme 2.202. Fatty add biosynthesis. 
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The acetoacetyl ACP (85b) thus formed is sequentially reduced by a 
series of enzymes. Firstly by P-ketoacyl dehydogenase (KR) to yield (R)-3-
hydroxybutyryl ACP (86b), subsequently dehydrated by syn elimination to 
crotonyl ACP (87b) by a dehydratase (DH) activity. Full reduction is effected 
by an enoyl reductase (ER) utilising NADPH as the co-factor to yield butyryl 
ACP (79b). The stereoselectivety of this reaction is known to vary depending 
on the organism concerneds. For instance E. coli FAS mediates syn addition 
of hydrogen to the double bond such that protonation occurs on the Re face 
at the a.-carbon, whilst rat liver FAS mediates syn addition of hydrogen on 
the opposite face9. The FAS from yeast reduces the double bond by anti 
addition of hydrogen from the a.-Si-P-Si faces10. Recently the fourth mode 
of hydrogen addition, a.-Re-P-Re, has been observed in plant (dyers thistle, 
Carthamus tinctorius) and insect (flour beetle, Tribolium castaneum) 
systems11. The stereochemical course of FAS is summarised in Scheme 
2.203. 
Further condensation with malonyl CoA extends the chain length by 
two carbons and another cycle of reductions and dehydration furnishes 
hexanoyl ACP (SOb). The cycle of condensations followed by full reductions 
is repeated until the fully formed fatty acid is released from the FAS 
complex by a thiolesterase (TE). In the case of the Ct6 fatty acid palmitic acid 
(46) seven cycles (including the initial priming reaction with acetyl CoA) are 
required to condense the seven molecules of malonyl CoA with the acetyl 
CoA starter unit. In this way the fully saturated fatty acids are formed from a 
head to tail arrangement of acetate units. Carbon dioxide used to activate 
acetyl CoA to malonyl CoA is regenerated. The major product of FAS is the 
Ct6 acid palmitate (46). 
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Scheme 2.203. Stereochemical course of fatty acid biosynthesis, showing the 
It 
four modes of fl2 addition by enoyl reductases. 
A few fatty adds are known which do not conform to the rigidly linear, 
non functionalised even carbonenumbered products of FAS. These 
examples are most usually explained by the incorporation of a non-acetate 
starter unit. Since the first unit of the chain need not be activated to a 
malonyl functionality (as must all subsequent units), specific carboxylases 
are not required and a certain degree of flexibility of substrate specificity can 
occur in some systems. Thus the novel ro-fluorooleic add (52)12 arises from 
the utilisation of fluoroacetate (53) as the starter unit in seeds of the 
southern African plant Dichapetalum toxicarium, whilst. the cyanobacterial 
ro-cyclohexyl (Bacillus acidocaldarius)13 and ro-cycloheptyl (Bacillus 
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cycloheptanicus )14 undecanoic acids (54a,b) arise from the employment of 
cyclohexyl and cycloheptyl carboxylic acids as starter units. In the case of B. 
acidocaldus the FAS was shown to have a wide substrate specificity for the 
starter unit, utilising a varied selection of linear, branched and alicyclic 
short chain fatty acids that were presented to a whole cell system, as starter 
units for fatty acids13. 
F 0 
(52). 
0 
(54a). 
0 
(54b). 
ro-Fluorooleic acid (52), ro-cyclohexyl (54a) 
and ro-cycloheptyl (54b) undecanoic acids. 
OH 
OH 
The acyl carrier protein (ACP) from Escherichia coli FAS has recently 
been isolated, and the sequence of its seventy seven constituent amino acid 
residues determined15, The three dimensional structure of the polypeptide 
has thus fa·r proved difficult to obtain by crystallographic methods, but a 
method combining nmr distance measurements with computerised energy 
minimisation calculations has yielded valuable information about the 
shape of this protein. The most interesting feature is the presence of a 
hydrophobic cleft stretching along the top surface of the protein, 
terminating in a serine hydroxyl residue at one end. This cleft is a possible 
site of residence of the growing acyl chain bound to the serine residue via 
the phosphopantetheine prosthetic group. The exact shape and length of 
this deft may be importantly involved in directing the final length of the 
fully formed fatty acid and thus the point at which chain growth terminates 
and the fatty acid is released. 
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2.21 Unsaturated fatty adds as the startins point for secondary 
metabolite biosynthesis. 
Palmitate (46) is subject to post assembly modification by various enzymes 
located in the endoplasmic reticulum which can lengthen or shorten the 
chain, by two-carbon units, or introduce unsaturation to produce the range 
of structures commonly found as constituents of fats and oils such as oleic 
(48), linoleic (49) and linolenic acids (50)16, 
0 
(48) 0 
Fig. 2.211. Palmitic add (46) is converted to a range of other fatty adds such 
as oleic acid (48), linoleic acid (49) and linolenic acid (50). 
Mammals are devoid of a C-12 desaturase and are unable to synthesise 
linoleate (49) and linolenate (50). These substances are termed essential fatty 
acids and are a dietary requirement. They are necessary for the synthesis of 
the C20 tetraunsaturated compound arachidonic acid (51) and other poly-
unsaturated fatty acids. These material are precursors for the highly 
important class of bio-active compounds known as the eicosanoids 
including the prostaglandins, the thromboxanes and the leukotrienes (Fig. 
2.212). 
-40-
OH OH 
leucotriene B4 
o I 0 
arachidonic acid (51) 
OH 
-
-
. 
.. 
\ 
. 
. 
. 
OH 
thromboxane B2 
0 
. 
-
-
-OH 
prostaglandin A2 
Fig. 2.212. The eicosanoid class of hormones are derived 
from arachidonic add (51). 
In many plant species, such as Compositae (daisy family) and 
Umbelliferae (carrot family), the unsaturated fatty acids serve as precursors 
to acetylenes and allenes, many of which are biologically active, or in some 
cases extremely toxic. 
Unsaturation also serves as a starting point for hydroxylations, 
methylations and the formation of cyclopropane and cyclopropene rings as 
in the Sarcolaenaceae family of plants17, 
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2.3 Polyketide biosynthesis. 
Numerous biosynthetic studies have shown the close analogy between the 
biosynthesis of fatty acids by the classical mechanism discussed above and 
the biogenesis of the polyketides1. Traditionally the approach of the chemist 
has been to probe polyketide biosynthesis by utilising appropriate 
isotopically labelled substrates in feeding experiments, and subsequently 
detecting the fate of the label in the fully formed metabolite. More recent 
work has focused on the genetic aspects of polyketide biosynthesis, especially 
in delineating the enzymes responsible for each PKS transformation. Taken 
in tandem these two approaches have led to an increased understanding of 
the processes and mechanisms of polyketide biosynthesis. General 
conclusions obtained by these studies and three representative examples are 
presented here. Together they demonstrate many of the factors which have 
so far been discovered. 
2.31 The relationship between polyketides and the fatty acids. 
Very many studies on the biosynthesis of both fungal and bacterial 
polyketides have reinforced the observation that polyketide biosynthesis 
parallels FAS. Most studies have concentrated on tracing the primary units 
of PKS such as acetate and malonate, propionate and methylmalonate, 
butyrate and ethylmalonate and in a few cases isobutyrate and other short 
chain fatty acids. 
2.32 Simple precursors. 
The flexibility in the choice of starter unit for PKS mirrors that observed in 
FAS, so that a variety of non acetate units are observed in this position. The 
fungal metabolites aurovertin-B (36b) (Calcarisporium arbuscula)18 and 
pseurotin-A (16) (Pseudeurotium ovalis Stolk) 19 incorporate propionate (78) 
as the starter unit whilst the bacterial metabolite piloquinone (55) 
(Streptomyces pilosus)20 uses isobutyrate (118), derived efficiently from L-
valine (91), as the starter unit. The anthraquinone averantin (56)21, a 
precursor to aflatoxin-B1 (57) produced by a blocked mutant of Aspergillus 
parasiticus, has been shown to incorporate an intact hexanoate group (80) as 
a starter unit. The a-amino acid cysteine (93) has been postulated as the 
starter unit in the marine sponge metabolites latrunculins A and B (58a,b)22 
produced by Latrunculia magnifica. In a study utilising Streptomyces 
parvalus23 it was found that novel analogues of the usual metabolite 
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manumycin (59) containing alternative starter units could be produced 
when the culture broth was supplemented with high concentrations of 
suitable carboxylic acids. 
OH 0 
(55) 
(36b) 
OH 
latrunculin-A, n=2, (58a). 
latrunculin-B, n=l, (58b). 
Fig. 2.321. Aurovertin-B (36b), pseurotin-A (16), piloquinone (55) 
and latrunculins-A and B (58a,b). 
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HO 
o averantin (56) 
aflatoxin B1 (57) 
Fig. 2.322. Averantin (56), a precursor to aflatoxin-Bl (57), incorporates 
hexanoate as a starter unit. 
Malonyl CoA (82a) is the chain extending group in FAS, and indeed 
this group is used for the same purpose in PI<S. In addition to malonyl CoA 
(82a) however, it has been observed that methylmalonyl CoA (83a) and 
ethylmalonyl CoA (84a) thiolesters can also be incorporated in a head to tail 
manner to build a branched carbon backbone in bacterial and marine 
organisms but not in fungi (see section 2.4). 
In contrast to the complete reduction of ~-keto functionality in fatty 
acid synthesis by the cycle of ~ket~reductase (KR), dehydratase (DH) and 
enoyl reductase (ER) activities, the level of reduction of the ~-keto 
functionality in polyketide synthesis is variable. The cycle for chain 
elongation is envisaged as being very similar to that for FAS, with similar 
activities contained within the polyketide synthase (PKS). The major 
difference beween PI<S and FAS lies in the selective editing of the reduction 
and dehydration steps. To maintain the analogy between FAS and PI<S the 
model for PKS has been modified so that it is postulated that intermediates 
in the cycle 'loop back' (dashed arrows in Fig. 2.323) to the start of the cycle 
after the appropriate oxidation level has been reached, missing out later 
enzymic activities to leave correct functionality intact as the chain grows. 
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-----------~ PKS 'edited' pathways. 
Fig. 2.323. Polyketide biosynthesis. 
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Thus a keto functionality, originally present at the (3-position, is 
introduced into the growing chain if the acetoacyl intermediate is passed 
directly back to the beginning of the cycle before the operation of 
ketoreductase (KR), dehydratase (DH) or enoyl reductase (ER). Similarly 
hydroxyl and alkenic functionalities are introduced by jumping to the start 
of the cycle after (3-ketoreductase (KR) and dehydratase (DH) activities 
respectively. In combination, the variability of chain starter and extender 
units and the variability in level of reduction at carbons derived from C-1 
positions of acetate or propionate etc, produces the observed vast diversity 
in structure of the polyketides. Post assembly modification, as discussed in 
chapter 1, further diversifies this group of secondary metabolites. 
2.33 Orsellinic and 6-meth.ylsalicylic acids. 
The PKS systems responsible for the biosynthesis of two of the simplest 
polyketides, orsellinic acid (60) and 6-methylsalicylic acid (25) have been 
thoroughly investigated and are well understood. The compounds are 
structurally very similar, differing only by the presence of an extra hydroxyl 
group in orsellinic acid (60). 
Orsellinic acid (60) is one of the simplest polyketides, this simplicity led 
to it being one of the first of the class to be shown to be derived from head to 
tail condensation of acetate units24. 
The biosynthesis of orsellinic acid (60), has been investigated using 
orsellinic acid synthase (OAS) isolated from strains of Penicillium 
cyclopium and Penicillium madriti which produce this metabolite25. It was 
found that the acid could be synthesised in a cell-free system consisting only 
of acetyl CoA (77a), malonyl CoA (82a) and OAS suspended in aqueous 
buffer. These results can be rationalised by analogy to FAS, the acetyl (77) 
starter unit being extended by three rounds of condensation with malonyl 
CoA (82a), with concomitant loss of three equivalents of carbon dioxide, to 
form the poly-(3-keto intermediate (88) (Fig. 2.331). Stepwise reduction of the 
(3-keto functionality, which is the inevitable fate of these groups during 
FAS, does not occur however, and a tetra-(3-keto structure is built up on the 
synthase. The close proximity of keto and acidic methylene functionalities is 
possibly stabilised by metal chelation. Cyclisation of the tetraketide, followed 
by two enolisations, yields orsellinic acid (60). Jordan has very recently 
shown in an elegant series of experiments26, in contradiction of the earlier 
results of Floss et al.,27 that removal of hydrogen during enolisation is 
stereospecific, and thus cyclisation must be under enzymic control. This type 
of chemistry has been proven reasonable in vitro, by the synthesis of the 
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analogous linear triketone methyl ester. The triketone methyl ester was 
efficiently cyclised to give methyl orsellinate after treatment with silica gel28. 
0 0 0 
CoASJ.... COAS.Jl...J.-_OH 
acetyl CoA (77a) malonyl CoA (82a) j OAS 
~~LU~L~ 
(OAS) (OAS) (0:) (OAS) r<82a) 
~02 
0 0 0 0 0 
-
- (OAS) 
tetraketide (88) 
0 ! -~0, 2 enolisations. 
0 
OH 
orsellinic acid (60) 
OH 
Fig. 2.331. Orsellinic acid (60) biosynthesis. 
The enzyme system responsible for the biosynthesis of the tetraketide 
6-methylsalicylic acid (25) (6-methylsalicylic acid synthase, 6MSAS) from 
acetate (77) and malonate (82) has also been isolated and purified29. In 
contrast to orsellinic acid (60), the biosynthesis of 6MSA (25) from acetyl 
CoA (77a) and malonyl CoA (82a) requires the presence of NADPH. The 
absence of this co-factor leads to the unreduced triketide metabolite triacetic 
acid lactone (61) (TAL), which is also produced by FAS when devoid of 
NADPH30. 
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Fig. 2.332. The biosynthesis of 6-methylsalicylic acid (25). 
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The formation of 6MSA from an acetate starter unit and three 
malonate extender units parallels that of orsellinic acid, but is more 
complex due to the reduction and subsequent dehydration of the keto 
functionality arising from the first round of malonate extension. The 
timing of this reduction has been determined to occur at the tri-acetic acid 
level, before the final chain extension with malonyl CoA (82a). This 
modification, rendering a cis double bond in the pre-cyclised intermediate 
represents the simplest example of 'programming', i.e. the control of timing 
of functional group modification in PI<S systems. 
More recent work to increase the understanding of 6-MSAS has 
focused on the mechanism of aromatisation. Feeding experiments utilising 
tri- and mono-deuteroacetate, labelled with .13c at C-1, determined that 
hydrogen removal during aromatisation was stereospecific31,32. These 
studies were confirmed by a series of experiments utilising malonates, 
rendered chiral by the incorporation of 13c and 2H33, which determined the 
absolute stereospecificity of hydrogen removal34,35. This stereospecificity is a 
powerful indication that hydrogen loss is mediated enzymatically. The 
stereochemical course of the dehydrations leading to the aromatisation of 
6MSA (25), mirrors that recently shown for orsellinic acid (60). 
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2.34 Dehydrocurvularin. 
In contrast to orsellinic acid (60), the fungal octaketide dehydrocurvularin 
(30), isolated from the plant pathogen Alternaria cinerariae, is more heavily 
reduced. The origin of the carbon skeleton, as well as some of the pendant 
oxygen and hydrogen atoms has been determined to be from acetate (fig 
2.341)36. The variation in oxidation level of carbons derived from C-1 of 
acetate in dehydrocurvularin (30) requires the operation of a reductase 
activity at these positions. Notionally the reduction could occur after the 
formation of a polyketo chain analogous to, but longer than, the 
intermediates in orsellinic acid (60) and 6-MSA (25) biosynthesis. 
Alternatively the possibility of a processive mechanism exists where 
reduction occurs as chain growth progresses, much as in FAS. 
7x ~0 0 HO 
A. cinerariae. 
HO OH 
acetate (77) malonate (82) 
HO 0 
dehydrocurvularin (30) 
Fig. 2.341. Dehydrocurvularin (30) is an octaketide. 
Convincing evidence for the operation of a processive mechanism in 
the biosynthesis of polyketides has been obtained by Cane48 and 
Hutchinson51 in Actinomycetes, whilst in fungal systems Vederas et aJ37 
have also been able to show that a processive mechanism is operative 
during the biosynthesis of dehydrocurvalarin by synthesing doubly 13c-
labelled di- (30a) and tetra-ketide (30b) putative precursors. When these 
compounds were incubated with a mutant of A. cinerariae which was 
incapable of oxidising fatty acids, dehydrocurvularin (30) was obtained 
which was found to be enriched in 13c at sites corresponding to the position 
of label in the supplemented materiaJ37. 
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HOY [2,3_13C,l-diketide 
ys~NHAc 
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(30a) 
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[1,2_13~]-tetraketide 
HO 
Fig. 2.342. The reduced di- (30a) and tetra-ketides (30b) are incorporated 
intact into dehydrocurvularin (30). 
The use of doubly labelled material in these experiments highlights an 
important factor which has to be addressed when feeding more complex 
precursors to whole cell systems. It is generally found that the cellular 
mechanism of P-oxidation38, the process responsible for the catabolism of 
fatty acids, results in very extensive degradation of carbon chains of four 
cabons and longer to acetate and propionate. Labelled materials are no 
exception, and the resulting labelled acetate (77) and propionate (78) can be 
used in the de novo synthesis of the secondary metabolite under 
investigation. This process usually results in a uniform distribution of label 
throughout the metabolite, and indeed this was the case when these 
precursors were fed to wild type A. cinerarille. 
In order to overcom~ these problems a strategy was adopted to cut the 
level of operation of P-oxidation in the cell to a minimum. Firstly a uv-
mutant of the wild type organism was generated. The mutant selected was 
unable to utilise fatty acids as a carbon source. Secondly this mutant was 
utilised for feeding experiments in a high glucose replacement medium so 
that glucose, and not fatty adds, was the main source of carbon for the cell. 
Thirdly the known P-oxidation inhibitor 4-pentynoic acid (62) was 
supplemented to the cells at the same time as the labelled substrates. 
-51-
(63).,-" 
0 
HO~~ 
~CH 
<t~S 
The J}-oxidation inhibitors 3-(tetradecylthio)propionic add (63) and 4-
pentynoic acid (62), and the CoA mimic N-acylcysteamine (122). 
Labelling carbons at both ends of a bond effectively labels the bond 
itself, and this strategy was used to monitor the substrates used in this study. 
If the bond in question were cleaved, it would be statistically unlikely for the 
labels to come together again because of the dilution of labelled acetate (77) 
and propionate (78) by unlabelled material in vivo. The observation of 
dominant 13c.t3c vicinal coupling in the 13c nmr spectrum of the 
recovered dehydrocurvularin (30) for carbons corresponding to labelled 
carbons of the supplemented substrates was the evidence required to 
substantiate incorporation of the intact substrates. 
Additionally the substrates were administered as N-acetylcysteamine 
(NAC) thiolesters to aid trans-esterification onto the PKS system. NAC thiol 
esters have been used extensively for this purpose, and it is often found that 
incorporation of labelled substrate is only possible when the substrates are 
activated in this way. The NAC portion of the thiol ester is thought to 
mimic the SCoA moiety of acyl CoAs and ACPs in vivo. N-Octanoyl 
cysteamine thiolesters have also been used with success for this purpose39, 
presumably the longer alky chain increases the lipophilicity of the 
thiolester. 
Together these four strategies resulted in a 12% incorporation of the 
diketide precursor (30a) and a 2% incorporation of the tetraketide precursor 
(30b) into dehydrocurvularin (30). In a further study40, Vederas et al were 
able to observe up to 70% intact incorporation of doubly labelled tetra-
ketides (30b) into dehydrocurvularin (30) produced by wild type A. 
cinerariae in conjuction with the powerful Ji-oxidation inhibitor 3-
(tetradecylthio)propanoic acid (63)41. 
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2.35 The macrolides. 
The economically important pair of macrolide antibiotics erythromycins A 
and B (26a,b) (Saccharopolyspora erythraea) consist of fourteen-membered 
lactone rings substituted at two hydroxyl positions by sugars. 
0 
R=OH erythromycin-A (26a). 
R=H erythromycin-S (26b). 
The parent aglycone, 6-deoxyerythronolide-B (6-dEB) (26c), is a highly 
reduced polyketide derived from propionate (78) as a starter unit extended 
by six methylmalonate (83) units42, The utilisation of methylmalonate (83) 
as an extender unit ensures the introduction of methyl groups at alternate 
positions around the ring. These methyl groups are ultimately derived from 
C-3 of propionate (78) which is activated in bacterial systems to 
methylmalonyl CoA (83a) by a propionyl carboxylase activity analagous to 
the acetyl CoA carboxylases discussed for other systems above (Fig. 2.351). 
Feeding experiments with propionates doubly labelled [1-13c, 1-18o2] 
have been used to show that oxygens at carbon positions C-1, 3, 5, 9, 11 and 
13 are also derived intact from propionate42. 
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Fig. 2.351. The biosynthesis of the erythromycin skeleton 
6-deoxyerythronolide-B (26c) involves the condensation of 
propionyl CoA (78a) unit with six methylmalonyl CoA (83a) units. 
The macrolide class of polyketides has been studied extensively to 
further increase the knowledge about the mechanisms of chain extension. 
In the case of erythromycin (26) itself, extensive details about the post-
assembly functionalisation of the complete aglycone, 6-deoxyerythronolide-
B (6-dEB) (26c), have been determined by isolating partially assembled 
metabolites from the fermentation broth of mutants of the producing 
organism Saccharopolyspora erythraea. No intermediates between 
propionyl CoA (78a) and the fully assembled macrolactone ring have ever 
been isolated however42. 
Good evidence for the operation of a processive mechanism in the 
assembly of the macrolides comes from the discovery of a tetraketide in the 
fermentation broth of a mutant of Streptomyces fradiae which usually 
produces the sixteen membered macrolide tylosin (38)43. This tetraketide 
corresponded to a proposed precursor to tylactone (37), the aglycone of 
tylosin (38)44. 
-54-
0 0 
acetate (77), S. fradiae. 
OH I ,,, 
. .. S. fradiae. 
propionate (78). 
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Fig. 2.352. A fully formed tetraketide fragn\ent of tylactone (37) has been 
isolated from a mutant of the tylactone (37) producing organism 
Streptomyces fradiae. 
In one further case triketide, tetraketide, pentaketide45 and hexaketide46 
intermediates to the sixteen membered macrolide mycinamicin (64) have 
been isolated from a mutant of the mycinamicin (64) producing strain 
Micromonospora griseorubida disabled in its ability to produce the 
complete metabolite. Not only did the structures of these fragments 
accurately correspond to the postulated intermediates of a processive 
mechanism, but the stereochemistry of each chiral centre of each respective 
fragment also matched identically the corresponding centre in 
protomycinolide IV (65), the aglycone precursor to mycinamicin (64) itsel£47. 
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Fig. 2.353. The four polyketides isolated from the mycinamicin producing 
strain Micromonospora griseorubida, and their structural relationship to 
protomycinolide IV (65). 
OH 
The accumulating evidence in favour of a processive mechanism 
during the biosynthesis of the macrolides is backed up by biosynthetic 
feeding experiments utilising each of the three macrolides discussed above, 
erythromycin-A (26a), tylosin (38) and mycinamicin (64). In the case of 
erythromycin-A (26a), a doubly 13C-labelled diketide was successfully 
incorporated into the macrolide without prior degradation by P-oxidation, 
when it was activated to an NAC thiolester48. In a separate experiment the 
same substrate, this time labelled with 13c and 2H was also incorporated 
when supplemented to S. erythraea as a NAC thiol ester49. A singly labelled 
NAC thiolester activated diketide precursor to mycinamicin (64) was 
incorporated into the macrolide skeleton, and intact incorporation was 
judged by the specific enhancement of a single peak in the 13c nmr 
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spectrumSO. Diketide and triketide singly 13C-labelled precursors were 
similarly incorporated intact into tylactone (37) when supplemented to the 
fermentation broth as NAC thiolestersst. 
OYSNAC M. 
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Ill 0 
-
. 
. 
. 
. 
0 
protomycinolide IV (65) 
0 
~-sN_:_.c_F_rad_ia_e_ . ...._. 
,, .... lOH 
tylactone (37) 
I 0 
0 
SNAC 
S. erythraea. 
SNAC 
.,,'OH ...,.,~'(~ 
•·· -lsy 
···r "SNAC 
(!''''OH erythromycin-A (26a) 
Fig. 2.354. The incorporation of N-acetylcysteamine (NAC) thiolesters 
of labelled di- and tri-ketides into mydnamicin (64), tylactone (37) 
and erythromycin-A (26a). 
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Together, the results from feeding experiments with the simple 
precursors (acetate (77), propionate (78) etc), the successful incorporations of 
di- and tri-ketides into mycinamicin, tylactone and erythromycin and the 
discovery of PKS intermediates in a limited number of systems lend 
significant support for the theory that PKS closely resembles FAS in the 
stepwise modification of oxidation level at C-1 derived carbons in a 
processive manner as the chain grows. The similarity is strongest in the 
mode of assembly between the growing acyl chain and a malonyl CoA 
thiolester. Both FAS and PKS show some flexibility in the choice of starter 
unit. In FAS generally only malonyl CoA serves as the chain propagator, 
contrasting with malonyl and both methyl-, and ethylmalonyl CoA 
thiolesters in PKS. The striking difference between the two systems, 
however, is the variable nature of the oxidation level at the ~-position of 
the growing acyl chain left intact in PKS. 
Results of the numerous feeding experiments probing PKS, whilst 
illuminating aspects of the assembly, are inherently unable to shed light on 
the control mechanisms governing the level and degree of oxidation at the 
~-position of the growing acyl chain. In the case of FAS, complete enzyme 
systems capable of synthesising fatty acids have been isolated and 
characterised, in particular the role of the acyl carrier protein has been 
investigated and the protein itself has been characterised by n.m.r. 
techniques. PKS enzyme systems have been less tractable to this type of 
investigation and so investigators have approached the problem of PKS 
characterisation from a radically different direction. 
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2.36 Genetic aspects of PKS. 
The study of the enzyme systems that synthesize both t.lte fatty acids and the 
polyketides has proceeded classically by two approaches, feeding 
experiments with labelled substrates using whole cell and cell free systems, 
and the direct isolation of the enzyme systems themselves. A third method 
has relied on the generation of mutants, by interference with genetic 
material, of organisms leading to systems that are disabled in one or more 
aspects of enzymic transformation. The accumulation of different 
precursors to the metabolite under study can give clues to the order of 
assembly of simple precursors, and in the case of the macrolide antibiotics 
such as erythromycin (26), have provided valuable information about the 
steps leading to the active form of the antibiotic from the unfunctionalised 
products of the polyketide synthase (PI<S). 
Erythromycin (26) has proved one of the most heavily studied 
polyketides in this respect. Whilst feeding experiments with 
Saccharopolyspora erythraea have identified the carbon skeletal origin to be 
from seven units of propionate (78) and blocked mutant studies have 
identified 6-dEB (26c) as the first free intermediate42, the paucity of 
information about mechanistic steps between these extremes has been 
glaring. 
The PKS system generating 6-dEB (26c) has resisted attempts at 
isolation, but the genes coding for this set of enzymes have been located and 
recently sequenced. Leadlay and co-workers initially found one large open 
reading frame (orf) located about 12kB away from the erythromycin 
resistance gene (ermE)52. The exceptionally large protein (3178 amino acid 
residues) coded for by this gene was deduced to contain nine activities when 
the amino acid sequence was compared to the sequences of individual FAS 
proteins. 
Katz and co-workers have discovered two more similarly sized orfs, 
containing nine and ten activities respectively, at positions adjacent to the 
orf reported by Leadlay53. These three orfs, each capable of being expressed as 
a single giant protein, were found to contain all of the activities necessary 
for the de novo synthesis of 6-dEB from propionyl CoA and methylmalonyl 
CoA. Each of the three proteins was found t~ contain the necessary 
functionality to perform two condensations between a growing acyl chain 
and methylmalonyl CoA and the appropriate number of reduction and/ or 
dehydration steps. 
Each orf was deduced to code for a giant protein made up of two 
biosynthetic modules, each module was responsible for a chain extension 
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and an appropriate number of transformations to render the correct 
functionality at the ~-keto position of the growing acyl chain. Each module 
carries an acyl carrier protein which holds the growing acyl chain for that 
chain extension cycle, and an acyl transferase activity responsible for 
transesterifying the growing chain onto the ACP. Staunton has coined the 
term 'cassette•54 to describe a group of modules that are bound together, in 
this case each or£ corresponds to one cassette, and each cassette contains two 
modules (Fig. 2.361). 
Or£ 1 contains the first cassette of two modules. Module 1 has an acyl 
transferase (AT) to transfer propionyl CoA onto an acyl carrier protein 
(ACP), also coded for on this protein. There is also a ~-keto synthase (I<S) to 
perform the first condensation with methylmalonyl CoA and another acyl 
transferase to transfer this ~-keto acyl residue onto a second ACP where the 
first ~-keto reductase activity (KR) performs reduction to an alcohol. A 
further set of ACP and KS, AT, and KR activities are located on this protein, 
constituting module 2, for the second condensation/reduction cycle. 
Similarly the second open reading frame codes for a single protein 
containing the next cassette of two modules, each with its own ACP and AT 
units. The lack of a KR region in module 3 ensures the preservation of the 
keto group, whilst the presence of ketoreductase (KR), dehydratase (DH), 
and enoyl reductase (ER) domains in module 4, ensures full reduction after 
this chain elongation step. 
The third open reading frame (the or£ discovered by Leadlay) contains 
the modules necessary for the final two condensations and reduction cycles, 
with two more ACP units, in addition to a thiolesterase activity in module 
6, responsible for lactonisation and the release of the completed 6-dEB (26c). 
These findings are in full agreement with results obtained from 
feeding experiments with labelled precursors. They show that the level of 
oxidation at sites derived from C-1 of propionate is controlled by the 
presence or absence of the relevent activities (KR, DH and ER) in each of 
the six modules. 
Katz and co-workers set about verifying their conclusions by generating 
a mutant of S. erythraea in which the DNA base sequence corresponding to 
KR of module 5 was selectively deleted from the gene (or£ 3). They predicted 
that this deletion should have the effect of leaving intact a keto group at C-5 
of the erythromycin skeleton, leading to the new metabolite 5,6-dideoxy-3-
mycarosyl-5-oxoerythronolide-B (26d). Indeed this compound was found to 
be the major product of this mutant. Furthermore they went on to 
demonstrate that the acyl transferase (An catalytic activities are responsible 
in some measure for the specificity in the choice of starter unit and chain 
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1 
extender units. 
The discovery that discreet activities are responsible for each and every 
step of erythromycin (26) biosynthesis, and that no less than seven ACPs are 
specified, one for the starter unit and one for each subsequent chain 
elongation step, goes somewhat beyond the model proposed for PKS as a 
system closely analagous to FAS. The almost baroque complexity found in 
the proteins responsible for erythromycin (26) biosynthesis is however 
e_entirely necessar* explaining how the control processes making choices for 
starter unit and chain extender operate, and also how the level of oxidation 
at each C-1 derived position is determined. 
It is expected that the type of enzyme system responsible for the 
assembly of the erythromycin aglycone is also responsible for the assembly 
of the tylactone (37) and mycinamicin (64) lactone rings. The discovery that 
each protein of the enzyme system contains modules, each module 
programming for one cycle of condensation and reduction, helps to explain 
the structural and stereochemical homologies found through and between 
the different classes of polyketidesSS, It is easy to visualise how genetic 
cassettes coding for proteins, containing the entire machinery for assembly 
of individual stretches of polyketide chain, could be disseminated through a 
genus, family or order of organisms. The genetic use of cassettes could be a 
way of preserving polyketide stretches of biological activity, especially in 
systems of the complexity of the macrolides and polyethers where many of 
the structural homologies have been observedss. 
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Scheme 2361. The relationship between the DNA and the polyketide chain intermediates during the 
· biosynthesis of 6-dEB by S. erythreae. 
2.4 Branching strategies. 
A significant difference has been observed between the biosynthesis of 
fungal and bacterial polyketides containing pendant methyl (and in the case 
of some bacterial metabolites, ethyl) groups. As discussed above for the 
macrolide antibiotics, bacterial PKS systems effect branching of the 
polyketide backbone by the utilisation of methylmalonyl (or ethylmalonyl) 
CoA extender units as appropriate. It has been observed however that in 
fungal systems chain methylations occur by the reaction between the carbon 
chain and the S-methyl group of L-methionine56. The divide in mechanistic 
approaches between the bacteria and the fungi is almost complete, with only 
rare indiscretions. One example is the incorporation of a single methionine 
derived pendant methyl group into the bacterial metabolite ambruticin-S 
(66) (Polyangium cellosum) which also incorporates propionate groups via 
methylmalonate (83)57. 
0 
0 HO~ )# RS acetate (77) propionate (78) 
CH3Cs•-Met 
ring closure and methylation l !.. 5-adenosyl-L-methionine (90a) 
0 
HO 
RS 
OH 
. 
. 
-CH3 
ambrutidn-S (66) 
. 
. 
. 
CH3 
Fig. 2.401. Biosynthesis of ambruticin-S (66) from acetate (77), 
propionate (78) and L-methionine (90). 
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One possible explanation (Fig. 2.401) for this observation is that 
methylation accompanies ring closure of the terminal pyran ring. This 
would imply that the methylation event is an adornment and not a feature 
of polyketide chain building per se. 
The bacterial strategy ensures that the growing chain is appropriately 
functionalised as each malonyl unit is added, and so the timing of chain 
branch addition is not in dispute. In the case of the fungi however the 
timing of chain methylation has not been determined and there is a dearth 
of information concerning this point. 
The operation of a processive mechanism during the assembly of 
fungal polyketides has been comprehensively demonstrated for the case of 
dehydrocurvularin (30) elaborated by Alternaria cinerariae (section 2.24). 
Although this metabolite does not contain pendant methyl groups, it would 
be expected that a very similar process could operate in the cases of branched 
chain metabolites such as tenellin (1) and cubensic acid (24). Methylation of 
a growing polyketide chain, with the chain extender being derived from 
acetate and the pendant methyl group being derived from methionine, can 
be envisaged to occur by two mechanistically distinct routes. 
0 
eoASA 
acetyl CoA (77a). 
ACPS 
0 0 
eoAsAAoH 
malonyl CoA (82a). 
0 PKS 
... 
_ .. 
ACPS 
0 
2-methylbutyrate (108). 
Fig. 2.402. Modification of PKS to enable methylation by SAM. 
-64-
0 
CoASA 
acetyl CoA (77a) 
+ 
0 0 
CoASA,Jl_OH 
malonyl CoA (82a) 
c~ 
(82a) 
HO 
0 0 
ACPSAA 
(BSb) 
0 0 
ACPS 
(B2a)if:' DH, ER, I<S. 
co 0 0 
2 
ACPS 
MT 0 0 
ACPS 
ACPS 
tenellin (1) 
MT 
Scheme 2.403. Possible intermediates to the polyketide sidechain of 
tenellin(l), where methylation occurs as an integral part of PI<S. 
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It can be envisaged that the methylation event occurs as an integral 
part of the PKS system (Fig. 2.402). The ~-keto acyl group formed by chain 
extension with malonyl-CoA would then attack the methyl group of 5-
adenosyl methionine (SAM), methylating the growing chain directly. The 
usual programmed cycle of ~-keto reduction would then render the correct 
oxidation level at this position before the methylated chain could be 
extended by another round of malonyl-CoA condensation. 
In the case of tenellin (1) (Scheme 2.403) this type of mechanism would 
require that the first chain buildin:g condensation between the acetyl starter 
unit and malonyl CoA (82a), forming an acetoacetyl residue (85a), would be 
followed by methylation with a SAM (90a) dependent methyltransferase 
(MT) and a full round of ~-keto reduction affording a 2-methylbutyryl (108) 
residue. The second condensation and methylation would be followed by 
only ~-keto reduction and dehydration. The next two chain extensions with 
malonyl CoA would not be accompanied by a MT, so that the complete 
pentaketide with two appended methyl groups would be the product of the 
PKS. Methylation of the growing chain in this way would involve the 
participation of a methyltransferase activity as an integral part of the PKS 
system. 
There is limited experimental evidence to support the operation of 
such a methylation strategy. It has been shown that the methylation event 
during the biosynthesis of 5-methylorsellinic acid (67) occurs by the 
electrophilic attack of a methyl group of SAM onto a complete tetraketo 
chain before cyclisation to form the aromatic ring58. Other electrophilic 
moieties such as isoprenyl groups, have also been implicated in 
electrophilic attack at an activated methylene during polyketide 
biosynthesis. In these and other such systems, however, alkylation occurs 
after complete assembly of the polyketide chain, rather than as part of a 
processive assembly. 
In an alternative scenario the methyltransferase activity would be 
separate from the PKS. Methylation of malonyl CoA (82a), generated by the 
familiar carboxylation of acetyl CoA (77a), would furnish methylmalonyl 
CoA (83a). Methylmalonyl CoA could then be used as the chain extender 
unit, as is the case in bacterial PKS systems. For tenellin (1) (Scheme 2.404) 
this would mean that in addition to the acetate starter unit, the first two 
extender units would be methylmalonyl CoA (83a), the second two being 
malonyl CoA (82a). The reduction steps would follow as before. 
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0 0 
CoASA)lOH 
malonyl CoA (82a) 
MT SAM• 
0 0 
CoAS~OH 
methylmalonyl CoA (83a) 
propionyl CoA 
carboxylase ? ? 
0 
CoASJL) +C02 
propionyl CoA (78a) 
HO 
0 
CoAS~ 
acetyl CoA (77a) 
0 0 
ACPS 
tenellin (1) 
Scheme 2.404. Intermediates during the biosynthesis of the polyketide 
sidechain of tenellin (1) from SAM (90a) and acetate(77): the possible use of 
methylmalonate as a chain extender. 
The generation of methylmalonyl-CoA (83a) in this case differs from 
the bacterial systems where the branched chain extender unit is generated by 
the carboxylation of propionyl-CoA (78a) by a specific propionyl CoA 
carboxylase. This carboxylase is presumed missing from the fungi because of 
the observation that propionate (78) is incorporated into fungal polyketides 
only as a starter unit in a few rare cases, and is not involved mid-chain. 
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The presence of methylmalonyl-CoA (83a) in fungal systems, 
however, is evinced by the dual pathways leading to the propionate starter 
unit of the aurovertin (36) group of metabolites in the fungus 
Calcarisporium arbuscula. In one pathway incorporation of propionate (78) 
as an intact starter unit is ooserved, whilst in an additional pathway the 
starter group is derived from L-methionine (90) and acetate (77). These 
observations can be rationalised in two ways. Vleggaart8 supposed that two 
independant pathways were operating, one where propionate acts as a 
direct starter unit, the other where an acetyl starter unit is cleaved from the 
terminus of a methylated polyketide chain. The observations may also be 
explained by a unifying mechanism involving the formation of 
methylmalonyl-CoA (83a) from acetate, activa~ed to malonyl-CoA (82a), and 
L-methionine (90). In vivo decarboxylation of methylmalonyl-CoA (83a) 
would furnish propionyl-CoA (78a) thus generated from acetate (77) and L-
methionine (90) (Scheme 2.404). Circumstantial evidence for 
methylmalonate generation from propionate in the fungus Pseudeurotium 
ovalis was gathered by Tamm who observed deuterium wash-out from [2-
13c, 2-2H2]-propionate during the incorporation of propionate as a starter 
unit in pseurotin-A (16)19. 
0 
_)l SAM+ 
• __ oH ___ __,) 
y 
+ 
OCH, 
aurovertin-B (36b) 
0 
Fig. 2.405. The dual incorporation of propionate, acetate and methionine 
into aurovertin-B (36b). 
Clearly in the case of tenellin (1) these two possibilities are 
distinguished by the intermediacy of methylmalonate (83) in one pathway 
and its absence from the other. 
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2.5 Experimental investigation into the origin of carbon and 
hydrosen atoms durins the biosynthesis of the polyketide sidechain 
of tenellin (1), 
2.51 Experimental inyestication into the ori~in of the sidecbain 
hydro1ens. 
Vining et al. demonstrated the acetate origin of the sidechain carbons of 
tenellin (1) by a series of feeding experiments utilising singly and doubly 
labelled acetates59, In an extension of this work the origin of side-chain 
hydrogens was investigated by supplementing cultures of B. bassiana with 
sodium [1-13c, 2..2H3]-and [2-13c, 2-2H3]-acetates60 immediatly prior to 
tenellin (1) production. 
Tenellin (1) enriched at carbon positions 2, 7, 9, 11 and 13 (Table 2.513 
for 13c nmr peak assignments) was obtained when B. bassiana was 
supplemented with sodium [1-13c, 2..2H3]-acetate to a concentration of 
14.5mM. In addition to the carbon enhancements (Fig. 2.514), the presence of 
deuterium in the terminal methyl group was indicated by the presence of~­
shifted peak enhancements upfield of carbon position 13 (Fig. 2515). Upfield 
~-shifts were not observed for either C-7 or C-11, indicating that deuterium 
is probably not present at C-8 or C-12. However downfield (3-shifts have 
been observed61 for keto-functionalised reporter nucleii, and in the case of 
C-7 it was thought possible that either a very small, or even zero, ~-effect 
could be operating. In order to be able to conclusively determine whether 
deuterium was present at C-8 an experiment was performed to observe a-
shift effects. 
A complementary pattern of carbon enrichment in the sidechain of 
tenellin (1) was observed when B. bassiana was cultured with sodium [2-
13c, 2-2H3]-acetate to a concentration of 14.5mM, enrichments (Fig. 2.514) 
being observed for carbon positions 3, 8, 10, 12 and 14. A large a-shifted 
multiplet was observed upfield of C-14 indicating the presence of deuterium 
at this site. Simultaneous proton and deuterium decoupled 13c nmr 
revealed the presence of four methyl species, CD3, CD2H, CDH2 and CH3 
(Fig. 2.516,· Table 2.517). The incorporation of 13CH3 was estimated by 
calculation of peak enhancement in comparison with the unlabelled peak 
corresponding to C-16. The dual decoupling experiment also revealed that 
no deuterium was retained at carbon positions 12 or 8. 
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Ambient temperatura 
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DATA PROCESSING 
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FT a1Ze 13i072 
Total acquisition time 7.1 hours 
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Fig. 2.511. 13c nmr spectrum of tenellin (1). 
B. bassiana. 
Fig. 2.512. Pattern of incorporated labels from tenellin (1) supplemented 
with [1-13c, 22M3] and [2-13c, 2-2fi3] acetates. 
Carbon 
N2. 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
1' 
2'6' 
3'5' 
4' 
Be Type. % enrichment % enrichment 
(DMSO- from [1-13c] from [2-13c] 
06) acetate acetate 
157.5 CON 0.75 -
105.9 c 
-
2.24 
173.1 COH 
- -
110.8 c - -
140.3 CH 
- -
193.8 co 0.80 -
123.1 CH - 1.85 
149.9 CH 0.82 -
132.6 c 
-
251 
151.1 CH 0.81 -
34.7 CH 
-
2.59 
29.4 CH2 1.64 -
11.8 CH3 - 2.48 
19.9 CH3 - -
12.4 CH3 - -
122.7 C(Ph) 
- -. 
130.3 CH(2xPh) 
- -
115.0 CH(2xPh) 
- -
156.9 COH(Ph) 
- -
Table 2.513. 13c nmr peak assignments for tenellin (1). 
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Fig. 2.514. 13c nmr spectra of tenellin (1) obtained from B. bassiana cultures (a) supplemented with sodium [l-13c, 2-2H3]-
acetate, (b) ·supplemented with sodium [2-13c, 22H3]-acetate, (c) unfed. 
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Fig. 2515. Expansions of peaks corresponding to tenellin (1), obtained from B. bassiana cultures 
supplemented with sodium [1-13c, 2-2H3]-acetate, · 
corresponding to positions 7, 11,9 and 13. 
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14 (a) (lH) 
16 
13 12 11 18 9 
a-Effect CD3 (b) (1H,2H) 
14 
16 CHJ a-Effect CD2H 
14 13 12 11 18 ppm 
Fig. 2.516. 13c nmr spectra of tenellin (1) obtained from B. bassiana cultures 
supplemented with sodium [2-13c,22H3]-acetate, (a) proton decoupled only, 
(b) dual proton and deuterium decoupled. 
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13CHJ% 13CH2D% 13CHD2% 13CD3% 
4.3 7.2 21.7 66.6 
Table 2.517. Distribution of deuterium labelled 13c species in the terminal 
methyl group of tenellin (1) obtained from [2-13c, 2..2H3]-acetate. 
Of the three acetate C-2 derived carbons which carry hydrogen in 
tenellin (1), only the terminal methyl group was observed to incorporate 
significant deuterium from [2-13c, 2-2H3]-acetate. The loss of some 
deuterium from the acetate starter group indicates an equilibrium between 
acetyl CoA (77a) and malonyl CoA (82a) in vivo. If the mechanism of 
polyketide synthesis involved in the construction of the tenellin sidechain 
closely resembles that of FAS then no deuterium would be expected at C-12, 
as observed, because of the intermediacy of a C-12-C-13 double bond. 
However deuterium could be expected at C-8 of tenellin (1) where 
incomplete reduction has occurred. The clear 13c enrichment at this 
position, but lack of deuterium, can however be explained by extensive 
exchange of the acetoacyl intermediate with the medium, from both [t-13c, 
2..2HJ] and [2-13c, 2If3] acetates. 
In an attempt to obtain further information on the side chain protons, 
experiments were carried out utilising partially deuterated medium. 
Tenellin (1) obtained from a broth of B. bassillna cultured in a medium 
containing 50% 020 was examined by 13c nmr in the hope that solvent 
donated hydrogen positions could be observed. That all hydrogen bearing 
carbons of tenellin (1) had incorporated deuterium from the medium was 
evident by the observation of extensive line-broadening caused by a-effects 
and coupling, as well as multiple P-effects (Fig. 2.518). This result is not 
unexpected since all of the starting materials for tenellin (1) must have been 
biosynthesised from deuterium containing species. In order to attempt to 
circumvent this problem, non-deuterated acetate and methionine were 
added to a broth of B. bassillna containing 50% 020 immediately prior to 
tenellin (1) production. A similar result was obtained, with widespread 
deuterium incorporation, and it was not possible to unambiguously show 
the positions of media donated protons in the sidechain of tenellin (1) by 
this method. 
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Fig. 2.518. Methyl region of 13c nmr spectra of tenellin (1) obtained from B. bassiana cultured 
in 50% 020, (a) proton decoupled only, (b) dual proton and deuterium decoupled. 
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2.52 Experimental investigation of the mode of methylation during the 
biosynthesis of tenellin (1). 
In a preliminary experiment cultures of B. bassiana were supplemented 
with [S-methyl .13c2H3]-L-methionine to a concentration of 2.4mM just 
prior to tenellin (1) production. After four days, crude tenellin (1) was 
obtained and examined by high field 13c nmr under two different sets of 
conditions. In the (1H)-13c spectrum the presence of incorporated label into 
tenellin (1) was evinced by the observation of large multiplets 
approximately 1 ppm upfield from the unlabelled positions of the two 
pendant methyl groups C-15 and C-16 (Fig. 2.521). That a large proportion of 
the original deuterium was also present was indicated by the apparent 13c-D 
couplings and the a-shifted positions of the labelled peaks. 
When the sample was examined under the same conditions but with 
additional broad band deuterium decoupling, (1 H, 2H}, the multiplets were 
observed to collapse to singlets (Fig. 2.522). Very high enrichment levels (-
8%, compared to 1-2% for acetate) for the methyl group of [S-methyl-
13c2H3]-L-methionine were calculated by the measurement of relative peak 
heights. The magnitude of the a-shift for each enriched methyl position 
(approximately 1ppm), and the lack of resonances corresponding to partially 
deuterated methyl groups, showed that all three of the original deuteriums 
of the labelled precursor were incorporated intact during the methylation 
event. 
The retention of deuterium indicates that methylation can not proceed 
by a mechanism involving either the transfer of a methylene group from a 
sulphur ylide62 or by the intermediacy of exo-methylene groups or 
cyclopropanes as in the biosynthesis of 24-propylidenecholesterol63 in the 
marine alga Chrysoderma mucosa. The retention of all three deuterium 
atoms is consistent with the attack of an activated methylene group on SAM 
and is in agreement with other fungal polyketides where methionine 
donates a methyl group to a carbon centre. 
These results are consistent with both of the scenarios for methylation 
of tenellin (1), by methionine, outlined in section 2.5. In order to attempt to 
delineate between these two possible routes, a series of experiments was 
devised to probe the possible involvement of mef;bylmalonate (83) during 
the biosynthesis of the polyketide sidechain of tenellin (1). 
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Fig. 2.521. 13c runr spectra of tenellin, 
(a) unlabelled, 
(b) supplemented with L-[S-methyl-13c2H31-
methionine, (lH), 
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(c) as (b), (lH, 2H). (b) (lH) 
(c) (lH, 2H) 
DMSOD6 
12 13 15 14 
' I 16 
ppm 
PP• 
14 
a-Effect CD3 
a-Effect CD3 
' 
"' 
~ (a){1H) 
a-Effect CD3 
a-Effect CD3 
E 
i II ~ 
... 
... 15 " 
-
-
21 21 lSI II 17 II 15 14 13 12 II II 
ppm 
Fig. 2522. 13c nmr spectra of tenellin obtained from B. bllssianJJ supplemented with 
L-[S-methyi-13c2H3]-methionine, (a) proton decoupled, 
(b) proton and deuterium decoupled. 
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In an initial set of experiments the possibility that propionate (78) 
could provide the pendant methyl groups, via methylmalonate (83) as in 
the bacterial systems, was rejected. A fermentation broth of B. bassiana 
supplemented with sodium [1-13c]-propionate (78) to a concentration of 
12.9mmol, produced tenellin (1) which after 13c nmr analysis contained no 
observable carbon enrichments. 
The lack of propionate involvement could be due to the absence of a 
specific propionyl-CoA carboxylase which would be required to produce 
methylmalonate (83) in the fungal systems. Methylmalonate (83) however 
can be supplied in vivo by a number of other metabolic pathways. Direct 
methylation of malonate (82) by a SAM (90a) donated methyl group is one 
possible process, but methylmalonate (83) _is also generated during the 
catabolism of valine (91) via isobutyrate (118)64 and by the direct 
isomerisation of succinate (45) (chapter 1, section 1.4). 
In order to establish the intermediacy, or otherwise, of 
methylmalonate (83) during the assembly of the polyketide side-chain of 
tenellin (1), the following experiments were performed. Firstly [methyl 
_13c]-methylmalonate (115) was synthesised (chapter 5, section 5.03) and 
supplemented to fermentation broths of B. bassiana (9.2mM and 23.5mM) 
immediately prior to tenellin (1) production. In a second experiment, 
cultures of the producing strain were supplemented with [3,3'-13C2]-sodium 
isobutyrate (118) to a concentration of 10mM, (synthesis chapter 5, section 
5.03) also prior to tenellin (1) production. Tenellin (1) obtained from these 
experiments was examined by 13c nmr but no significant enrichment of 
carbons was observed in either case. In order to increase the sensitivity of 
the experiment doubly labelled diethyl [2,3-13C2] -2-methylmalonate (115a) 
(kindly supplied by T. J. Simpson) was supplemented in a third experiment 
to a concentration of 8.4mM. The. incorporation of intact [2,3-13C2]-2-
methylmalonate (115a) would be expected to lead to the observation of 13c-
13c coupling in the 13c nmr spectrum of tenellin (1), but no such coupling 
was observed. 
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isobutyrate (118) methylmalonate (115) 
Scheme 2.523. Propionate, methylmalonate and isobutyrate are not 
involved in tenellin (1) biosynthesis. 
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2.53 Experimental investiption into the timing of chain methylations. 
Clearly the operation of a PI<S system utilising methylmalonate in chain 
extension during the biosynthesis of the methylated side-chain of tenellin 
(1) would appear to be unlikely, and methylation may well be intimately 
connected with a processive method of polyketide construction. The 
involvment of a methyltransferase activity coupled to the PKS in the 
processive assembly of the sidechain would require early intermediates to 
tenellin to be methylated. In the this processive hypothesis, methylation of 
the growing chain would occur at the ~-keto stage, immediately after chain 
extension by malonate and prior to the cycle of reductions. If this were the 
case for tenellin (1), the intermediates involved in a processive mechanism 
leading to the polyketide moiety of tenellin (1) are those depicted in Scheme 
2.403. The product of the first condensation, methylation and round of 
reductions would be an enzyme bound 2-methylbutyrate (108) residue. 
Evidence for the involvement of 2-methylbutyrate (108) as a building 
unit for fatty acid or polyketide synthesis is scant. It is known, however, that 
2-methylbutyrate (108), derived from the in vivo breakdown of isoleucine 
(94), forms the the initial diketide residue of the aromatic plant pentaketide 
lathodoratin (68)65 biosynthesised by Lathyrus odoratus (sweet pea), and the 
branched carboxylic acid has also been utilised as a starter unit for fatty add 
synthesis by Bacillus acidocaldarius when supplemented to this organismt3. 
2-Methylbutyrate (108) has been more closely linked to polyketide synthesis 
by the observation that the 2-methylbutyryl acyl group of the fungal 
polyketide mevinolin (69) (Aspergillus terreus) is derived, not from 
isoleucine catabolism, but efficiently from acetate and methionine66. It is 
therefore plausable that 2-methylbutyrate (108) could be an intermediate to 
the sidechain of tenellin (1). 
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Fig. 2.531. Occurrence of 2-methylbutyrate (108) in lathodoratin, the anteiso 
series of fatty acids in Bacillus acidocaldarius and mevinolin (69). 
In order to test this hypothesis a number of 13c and 2H labelled 2-
methylbutyrates were synthesised (chapter 5, section 5.02) and administered 
to growing cultures of B. Bassiana. The use of a strategy to limit the effects of 
possible P-oxidation of this substrate was also adopted in a number of 
experiments. The results of the feeding experiments are summarised in 
Table 2.532. It was found in control experiments that high concentrations of 
the N-propionylcysteamine thiolester (110c,d) severely inhibited normal cell 
growth, and the maximum tolerable concentration for this material was 
determined to be 5.0mM. Similar experiments determined a tolerable 
concentration of the p-oxidation inhibitor 4-pentynoic acid (62) to be 
approximately l.OmM. 
The labelling patterns of molecules labelled with adjacent 13c and 2H 
labels (110c) were designed to facilitate the observation of incorporation of 
intact 2-methylbutyrate units into the polyketide chain. Incorporation of 
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these groups should lead to an observed 13-shift of the enriched resonance in 
the 13c nmr of tenellin (1). In order to increase the sensitivity of the 
experiments, 13CD3 labelled precursors were also synthesised and 
supplemented to B. bassiana. The intact incorporation of one of these 
groups should lead to the observation of an a-shifted enriched peak, shifted 
by up to 1ppm from the unlabelled resonance. It was hoped that comparison 
of 13c spectra of tenellin obtained under standard {1H) conditions and 
under simultaneous proton and deuterium decoupled conditions, (1 H, 2H}, 
would enable the observation of low (<0.5%) carbon enrichments. 
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Substrate. NO· Feeding amditions and Crude % Tenellin enriched 
final concentration tenellin incmpo carbon positions. 
yield ration. 
mg/1 
0 Single feeding to 750 - no NaO~ (109d) 9.4mM enrichments. 
eco:~ 
0 Pulse fed over 3 days 
- - -
NACS.JlJD (llOc). to 16.0mM. 
0 Single 500 - no NACS~ (llOc). supplementation to enrichments. S.OmM in the 
presence of 13-
oxidation inhibitor. 
0 Single - - -DdO~ (112d). supplementation to S.OmM. 
eco~ 
0 Single 900 - no OdS~ (llld). supplementation to enrichments. 3.4mM. 
eCD3 
0 Single 300 
-
no NACS~ (llOd). supplementation to enrichments. re-suspended cells in 
eco3 glucose replacement 
medium with ~-
oxidation inhibitor 
(1.2mM), to S.OmM. 
Table 2.532. Summary of 2-methylbutyrate feeding experiments 
with B. bassiana. 
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The uniform failure of any of the 2-methylbutyrates administered in 
this series of experiments to become incorporated into the polyketide side-
chain of tenellin (1) may indicate that methylation of the chain occurs by 
some mechanism not considered here. Alternatively the 2-methylbutyrates 
may be unable to intercept the PKS system and be taken up by it. Numerous 
possibilities exist to account for this inability, not least the operation of 
efficient catabolic processes degrading these short-chain fatty acids. 
Other more subtle factors may also account for the inability of the 2-
methylbutyrates to be taken up by the PKS system. If it were assumed that 
the PKS system of tenellin (1) resembled that of erythromycin (26) in as 
much as the activities for PKS were arranged in 'cassettes', that is a system 
consisting of a few multifunctional protein~, with each individual enzyme 
system responsible for, say, two condensation and modification sequences, 
then it may only be possible to intercept the fungal PKS system between 
'cassettes'. It is plausible to imagine that the first enzyme 'cassette' involved 
in the biosynthesis of tenellin (1) would take an acetyl CoA starter unit and 
perform the first condensation with malonyl ACP, methylate at the ~-keto 
stage, perform a full round of reductions, add the second chain extending 
malonate, methylate a second time and reduce the keto functionality to an 
enoyl system, all as enzyme bound species. The formed ACP-bound doubly 
methylated triketide would then be passed to a second cassette responsible 
for the third and fourth chain extensions, this time without methylation 
steps. This idea gains credance in the light of the existance of other fungal 
polyketides possessing the exact same moiety, especially bassianin (2) which 
would be expected to share much of the hardw~e responsible for polyketide 
synthesis with its shorter sibling tenellin (1), as well as for example the (-)-
sclerotiorin (70) family67,68, the postulated putative precursor to (-)-
betaenone69 (27), and the the oxidatively modified alternaric acid (71)70. Very 
many other examples are known of a doubly methylated triketide unit at 
the beginning of a polyketide chain where only the oxidation level differs 
from tenellin (1). Examples include funiculosin (5), citreomontanin (32) 
and radiclonic acid (39) amongst others. A doubly methylated triketide 
occurs as an 0-acyl moiety in lunatoic acid-A (72)71 elaborated by the fungus 
Cochliobo.lus lunata. 
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HO 
HO 
bassianin (2) 
(-) sclerotiorin (70) 
0 
-
-: . ~ ~o\ 
0 OH 
lunatoic acid-A (72) 0 
0 
HO 
postulated precursor to (-)-betaenone-B (27) 
OH 0 
alternaric add (71) 
Fig. 2.533. Metabolites bearing doubly methylated triketide groups. 
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This idea was tested by the synthesis (chapter 5, section 5.10) and 
administration of the triketide ethyl [t-13C]-E-2,4-dimethylhex-2-enoate 
(148b) to a growing culture of B. bassiana in a preliminary experiment. The 
labelled precursor was pulse fed over three days to a final concentration of 
3.9 mM. Tenellin (1) obtained after seven days incubation was examined by 
13c nmr, however no carbon enrichment at C-9 or any other carbon 
position was apparent. 
In order to overcome the possibility that the ethyl ester was consumed 
by efficient (3-oxidation, the N-propionylcysteamine thiolester of [t-13c]-E-
2,4-dimethylhex-2-enoate (150b) was also synthesised (chapter 5, section 5.10) 
and supplemented to B. bassiana in conjunction with the (3-oxidation 
inhibitor 4-pentynoic acid (62). A final concentration of 3.0 mM was 
achieved by pulse feeding the thiol ester over three days as tenellin (1) 
production progressed. The (3-oxidation inhibitor was added to a 
concentration of 1.0 mM. Tenellin obtained after 5 days fermentation was 
examined by 13c nmr, however no carbon enhancements were observed. 
An ethereal extract of the aqueous medium was analysed by t.l.c and showed 
no sign of the supplemented triketide thiolester. 
2.54 Discussion. 
Feeding experiments with sodium [1-13c, 2..2H3]- and [2-13c, 2..2H3]-acetates 
have shown that the sidechain of tenellin is a pentaketide, incorporating an 
intact acetate group containing three deuteriums as a starter unit, but not 
incorporating deuterium at any other position. All positions were heavily 
labelled when tenellin (1) was obtained from B. bassiana cultured in 50% 
D20. Equilibrium between acetate and malonate in vivo could be observed 
as evinced by low levels of deuterium wash-out from the terminal methyl 
position. In contrast no deuterium was lost from the methyl group of L-[S-
methyl _13c2H3]-methionine, intact incorporation of 13CD3 groups into 
tenellin (1) being observed. This is consistent with the nucleophilic attack of 
an activated methylene group on 5-adenosyl methionine (SAM). 
The possibility that methylmalonate is utilised as a chain extender 
during the biosynthesis of the sidechain of tenellin (1) was rejected because 
of the failure to incorporate the known precursors to methylmalonate, 
sodium [1-13c]-propionate and sodium [3,3'-13C2]-isobutyrate, as well as 
sodium [methyl _13c]-and [2,3-13C2]-methylmalonate itself. Methylation is 
therefore likely to involve a SAM dependent methyltransferase and be 
intimate with the PKS. However positive evidence for the operation of a 
processive mechanism involving methylation of the growing chain at a (3-
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keto stage is also lacking due to the failure of numerous feeding 
experiments utilising [1-13c] labelled monomethylated diketides and 
dimethylated triketides. These more complex putative precursors may be 
subject to efficient J3-oxidation, even when strategies were used to limit this 
process. These compounds were rarely detectable in the medium a few days 
after supplementation, and instances where recovery of labelled material 
was possible were usually from unhealthy cultures. J3-0xidation of the 
labelled di- and tri-ketides used in this study would afford labelled 
propionate, which was shown not to play a part in tenellin (1} biosynthesis, 
and so detection of label in tenellin (1} by incorporation of J3-oxidation 
products is unlikely, and in fact was never observed. It may prove 
worthwhile using the more powerful J3-oxidation inhibitors investigated 
recently by Vederas et. al. in order to press these experiments further. 
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Chapter 3o 
Phenylalanine metabolism and the 
biosynthesis of the pyridone 
moiety of tenellin" 
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3.1 Phenylalanine metabolism. 
The a-amino acid L-phenylalanine (99) is often found as a constituent part 
of plant and microbial secondary metabolites. The ready availability of both 
enantiomers of this amino acid in 13c and 14c labelled forms, as well as in 
2H and 3H stereospecifically labelled formst has meant that its incorporation 
into a number of metabolites is well studied. The use of these materials has 
allowed the fate of individual phenylalanine protons to be traced, and has 
led to an understanding of the metabolic processes operating on 
phenylalanine in vivo (Fig. 3.101). 
Phenylalanine is synthesised in vivo by the reversible amination of 
phenylpyruvate (95)2. L-Phenylalanine (99) is for example in rapid 
equilibrium by way of phenylpyruvate (95) with D-phenylalanine (99) in the 
cytochalasin-D (18) synthesising fungus Zygosporium masonii. Enolisation 
of the a-ketoacid lead to the rapid exchange of the benzylic protons3. A 
similar process was found to be operating during the biosynthesis of 
cyclopenin and cyclopenol (21a,b)4. In these two cases the intermediacy of 
phenylpyruvate (95) explained the observation that both D and L forms of 
the amino acid are incorporated into the metabolites. Other processes 
affecting phenylalanine have been shown to occur more stereospecifically. 
For example ammonia elimination catalysed by L-phenylalanine ammonia 
lyase (PAL) occurs by the specific removal of the 3-pro-S hydogen and the 
amino group, to yield trans-cinnamic acid (89)1. Kirby et al. have also shown 
that the 3-pro-R proton is subject to stereospecific exchange with retention 
of configuration during the biosynthesis of gliotoxin (75)5 in the fungus 
Trichoderma viride. 
Phenylalanine (99) is also frequently p-hydroxylated to provide an 
additional source of tyrosine (98), and the enzyme systems responsible are 
known to be widespread in the microfungi, plants and higher animals, but 
largely absent from other species6. 
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L-phenylalanine (99) 
PAL 
L-phenylalanine (99) trans -cinnamic acid (89) 
OH T. Viride. 
L-phenylalanine (99) 
gliotoxin (75) 
0 
OH 
------~~ 
OH 
HO 
L-phenylalanine (99) L-tyrosine (98) 
Fig. 3.101. Some aspects of L-phenylalanine (99) metabolism. 
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3.2 L-Phenylalanine undergoes a rearransement durins the 
biosynthesis of tenellin (1) and tropic acid (42). 
The most intriguing feature of tenellin (1) biosynthesis is the formation of 
the six-membered 2-pyridone ring from an intact L-phenylalanine unit and 
the terminal acetate residue of a polyketide chain7. The same precursors 
account for the 2-pyridone moiety of ilicicolin-H (6)8, and would seem the 
most likely candidates for the origin of the 2-pyridone rings of bassianin (2) 
and leporin-A (7)9. The sidechain of harzianopyridone (9) has been shown 
to be polyketide in nature (acetate and methionone derived)lO, but the 
origin of the rest of the pyridone ring has not been conclusively determined, 
although the amino acid aspartate has been implicated. Visual inspection of 
the structure of funiculosin (5) would suggest that this too could be derived 
from a polyketide chain and an unusual amino acid residue, perhaps 
derived ultimately from phenylalanine (99) or tyrosine (98). (N.B. The 
origin of these metabolites differs from the origin of two of the fungal 2-
pyridones, viridicatin (Sa) and viridicatol (8b), which have been shown to be 
products of the metabolism of the cyclic bis-aminoacids cyclopenin (21a) and 
cyclopenol (21b)11,12, respectively.) 
Rearrangement of the amino acid moiety, formally by a 1-2 carboxyl 
shift, is necessary to form the requisite structural framework of the six-
membered pyridone ring. Vining et al. showed that this rearrangement is 
intramolecular in the case of tenellin (1). The supplementation of [1,3-13C2]-
phenylalanine to a fermentation broth lead to the isolation of tenellin (1) 
labelled specifically at carbon positions 4 and 5 (Fig. 3.211)13. The retention of 
the amino nitrogen from phenylalanine during tenellin (1) biosynthesis 
was also shown by a 15N feeding experiment. L-Phenylalanine (99) was also 
shown to be a better precursor to tenellin (1) than L-tyrosine (98), suggesting 
that aryl hydroxylation occurs after condensation with the polyketide chain. 
Two different mechanistic explanations have been advanced to 
account for this observed intramolecular rearrangement of phenylalanine 
during tenellin (1) biosynthesis (Fig. 1.402). In a pathway postulated by 
Vining et al. the expansion of a five membered ring tetramic acid precursor, 
formed by the condensation of L-phenylalanine (99) and a polyketide chain 
was considered, whilst we theorised14 an alternative scenario which 
involved the direct rearrangement of phenylalanine (99) prior to 
condensation, to provide the carbon framework necessary to form the six-
membered 2-pyridone. 
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3.21.Direct rearrangement of phenylalanine. 
Although the existence of an L-phenylalanine mutase ·activity is without 
precedent in fungi, Leete has shown that L-phenylalanine is subject to 
apparent intramolecular rearrangement, by 1-2 carboxyl shift, during the 
biosynthesis of the tropic acid (42) moiety of the alkaloids atropine (43) and 
scopolamine (44) (these two metabolites were previously known as 
hyoscyamine and hyoscine respectivelylS) in the Solanaceous16 family of 
plants. These two compounds are pharmacologically important smooth 
muscle relaxants, and account for the toxicity of the common plants17 
Deadly nightshade (Atropa belladonna), Henbane (Hyoscyamus niger, 
incidentally the plant used by Dr. Crippen to murder his wife, by poisoning, 
in 191018) and Thornapple (Datura stramonium) among others. 
Leete showed that the three sidechain carbons of tropic acid (42) are 
derived from the three propanoid carbons of phenylalanine using DL-
phenylalanine labelled with 14c at carbon positions 1, 2, and 319,20, The 
rearrangement was shown to be intramolecular by a feeding experiment 
with DL-[1-14c, 1,3-13C2]-phenylalanine which resulted in the alkaloids 
containing tropic acid with adjacent 13c labels21, Unlike the case of tenellin 
(1), the L-phenylalanine nitrogen is not retained, and is repaced by an 
hydroxyl functionality in tropic acid (42). 
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OH 
L-phenylalanine (99) (S)-tropic Acid (42) 
atropine (43) scopolamine (44) 
Biosynthesis. 
Extraction procedure. 
(RS)-tropic acid (42) atropic acid (42a) 
Fig. 3.211. ~~mary of biosynthesis and extraction 
procedure of tropic acid (42). 
In order to probe the stereochemistry of the carboxyl shift, Leete 
supplemented growing Datura stramonium and D. innoxill plants with a 
mixture of equal amounts of the four stereoisomers of [1-14c, 3_3H]-
phenylalanine22. The scopolamine (44) and atropine (43) isolated from the 
plants contained almost all of the supplemented tritium. When the 
alkaloids were hydrolysed, using barium hydroxide solution, tropic acid was 
afforded which contained 59% of the original tritium. Tritium loss during 
this hydrolysis step accompanied epimerisation at the benzylic position23. 
Exactly half of the original tritium was found to be present on the 
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hydroxymethylene carbon (C-2 of phenylalanine) of the tropic acid by its 
conversion to atropic acid (42a). Thus the carboxyl shift giving rise to the (5)-
tropic acid (42) of atropine (43) and scopolamine (44), is accompanied by back 
migration (vicinal interchange) of a proton from the benzylic carbon of 
phenylalanine to the hydroxymethylene carbon of tropic acid. 
The studies of Haslam et al. 24 are complementary to those of Leete. 
The supplementation of the two individual stereoisomers of L-[2-14c, 3-3H]-
phenylalanine to Datura stramonium plants in separate experiments gave 
rise to scopolamine (44) and atropine (43) which were not used for activity 
measurements. The alkaloids were hydrolysed instead with sodium 
hydroxide solution to give tropic acid (42). When L-[2-14c, 3-R-3H]-
phenylalanine was administered, tropic acid was obtained which contained 
7-12% of the original tritium. Supplementation with L-[2-14c, 3-S -3H]-
phenylalanine resulted in tropic acid (42) containing 65-70% of the original 
tritium. Since Leete showed that tritium is not lost in the biosynthesis of the 
alkaloids, but is lost mainly from the benzylic position during ester 
hydrolysis by epimerisation, these results essentially show the amount of 
tritium present on the hydroxymethyl carbon of tropic acid (42). It is thus 
the 3-pro-S hydrogen of phenylalanine which migrates and is retained at 
the hydroxymethylene position, the 3-pro-R hydrogen remains, but is 
washed out to a high extent during epimerisation. These conclusions were 
reinforced by a more rigorous repetition of Haslam's work by Leete25. 
Non-stereospecifically [1-14c, 3-3H]-labelled L-phenylalanine was also 
supplemented to a culture of B. bassiana.7 The tenellin (1) obtained had lost 
%.6% of the original tritium, leading Vining et al. to the conclusion that: 
"The loss of at least 96% of the 3 H from [3_3 HI-phenylalanine during 
incorporation rules out any rearrangement mechanism involving a 1,2 
hydride shift." 
However since any hydride shift occurring during phenylalanine 
rearrangement as part of tenellin (1) biosynthesis would be expected to be 
stereospecific, the rearranged amino acid would be expected to possess 
tritium at either the pro-R or the pro-S position of the aminomethylene 
carbon. In the case of tenellin (1), one of these two hydrogens is lost to form 
the unsaturated pyridone ring, also probably stereospecifically. If this step 
were stereospecific and the hydrogen lost in this step corresponded to the 
hydrogen involved in the 1,2 shift, then no tritium would be expected to be 
retained in the fully formed tenellin (1) (there is a 50% chance of this). Thus 
the results of Vining do not necessarily rule out the operation of a hydride 
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shift during the biosynthesis of tenellin (1), and his assertation is flawed. 
The vicinal interchange between C-1 and the 3-pro-R hydrogen of L-
phenylalanine during (S)-tropic add biosynthesis bears resemblance to the 
small group of 1-2 shifts catalysed by co-enzyme B12, and in particular to the 
isomerisation between succinyl-CoA (45) and methylmalonyl-CoA (83a) 
(chapter 1, section 1.4) known to occur in the bacteria and mammals. Co-
enzyme B12 catalysed rearrangements are characterised by the back-
migration of a proton accompanying the movement of the major group26. If 
tropic acid arises by a co-enzyme B12 catalysed rearrangement of L-
phenylalanine, then 3-amino-2-phenylpropionic acid (104) would be an 
intermediate. 
In the case of tenellin (1) a similar process could be postulated, bearing 
in mind that a hydride shift has not necessarily been ruled out, again 
yielding 3-amino-2-phenylpropionic acid (104). In this case however there 
would be no replacement of the amine group by an hydroxyl, and the 
rearranged amino acid would condense with the terminal residue of the 
polyketide chain to generate the six membered ring of tenellin (1). 
No intermediates between L-phenylalanine (99) and tropic acid (42) or 
tenellin (1) have so-far been identified, but a pathway unifying the 
biosynthesis of both metabolites would involve the intermediacy of 3-
amino-2-phenylpropionic acid (104). 
OH 
L-phenylalanine (99) 3-amino-2-phenylpropionic acid (104) 
HO 
tropic add (42) 
tenellin (1) 
Fig. 3.212. The possible intermediacy of 3-amino-2-phenyl propionic acid 
(104) in tropic acid (42) and tenellin (1) biosynthesis. 
-102-
To test this hypothesis 3-amino-2-phenylpropionic acid (104) was 
synthesised (chapter 5, section 5.01) carrying either [3-13c] (104b) or [3-14c] 
(104c) labels. The possible participation of this rearranged amino acid during 
the biosynthesis of tropic acid (42) from L-phenylalanine (99) was tested by 
the administration of [3-14c]-labelled material (104c) to growing Datura 
innoxia plants. The amino add was taken up in solution by the plants via a 
woollen wick threaded through the stems. After twenty eight days almost 
all of the radioactivity had been taken up, and the plants were harvested 
and the tropic add alkaloids atropine (43) and scopolamine (44) extracted (as 
detailed in chapter 7) and found to contain a negligible amount of 
radioactivity. 
In the case of tenellin (1), [3-13c]-3-amino-2-phenylpropionic acid 
(104b) was added to fermentation broths of B. bassiana, immediately prior to 
tenellin (1) production, to a final concentration of 2mM. A small amount of 
[UL-14c]-L-phenylalanine (s.a 1.7 tJ.Cimmol-1) was also added as an internal 
reference. The tenellin (1) obtained after fermentation for seven days had an 
absolute incorporation of 14c of 3.4%. This is in agreement with the results 
of Vining7, but examination of the 13c nmr spectrum showed no observable 
incorporation of label from [3-13c]-3-amino-2-phenylpropionic acid (104b). 
This experiment was repeated with a similar outcome. It remained possible 
that the exogenously added material could not penetrate the cells. This 
possibility was however eliminated after a three-day old B. bassillna culture 
was supplemented with unlabelled (104a) and L-phenylalanine (99) in equal 
amounts. Both amino acids were successfully detected by tlc analysis after 
several days from extracts of the washed cells. 
The known co-enzyme B12 mutase enzymes which catalyse carboxyl 
shifts utilise CoA-thiolesters directly26. It might therefore be concluded that 
the CoA thiolester produced after rearrangement of L-phenylalanine-CoA 
may actually be an intermediate species, which is involved in the 
condensation with the polyketide chain during tenellin biosynthesis. A 
specific CoA thiolester synthase may not necessarily be present in B. 
bassiana, and if the exogenously added 3-amino-2-phenylpropionic acid 
(104) were not activated to the CoA thiolester it then would not be able to 
participate in tenellin (1) biosynthesis. 
In order to test this possibility, syntheses (chapter 5, section 5.05) of the 
N-propionylcysteamine thiolesters of both L-phenylalanine (99) and 3-
amino-2-phenylpropionic acid (104) were developed. In a preliminary 
feeding experiment the incorporations of [UL-14c]-L-phenylalanine (99) and 
[UL-14c]-L-phenylalanine (N-propionylcysteamine) thiolester (125a) into 
tenellin (1) were compared. The two substrates were added to fermentation 
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broths of B. bassiana just prior to tenellin (1) production at equivalent 
concentrations (3.0mM) and specific activities (l.O~Cimmot-1 ). Tenellin (1) 
obtained from these broths showed a specific incorporation of 3.66% when 
[UL-14c]-L-phenylalanine (99) was the substrate and a specific incorporation 
of 3.69% when [UL-14c]-L-phenylalanine (N-propionylcysteamine) 
thiolester (125a) was the substrate. The near identical results do not 
convincingly show that activation to a thiolester provides additional 
impetus to push the amino acid substrate into the 2-pyridone synthase 
activity, and it could be more reasonably concluded that the thiolester was 
efficiently hydrolysed before incorporation. For this reason the synthesis 
and supplementation of 14c-labelled 3-amino-2-phenylpropionate (N-
propionylcysteamine) thiolester (128) was not pursued further. 
It would seem therefore that 3-amino-2-phenylpropionic acid (104) is 
not involved in either tenellin (1) or tropic acid (42) biosynthesis. In the case 
of tropic acid (42), other species suggest themselves as putative 
intermediates. Phenyllactate (96) and phenylpyruvate (95), known products 
of phenylalanine metabolism, may be a more direct source of the carbon 
framework which undergoes rearrangement. In the case of tenellin (1) the 
possibilities are more limited because of the retention of the amine 
nitrogen, and the intermediates of 2-pyridone ring formation during the 
biosynthesis of tenellin (1) may be more akin to the acyltetramic acids 
suggested by Vining. 
OH OH 
L-phenylalanine (99) phenylpyruvate (95) phenyllactate (96) 
Fig. 3.213. Phenylalanine, phenylpyruvate and phenyllactate are 
interconverted in vivo. 
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3.22 Ring expansion of an acyltetramic acid during tenellin 
biosynthesis .. 
Biosynthetic investigations into the tetramic acid family of natural products 
have revealed that the framework of the tetramic acid ring itself is derived 
from the amine nitrogen and carboxyl and a.-carbons of an a.-amino acid 
coupled to the two terminal carbons of a polyketide chain (Chapter 1, section 
1.4). Thus the simplest member of the family, tenuazonic acid (14), is 
derived from isoleucine coupled to a C4 diketide27• The more complex 
cytotoxin erythroskyrine (12) is derived from L-valine (91) with a 
polyunsaturated polyketide sidechain28. L-Phenylalanine (99) is observed as 
the intact amino acid moiety in pseurotin-A (16)29 and the cryptotetramic 
acid cytochalasin-D (18) (Chapter 1, section 1.2). 
The acyl tetramic acids occur in both fungi and bacteria and such 
precedent suggests a tetramic acid derived from L-phenylalanine and a 
pentaketide as a potential precursor to tenellin (1) in B. bassiana. A further 
set of enzymes would be required to modify such a tetramic acid to provide 
the 2-pyridone ring observed in tenellin (1). 
Vining et al. suggested a ring expansion mechanism which 
incorporated oxidation of the aromatic ring of phenylalanine (99). The 
oxidation of the aryl nucleus affords a quinomethine structure, the re-
aromatisation of which could provide some of the impetus for ring 
expansion (Chapter 1, section 1.4). 
In order to ascertain the validity of this hypothesis an experiment was 
designed to test for the possible existance of a specific aryl p-hydroxylation 
activity in B. bassiana. Two shortchain acyl tetramic acids carrying in one 
case a benzylic group (131a), and in the other a para-hydroxyl benzylic (131b) 
moiety were synthesised (chapter 5, section 5.06) as model systems. It was 
hoped that (131a) would act as a substrate for the hydroxylation enzyme to 
give (131b). An aqueous solution of the sodium salt of 5(5)-3-acetyl-5-benzyl-
2,4-dioxopyrrolidine (131a) was added to a fermentation broth of B. bassiana 
to a concentration of 1mM. After three days the fermentation broths were 
homogenised and filtered. The filtrate was acidified and extracted into 
diethyl ether, which was evaporated to provide a crude solution suitable for 
chromatographic analysis. Tic analysis of this concentrated solution showed 
the presence of the exogenously added starting material (131a) in addition to 
tenellin (1) and other unidentified spots. One faint spot corresponded to an 
authentic sample of 3-acetyl-5-(p-hydroxybenzyl)-2,4-dioxopyrrolidine (131b). 
HPLC analysis suggested the presence of a very low amount of this p-
hydroxylated material. The very low concentration in the extract of the 
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compound g1vmg the peak that corresponded with the authentic p 
-hydroxylated material meant that further characterisation was not possible. 
An attempt was made to characterise other compounds present in the 
extract by separating them by preparative tlc, but the very low 
concentrations of these compounds precluded this. 
To test for the possible intermediacy of an acyl tetramic acid during 
tenellin (1) biosynthesis directly, an acyl tetramic acid analogue of tenellin 
carrying a single 13c label was synthesised (chapter 5, section 5.08). The 
highly polar nature of this acyl tetramic acid meant that purification by 
column chromatography, or recrystallisation, was not possible (chapter 5, 
section 5.08). However crude material added to cultures of B. bassiana was 
characterised first by 13c nmr and mass spectrometry and shown to be free 
from traces of 13c labelled phenylalanine or its derivatives. This crude acyl 
tetramic acid (139) was supplemented to a culture of B. bassiana to a 
concentration of 1.2mM. Tenellin (1) obtained from this culture after seven 
days, was examined by 13c nmr which showed an enhancement of the 
resonance corresponding to C-4 (Fig. 3.221 and Fig. 3.222). 
3.23 Discussion. 
The results of the feeding experiments detailed above have shown that 3-
amino-2-phenylpropionic acid (104) is not an intermediate during either 
tropic acid (42) or tenellin (1) biosynthesis. The labelled amino acid was 
taken-up by both the D. innoxia plants and B. bassiana fungal culture, but 
was not incorporated into either metabolite. No further evidence for 
possible intermediates to tropic acid (42) was gathered, but the shortening 
list of possible candidate molecules (cinnamate (89)30, littorine30, 1-carboxy-
2-phenyloxirane31, atropic acid (42a)31 and 2-carboxyphenylacetaldehyde31 
have been shown not to be precursors to tropic acid (42)) means that 
phenyllactate (96), or phenylpyruvate (95), are becoming more likely direct 
precursors. 
In the case of tenellin (1), it seems likely that an acyl tetramic acid is a 
precursor, however the evidence gathered to date is tentative. It remains 
possible that catabolism of the supplemented labelled tetramic acid (139) 
could afford [1-13c]-phenylalanine, a known precursor to tenellin, in vivo. 
Further experiments using a doubly labelled acyl tetramic acid, with labels 
carried in both the amino acid and polyketide moieties, would show 
whether catabolism was an important factor in label incorporation. If the 
doubly labelled tetramic acid were a genuine precursor to tenellin (1) then 
the specific incorporation for each label should be identical. 
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Fig. 3.221. 13c nmr spectra of tenellin (a) unlabelled, (b) obtained from a culture of B. bassiana 
· supplemented with the acyl tetramic add (139). 
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Fig. 3.222. Expansion of C-4 region of tenellin (1) obtained from B. bassiana 
supplemented with the acyl tetramic acid (139). 
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Vining suggested that the mechanism of tetramic acid ring expansion 
was coupled to oxidation of the phenyl ring, so that a quinomethine 
structure underwent rearrangement to form the observed six-membered 
pyridone ring of tenellin (1) (Chapter 1, section 1.4). This hypothesis, 
however, cannot be invoked to explain the origins of leporin-A (7). An 
alternative mechanism could rely on the generation a radical at the benzylic 
position of the tetramic acid, followed by ring closure of the homo-allylic 
system to form a fused cyclopropane. Homolytic bond fission and the 
abstraction of hydrogen would furnish the pyridone system. The radicals 
involved in this scenario are stabilised species. 
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0 
!-He +20 HO 
tenellin (1) 
Fig. 3.231. Possible radical rearrangement of a benzyl tetramic acid to afford 
tenellin (1). 
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Chapter4e 
The determination of the absolute 
configuration of tenellin. 
4.1 The determination of the absolute configuration of tenellin. 
4.2 Discussion. 
4.3 References. 
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4.1 The determination of the absolute confisuration of tenellin (1). 
Tenellin (1) possesses a single chiral centre at C-12 of the polyketide sidechain. 
Although the specific optical rotation of pure tenellin is known to be -44 ° (1% in 
acetone)l, the absolute configuration at this position has not been determined. 
Two total syntheses of tenellin (1) have been achieved2,3, but both were 
racemic. We therefore set out to determine the absolute configuration of tenellin 
(1) by a degradative procedure. 
HO 
! teneUin (1) 
0 
acetate (77) HO~ethylbutyrate (108) 
0 
HO~ 
(108) 
diastereomeric complex 
Fig. 4.101. Method for determining the absolute configuration of tenellin. 
Crude tenellin (1), freshly obtained from approximately 1.5 litres of B. 
bassiana culture, was subjected to catalytic ruthenium tetroxide oxidation4 
using the improved method of Sharplesss. After three days of reaction when all 
colour had subsided, the free carboxylic acids were obtained as a mixture of 
their sodium salts. Acidification and lyophillisation afforded an aqueous 
solution containing only acetate <m and 2-methylbutyrate (108) by 1 H and 13c 
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nmr analysis. These acids were obtained as their sodium salts by freeze drying 
after the aqueous solution had been adjusted to pHS with dilute NaOH. 
The salts were treated with gaseous HO under COCl3 and the resultant 
solution was used directly for nmr assay of the absolute stereochemistry of the 
2-methylbutyrate (108). The method used was that of Parker6 and is a direct 
way of determining the enantiomeric purity of a-substituted carboxylic acids, 
relying on the observation that~chemical shift non-equivalence of the protons of 
chiral carboxylic acids can be induced when a diastereomeric salt complex is 
formed in situ. Thus the carboxylic add solution obtained above was treated 
with (RR)-(-)-1,2-diphenyldiaminoethane (76), and the 1H nmr spectrum 
compared with standard spectra of solutions containing the chiral diamine and 
(RS)- and (S)-2-methylbutyric acids respectively (Fig. 4.102). 
The 400MHz 1 H nmr spectrum of (RS)-2-methylbutyric acid complexed 
with (RR)-(-)-1,2-diphenyldiaminoethane (76) in CDCl3 (Fig. 4.102) showed a 
doubling of each proton resonance. The signals were most clearly resolved for 
the C-5 methyl protons, each enantiomer showing resolved doublets, however 
double resonances were also observed for other protons. The addition of (S)-
( + )-2-methylbutyric add increased the intensity of the upfield doublet. Thus the 
upfield doublet belongs to the 5-methyl resonance of 5-(+)-2-methylbutyric 
acid, whilst the downfield doublet belongs to (R)-(-)-2-methylbutyric add. 
The 2-methylbutyric add obtained after the oxidation of tenellin (1) was 
similarly complexed with (RR)-(-)-1,2-diphenyldiaminoethane (76) and its 
400MHz 1H nmr spectrum obtained (Fig. 4.103). The 5-methyl resonance was a 
single clean doublet, consistent with a single enantiomer (clearly no 
racemisation occurred during the oxidation process). The addition of a small 
amount of commercial racemic (RS)-2-methylbutyric add resulted in the 
appearance of a new doublet upfield of that originally observed. The upfield 
doublet was previously assigned to (S)-(+)-2-methylbutyric acid and so the 2-
methylbutyric acid obtained by the oxidation of tenellin (1) showed exclusively 
the R-configuration. Tenellin (1) obtained fro~ B. bassiana is therefore. (R)-(-)-3-
(E,E -4,6-dimethylocta-2,4-dienoyl)-1,4,-dihydroxy-5-(p -hydroxyphenyl)-2(1H)-
pyridone (1a). 
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Fig. 4.102. Methyl region of 400MHz1H nmr spectra of 2-methylbutyrates 
complexed with (76). (a) (RS)-2-methylbutyric acid + (76), 
(b) 75% (S) + 25% (R) 2-methylbutyric acid + (76) 
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Fig. 4.103. Methyl region of 400MHz 1 H nmr spectra of 2-methylbutyrate, isolated 
from tenellin oxidation, complexed with (76). 
(a) 2-methylbutyric acid from tenellin + (76) (contaminated with ether), 
(b) as (a) + (RS)-2-methylbutyric acid. 
HO 
Fig. 4.104. The absolute configuration of tenellin (1a). 
4.2 Discussion. 
The R-configuration of tenellin (1) matches similar configurations of methylated 
positions in the other 2-pyridones funiculosin (5) and ilidcolin-H (6). 
HO 
funiculosin (5) 
N 
I 
H 
ilidcolin-H (6) 
) 
Fig. 4.201. Metabolites containing R-methylated centres. 
The generation of R-configuration at methylated centres is not a general 
feature of fungal PKS systems, many metabolites are known to posess the (S) 
configuration. Notably, the Penicillium sclerotiorum metabolites7, (+)and(-)-
sclerotiorin (70a,b) possess a structurally identical triketide segment, differing 
from tenellin (1) only by virtue of the (S) configuration at the chiral centreS. The 
polyketide derived 2-methylbutyryl residue of mevinolin (69)9 (Aspergillus 
terreus) also possesses the (S)-configuration, as does altemaric acid (71)10, a 
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metabolite of the potato blight causing fungus Alternaria solani, and the acyl 
moiety of lunatoic acid-A (72)11 (Cochliobolus lunata). 
HO 
........ 
\, .. 
mevinolin (69) 
0 
Cl 
(-) sclerotiorin (70a) 
OH 0 
alternaric add (71) 
0 
-: . ~ ~o\ 
0 0 
lunatoic add-A (72) 
OH 
-
-. . 
0 
. 
0 
. 
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-
-
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Fig. 4.202. Metabolites containing 5-methylated centres. 
Making the assumption that methylations of the fungal polyketides occur 
at the ~-keto stage, as seems likely (Chapter 2, section 2.52), then the chirality 
will be generated at the methylated centre by the action of an enoyl reductase 
(ER) activity of the PKS. The formation of an (R)-stereocentre is consistent with 
presentation of hydrogen to the Si -face of the a-carbon of the methyl-enoyl 
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intermediate (Fig. 4.203), whilst presentation of hydrogen to theRe face of the 
a-carbon will generate a methylated centre with the opposite configuration. 
The lack of stereochemical consistency in different fungal metabolites is 
evidence of variation of the various fungal enoyl reductases and reflects the 
situation for FAS where the selectivity of the enoyl reductases also varies 
between organisms. In fact all four possible stereochemical combinations of 
hydrogen addition to the enoyl double bond have been identified in different 
systems (chapter 2, section 2.2). 
H 
' o Si: 
ACPS~--ER----1~ 
CH3 
methyl enoyl ACP 
0 ACPSY 
H..._/CH3 
Re 
methyl enoyl ACP 
ER 
0 
ACPSJL .• ;"" 
, ~'H '-
CH3 
(R)-2-methylbutyryl ACP 
0 
ACPS Jl .. ;"" 
, ~'CH~ 
H 
(S)-2-methylbutyryl ACP 
Fig. 4.203. Presentation of hydrogen to opposite faces of the a-methyl-enoyl 
ACP generates opposite absolute configurations at methylated centres. 
Several investigations of fungal PKS enoyl reductases have been carried 
out, utilising the non-methylated fungal polyketides cladosporin12 
(Cladosporium cladosporoides), dehydrocurvularin13 (Alternaria cinerariae), 
antibiotic A-26771B (Penicillium turbatum) and brefeldin-A14 (Penicillium 
brefeldianum). These studies have only probed the stereospecificity at the a-
carbon by determining the final location of deuterium from [2-13c, 2-2H3]-
acetate. In the four cases examined to-date the enoyl system is reduced by 
presentation of hydrogen to the Re face at the a-carbon as evinced by 
deuterium occupying the 2-pro-S position of the growing chain in all cases. 
Interestingly FAS from the same organisms processed the enoyl systems with 
the opposite absolute configuration, generating fatty acids where deuterium 
was incorporated into the 2-pro -R positions of the growing chaint2,t3,t4. 
Oearly the stereochemical course of the enoyl reductases generating the 
chiral centre of tenellin (1) and the other R-methylated metabolites, is opposite 
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to that observed for these non-methylated systems. In contrast the enoyl 
reductase activities which generate the 5-methylated positions of altemaric acid 
(71) and sclerotiorin (70), for example, have the same stereochemical course to 
those of the non methylated systems. In the case ofF AS all four possible modes 
of hydrogen addition (Re-Re, 1{e-5i, Si-Si and Si-Re) to the double bond have 
been discovered (chapter 2, section 22). For the fungal secondary metabolites, 
however, the lack of information concerning the stereospecificity of the various 
enoyl reductases at the f3-position precludes any deeper comparisons. It will be 
interesting to compare the modes of reduction of methylated and unmethylated 
enoyl systems by enoyl reductases within the same PI<S, this could be done for 
instance in the cases of leporin-A (7) and ilicicolin-H (6) (chapterl, section 1.1), 
where methylated centres are present toge.~her with acetate C-2 derived 
methylene groups. 
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Chapter 5. 
The synthesis of isotopically labelled 
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5.01 The synthesis of 3-amino-2-phenylpropionic acids (104a, b, d. 
OCH3 
~- • v-~ CN CN .. (i) (ii) 
100 101 102 
l(iii~ 
• 
a 12c 
b t3c 
c t4c 
104 103 
(i) KCN, 18-Crown-6, 18h, RT. (ii) tBuLi, C02, CH2N2. (iii)Hz, PtOz, 
EtOH/CHCl3. (iv) KOH, DOWEX. 
Scheme 5.01. The synthesis of 3-amino-2-phenylpropionic acid (104). 
Potassium cyanide, labelled as either [1-13c] or [1-14c], was chosen as a 
convenient source of a carbon labelled C-N unit. The reaction of benzyl chloride 
(100) with one equivalent of potassium [1-13c] or [1-14c] cyanide proceeded 
smoothly in acetonitrile at room temperature, when a catalytic amount of the 
phase transfer agent 18-crown-6 was used, to produce [1-13c] or [1-14c] benzyl 
cyanide (101a,b) in quantitative yield. The reaction was significantly slower, 
and in fact did not run to completion even under prolonged reflux conditions, 
when benzyl bromide was utilised as the alkylating agent. These findings are in 
agreement with Liotta et al. who showed a reversal of the normally accepted 
order of reactivities for primary alkyl halides to nucleophilic displacement 
under similar conditions!. It was also observed that the specific activity of 14c 
labelled 3-amino-2-phenylpropionic acid (104c) obtained via this route was 16% 
less than that of the [14c]-KCN used as a starting material, this fact can be 
explained if a low level of cyanide exchange occurs between the solvent and the 
labelled reagent. 
Benzyl cyanide (lOla-c) was carboxylated in moderate yield by treatment 
with one equivalent of !butyl lithium, followed by quenching with a suspension 
of solid carbon dioxide in diethyl ether. The carboxylate formed could be 
isolated as either the lithium salt or the free carboxylic acid, but was usually 
acidified and treated with an excess of an ethereal solution of diazomethane2, in 
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situ, to afford methyl cyanophenylacetate (102a-c) directly. Methylation was 
performed for two reasons, firstly to prevent the slow decomposition of 
phenylcyanoacetic acid back to carbon dioxide and benzyl cyanide, and also to 
protect the carboxylate group in order to prevent side reactions and salt 
formation in the next synthetic step. 
Catalytic hydrogenation3 was found to be the preferred method for 
converting the nitrile to an amine functionality, it being superior to the use of 
borane reagents (i.e. diborane4 and trifluoroacetoxy borohydrideS) in respect of 
convenience and yield. Methyl phenylcyanoacetate (102a-c) was hydrogenated 
under an atmosphere of hydrogen (3atm) using Adam's catalyst (Pt02) in 
ethanol. The addition of 10% chloroform to the reaction solvent conveniently 
ensured the in situ formation of the amine hydrochloride salt (103), and 
prevented side reactions between the formed amine and reaction intermediates. 
After the catalyst was removed by filtration, methyl 3-amino-2-
phenylpropionate hydrochloride (103a-c) was furnished, by evaporation of 
solvent, as a pure white crystalline solid, in excellent yield. Recovered catalyst 
was found to be equally active in further hydrogenations. The use of 
concentrated aqueous HCl as an in situ amine trap was also investigated, but 
catalysis of trans-esterification between the substrate and the reaction solvent, 
and generally poor yields of mixed ester products meant that chloroform was 
preferred in this rOle. 
Basic ester hydrolysis of the amine hydrochloride salt, followed by ion 
exchange chromatography, utilising Dowex SOX-8 resin, afforded the labelled 
amino acids (104a-c) in good yield as amorphous cream solids. One 
crystallisation from ethanol/water yielded [3-13c] and [3-14C] 3-amino-2-
phenylpropionic acids (104b,c) as pure white crystals. 
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5.02 The synthesis of £unctionalised 2-methylbutyrates 
(109-112a, b, c;, d). 
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(vi) C02, H30+. (vii) Mg. 
Scheme 5.02. The synthesis of functionalised 2-methylbutyrates (109-112). 
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At the outset Grignard methodology was used to access labelled 2-
methylbutyrates (108a,b). It was envisaged that [13c]-carbon dioxide, 
generated by the action of concentrated acid on [13c]-barium carbonate, would 
provide the source of label. 2-Butyl magnesium bromide was generated from 2-
bromobutane (142) and reacted with an ethereal suspension of solid carbon 
dioxide. Acidification afforded 2-methylbutyric acid (108a) in low yield. The 
route was rejected due to the large excess of carbon dioxide, the source of 
isotopic label, required. Additionally it was found that the introduction of 
deuterium at the 2-position into 2-methylbutyric acid (108a) was not 
straightforward using this route. Esterification followed by base treatment, 
D20 quench, and ester hydrolysis was not an efficient process, and the method 
of Atkinson et al. 6 involving five 24hr cycles of high pressure treatments in 
D20 at 180°C was also potentially low yielding. 
In an alternative, and ultimately more successful, strategy the required 
acids were generated by the decarboxylation of functionalised malonates7. 
Diethyl ethylmalonate (105) was alkylated by treatment with one equivalent of 
sodium hydride and one equivalent of appropriately labelled methyl iodide to 
afford labelled diethyl2-ethyl-2-methylmalonates (106a,c,d) in high yield. Basic 
ester hydrolysis gave 2-ethyl-2-methylmalonic acids (107a,c,d) in good yield. 
Decarboxylation of the malonic acids was achieved, again in near quantitative 
yield, by heating aqueous solutions of the labelled acids to 180°C for 3hr in an 
evacuated Carius tube. High (>95%, as evinced by observation of a and P shifts 
in 13c nmr spectra) deuterium incorporations at the a-position of the formed 
2-methylbutyric acids (108b,c) could be achieved by carrying out the 
decarboxylation reactions in D20. 
Thiolesterification and esterification of the 2-methylbutyric acids was 
achieved using DCC coupling methodology8,9. N-propionylcysteamine 
thiolesters were formed by the reaction of one equivalent of acid (108a-d), two 
equivalents of thiol (122), and one equivalent each of DCC 
(dicyclohexylcarbodiimide) and DMAP (4-dimethylaminopyridine) in diethyl 
ether at room temperature overnight. The thiolesters were purified and 
obtained in good yield by flash chromatography eluting with ether. The 
materials were stable when stored at OOC under N2, but decomposed somewhat 
in air. The octyl ester (112d) and thiolester (111d) were prepared in a similar 
fashion. The octyl-thiolester (111d) was seperable from 1-octane thiol by flash 
chromatography eluting with methylene dichloride:hexane/25:75, but the 
octyl-ester (112d) was not separable from octanol, and a mixture of the two 
compounds was isolated. Sodium [5-methyf-13c2HJ]-2-methylbutyrate (109d) 
was prepared by the combination and base hydrolysis of various [5-methyl 
_13c2H3]-2-methylbutyrates (llOd, 111d, 112d) obtained from fermentation 
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broths of B. bassiana at the end of unsuccessful feeding experiments. 
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5.03 The synthesis of methylmalonate (115) and isobutyrate (118). 
~ii) 
0 t 0 
NaO)l')lONa 
115 I 
(i) NaH, Mel. (ii) NaOH. (iii) 2NaH, 2Mel. (iv) NaOH, HJO+. (v) ll, NaOH. 
Scheme 5.03. The synthesis of sodium methylmalonate (115) 
and sodium isobutyrate (118). 
The alkylation of diethyl malonate was exploited in the synthesis of both 
disodium [methyi-13c]-methylmalonate (115) and sodium [3,3'-13C2]-
isobutyrate (118). Diethyl [methyl _t3c]-methylmalonate was synthesised by 
adding a small excess of diethylmalonate to one equivalent of sodium hydride, 
before the addition of one equivalent of [13c]-methyliodide. Heating under 
reflux afforded the singly methylated diethyl [3-methyl .13c]-methylmalonate 
(114) in high yield, which. was hydrolysed in aqueous base to furnish sodium 
[3-13C]-methylmalonate (115). 
Similar methodology was employed in the synthesis of sodium [3,3'-
13C2]-isobutyrate. One equivalent of diethylmalonate (113) was treated with 
three eqivalents of sodium hydride, and two eqivalents of [13c]-methyl iodide, 
and heated under reflux to afford diethyl [3,3'-13C2]-2,2-dimethylmalonate 
(116) in good yield. Aqueous base hydrolysis afforded [3,3'-13C2]-2,2-
dimethylmalonic acid (117) in near quantitative yield, and decarboxylation by 
heat treatment at elevated pressure for 3 hours gave [3,3'-13c2]-isobutyric acid, 
which was purified by lyophillisation and isolated in high yield as its sodium 
salt (118), after neutralisation. 
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5.04 The synthesis of N-propionylcysteamine (122). 
H 
~N~SH 
0 122 
(i) CH3CH2COC1, KOH. (ii) Na/Hg 3%, RT 90min, H+. 
Scheme 5.04, The synthesis of N-propionylcysteamine (122). 
Acylation of cystamine dihydrochloride (120) was achieved in high yield by the 
treatment of the free amine in aqueous basic solution with two equivalents of 
propionyl chloride to afford N,N'-dipropionylcystamine (121). The dipropionyl 
compound was a much more tractable material than the diacetyl analogue, 
which was insoluble in most solvents and only poorly soluble in methanol. 
Reduction of the disulfide bond of (121) could be performed by two 
methods. Reaction with finely divided zinc in refluxing methanolic 
tetrahydofuran afforded N-propionylcysteamine (122) after 18 hours in good 
yield, but reaction with 3% sodium amalgam (119)10, in methanol at room 
temperature, afforded the same compound in high yield after 90min, and was 
the preferred method. The free thiol (122) was prepared immediately prior to 
use, from the more stable disulfide (121), as significant degradation of the thiol 
(122) was observed over the period of several hours under ordinary conditions. 
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5.05 The synthesis of N-propionylcysteamyl thiolesters of L: 
phenylalanine and 3-amino-2-pbenylpropionic acid. 
0 
104 
0 
128 
a unlabelled. 
b [UL.l4C] -phenylalanine. 
(i) CBZCl, NaOH. (ii) (122), OCC, DMAP. (iii) BB1'3, H30+. 
Scheme 5.05. The synthesis of N-propionylcysteamyl thiolesters of 
L-phenylalanine (125) and 3-amino-2-phenylpropionic add (128). 
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The synthesis of the N-propionylcysteamine thiolester of 3-amino-2-
phenylpropionic acid (128) was initially attempted by a modification of the 
synthetic route leading to the amino add (104) itself. Thus benzyl cyanide (101), 
generated from benzyl chloride (100), was carboxylated to afford 
phenylcyanoacetic acid. Attempted coupling of this acid with N-
propionylcysteamine (122) using DCC coupling methodology was 
unsuccessful. The addition of DCC to an ethereal solution of phenylcyanoacetic 
acid led to rapid decarboxylation, as evinced by effervescence, and the 
formation of benzyl cyanide (101) in quantitative yield (see fig 5.051. for 
proposed mechanism). 
+ 
cyanophenylacetate . 
DCC 
R: --o 
VCN 
benzyl cyanide (100). 
Fig. 5.051. Proposed mechanism for the decarboxylation 
of cyanophenylacetate by DCC. 
The inability to synthesise this key intermediate led to the consideration of 
a second strategy based on the formation of the thiolester by reaction with the 
amino acid itself. Because of the insolubility of the amino acid in ether, and the 
possibility of oligormerisations of the amino acid under coupling conditions, an 
N-protection/deprotection protocol was devised. In order to circumvent the 
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synthesis of 3-amino-2-phenylpropionic acid (104) in bulk from scratch, the 
reaction sequence was developed using commercially available L-
phenylalanine and [UL-14c]-L-phenylalanine, and applied to generate the 
target molecule after optimisation. 
Thus L-phenylalanine (99), [UL-14c]-L-phenylalanine (99) and 3-amino-2-
phenylpropionic acid (104) were protected with the benzyloxycarbonyl (CBZ) 
group, in high yields, by reaction with a small excess of benzyloxycarbonyl 
chloride (CBZCI) in dilute aqueous basell. CBZ was chosen as the protecting 
group because of its ease of removal under neutral hydrogenolysis conditions. 
TheN-protected amino acids were then successfully converted to their N-
propionylcysteamine thiolesters (124a, 124b, 127), in good yields, by treatment 
with an excess of N-propionylcysteamine (122) and one equivalent each of DCC 
and DMAP in ether at room temperature overnight. TheN-protected amino 
acid thiolesters were purified by flash chromatography over silica eluting with 
acetonitrile. 
Deprotection of the amine proved to be a more formidable task than was 
originally hoped. Three hydrogenolysis methods were attempted. The standard 
methodll of benzyloxycarbonyl cleavage under hydrogen (3atm), utilising 10% 
palladium on charcoal as a catalyst, failed to remove the protecting group even 
on prolonged reaction time and increased catalyst concentration. 
Two methods of transfer hydrogenolysis were also investigated. Firstly 
the method of Felix12, utilising palladium on charcoal as the catalyst and 1,4 
cyclohexadiene as the hydrogen source in ethanol, was attempted at varying 
diene and catalyst concentrations. Secondly the use of formic acid as the 
hydrogen source was assessed13. Neither protocol resulted in even partial 
deprotection of the amine group. The three hydrogenolysis methods were also 
tried utilising platinum dioxide (Adam's catalyst) but without success. Acid 
promoted cleavage with concentrated aqueous HC114 or trifluoroaceticlS acid in 
organic solvents was similarly unsuccessful. 
Benzyloxycarbonyl cleavage was finally achieved by using a solution of 
boron tribromide in dichloromethane16. Thus solutions of the protected amino 
acid thiolesters (124a, 124b, 127) were treated with five equivalents of boron 
tribromide, giving rise to a yellow solid precipitate. After the addition of water 
to the reaction mixture, breaking up this solid with effervescence, the aqueous 
solution contained the hydrobromide salt of the aminoacid thiol ester, whilst 
the organic layer contained benzyl bromide. The free amine was isolated after 
basification of the aqueous solution and extraction into organic solvent. 
Prolonged standing of a chloroform solution containing the free amine 
thiolester resulted in the precipitation of a white insoluble material, presumably 
an oligomer or polymer of the amino acid. The amino acid thiolesters were 
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therefore isolated as their hydrochloride salts (125a, 125b, 128), materials which 
were stable to storage and which had the added advantage of being water 
soluble. 
-135-
5.06 The synthesis of short-chain acyl tetramic acids (131a, b). 
R 
R=OH98a 
R=H 99a 
R 
130 
GJ H H R 
0 
OMe 
HNYY 
0 0 
(ii) 
OH 
0 
(i) Acetone diketene adduct (129), toluene, !1. (ii) NaOMe/MeOH. 
Scheme 5.06. The synthesis of acyl tetramic acids (131a,b). 
L-Phenylalanine (99a) and L-tyrosine (98a) methyl esters were conveniently 
acetoacetylated by heating a toluene solution of the amino ester with one 
equivalent of the masked diketene (129) at reflux temperature. Heat treatment 
above lOO"C decomposes the acetone diketene adduct (129) to afford diketene 
in situ, which rapidly reacts with the amine nucleophile17. Acetone was 
observed as a gaseous by-product. This procedure conveniantly obviates the 
need to use the toxic diketene itself which has been used18 in the past to 
generate similar compounds. A high yield of the phenylalanine methyl ester J3-
ketoamide (130a) was obtained after purification by flash chromatography. The 
tyrosine methyl ester analogue (130b) was not so easily purified and was used 
in crude form. 
Dieckmann cydisations were effected by heating a methanolic solution of 
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the amino ester amides (130a,b) with a small excess of sodium methoxide for 
two hours under reflux. A moderate yield of 5(5)-3-acetyl-5-benzyl-2,4-
dioxopyrrolidine (131a) was obtained after recrystallisation. Much poorer 
yields of 3-acetyl-5-(p-hydroxybenzyl)-2,4-dioxopyrrolidine (131b) were 
obtained after recrystallisation, this was probably due to competing 0-
acetoacetylation in the first step of the synthetic sequence. 
The benzyl substituted acyl tetramic acid (131a) was observed to retain 
stereochemical integrity at C-5, whereas the p -hydroxybenzyl analogue (131b) 
was obtained in racemic form. This centre is evidently more susceptible to 
epimerisation under the basic ring closing conditions. Epimerisation at this 
position has been previously reported and is a general feature of base promoted 
ring closure in these systems19, 
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5.07 The synthesis of 2,4-dimethylhex-2-enal (134). 
(i) 
132 0 l~ T 133~ 
134 
(i) Buu, -7s·c. (ii) (133), -7s· c to o·c, H30+. 
Scheme 5.07. The synthesis of E-2,4-dimethylhex-2-enal (134). 
The directed aldol condensation method of Wittig20 was used to synthesise the 
E-unsaturated aldehyde (134). The condensation between lbutylamine and 
propionaldehyde afforded (1,1-dimethyl-N-propylidene)ethylamine (132)21 
after separation of the reaction mixture by standing over potassium hydroxide 
pellets at o·c overnight. The crude material had to be distilled three times from 
potassium hydroxide before pure, dry imine could be obtained. The compound 
was unstable over a matter of weeks when stored at O"C under dry nitrogen, 
and was routinely distilled from potassium hydroxide under dry nitrogen prior 
to use. 
Treatment of the imine (132) with butyllithium at -7s·c afforded the 
lithiated species which was condensed with one equivalent of freshly distilled 
2-methylbutyraldehyde (133). The lithiated imino alcohol thus formed was 
decomposed to E-2,4-dimethyl-hex-2-enal (134)22 by treatment with an excess of 
an aqueous slurrey of oxalic acid. The aldehyde was unstable, and did not store 
for more than a few days at -2o·c, it was therefore prepared and purified, by 
flash chromatography, immediately prior to usage. 
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5.08 The synthesis of an acyl tetramic acid analogue of tenellin (1). 
0 
(i) 
0 
(iii)~ 
137 
(iv) 
(i) LOA, -78"C, C2Cl6,-SO·c (ii) (Et0)2P(O)-, H30+. (iii) LHMDS, (134). 
(iv) (98), toluene, fl. (v) tsuo-, tsuOH. 
Scheme 5.08. The synthesis of tenellin tetramic add analogue (139). 
The protocol developed for the synthesis of the short-chain acyl tetramic adds 
discussed above was modified in order to be able to synthesise the putative 
tetramic add (139) intermediate in tenellin (1) biosynthesis. 
Treatment of freshly distilled acetone-diketene adduct (129) with one 
equivalent of LOA at -78 ·c yielded the lithiated species as a yellow suspension 
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in THF. This material could be chlorinated23 in high yield if the suspension, 
cooled to -78 ·c, was added dropwise to a solution of hexachloroethane in 
tetrahydrofuran, maintained at -5o·c. When addition was complete the 
hexachloroethane solution was allowed to warm to -2o·c. Quenching of the 
reaction mixture with ice-cold dilute hydrochloric acid and extraction into the 
organic phase led to the isolation of 2,2-dimethyl-6-chloromethyl-1,3-dioxin-4-
one (135). Poorer yields were obtained if the hexachloroethane solution was 
added to the solution of the lithiated 2,2,6-trimethyl-1,3-dioxin-4-one. The 
chlorinated acetone-diketene adduct (135) could be purified by flash 
chromatography, but was routinely adequately purified by trituration with 
hexane, to remove excess hexachloroethane prior to the formation of 
phosphonate (136). 
Preparation of the Wadsworth-Emmons reagent (136) proceeded smoothly 
when the chlorinated acetone-diketene adduct (135) was treated with a solution 
of potassium diethylphosphite in dimethylformamide. Acidification of the 
reaction solution and removal of excess solvent, and diethylphosphite, by 
distillation under diminished pressure afforded 2,2-dimethyl-6-
(diethylphosphonomethyl)-1,3-dioxin-4-one (136) in good yield. The crude 
material was conveniently stored at O"C and purified by flash chromatography 
immediately prior to use. 
Wittig olefination of the purified phosphonate to form the all E triene 
(137) proceeded in moderate yield24. The phosphonate (136) was treated with 1 
equivalent of lithium hexamethyldisilazide (UIMDS), forming the anion as a 
deep blood red solution in tetrahydrofuran at 0 ·c. The addition of one 
equivalent of freshly prepared and purified 2,4-dimethylhex-2-enal (134), at 
-78"C, afforded the key intermediate, triene (137), after purification by flash 
chromatography. LHMDS25 was found to be a more effective base for this 
reaction than either LOA or butyllithium. Sodium hydride gave very poor 
yields of triene (137) as the reflux temperatures required for full deprotonation 
of the phosphonate presumably caused significant decomposition of the 
protected diketene moiety. 
In one experiment where the triene (137), was purified using activated 
silica the decarboxylation product (140) was isolated. Apart from this one 
instance, the triene (137) was found to be stable to storage under nitrogen at 
o·c. 
Treatment of unlabelled L-phenylalanine or [1.13C]-DL-phenylalanine 
methyl esters (99a) with one equivalent of the protected ketene (137) in 
refluxing toluene afforded the corresponding P-keto amides (138a,b) after 
purification by flash chromatography in high yield. Treatment of these amides 
with sodium methoxide in methanol resulted in large-scale decomposition, 
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affording the methyl ester of phenylalanine as the only identifiable by-product. 
Deickmann cyclisation was achieved by utilising freshly sublimed potassium 
lbutoxide as the base in lbutanol as the solvent26. The highly polar acyl tetramic 
add was an orange waxy oil which could not be purified by chromatography 
over silica or by recrystallisation. The recovered material was not fully 
characterised due to this difficulty in purification (similarly poor 
characterisations of acy tetramic adds have been reported in the literature, 
however25,26), The recovered material was shown to be free from amide starting 
material, and more importantly free from phenylalanine, by 13c nmr and mass 
spectroscopy. The material was thus confidently used in a feeding experiment 
with B. bassiana. 
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5.09 The synthesis of phenylalanine methyl ester (99a). 
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(i)KCN, NH4Cl. (ii) 1-130+, ll. (iii) MeOH, SOC12. 
Scheme 5.09. The synthesis of t-13c labelled DL-phenylalanine (97). 
0 
OMe 
The synthesis of [t-13c]-DL-phenylalanine was achieved by Strecker 
methodology27. Phenylacetaldehyde was treated with [12c] or [13c] potassium 
cyanide and ammonium chloride in aqueous methanol to afford [1-12c] or [1-
13C] 2-amino-3-phenylpropionitrile hydrochlorides. The nitriles were 
hydrolysed in refluxing concentrated aqueous hydrochloric acid to afford [1-
12c] and [t-13c]-DL-phenylalanine hydrochlorides (99) in good yield after 
48hr. The amino acids were methylated, again in high yields, by treatment with 
a methanolic solution of an excess of thionyl chloride28, to form [t-12c]- and [1-
13c]-DL-phenylalanine methyl esters (99a) after basification with sodium 
bicarbonate solution. The free amines polymerised slowly on standing, and 
were usually prepared immediately prior to use. 
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5.10 The synthesis of N-propionylcysteamine thiolester of 
2.4 dimethylhex-2-enoate (150). 
• 
0 
a llc. 
b t3c. HO 
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Scheme 5.10. The synthesis of NAC thiolester of E-2,4-dimethylhex-2-enoate. 
[t-12c]- And [t-13c] propionic acids (142a,b) were a-brominated by a 
modification of the method of Ropp29, in quantitative yield by the treatment of 
the acids, activated to the trifluoroacetic mixed anhydrides, with bromine in the 
presence of red phosphorus. Methylation of the a-bromoacids by either 
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ethereal diazomethane2 or by reflux in acidic methanol afforded the methyl 
esters (144a,b) in low yield. The ethyl esters of (1.12c] and [J-13c] a-
bromopropionic acids (145a,b) were prepared by reflux in acidic ethanol in 
moderate yields. The N-propionylcysteamine thiolester (146a) was prepared in 
high yield by the treatment of a-bromopropionic acid (143a) with one 
equivalent of N-propionylcysteamine (122) and one equivalent each of DCC 
and DMAP in ether. 
The N-propionylcysteamine thiolester (146) could not be converted to the 
triphenylphosphonium bromide by treatment with one equivalent of 
triphenylphosphine in either refluxing toluene or acetonitrile. Further attempts 
using Arbusov conditions30, with triethylphosphite under reflux, also failed to 
provide the Wadsworth- Emmons reagent. 
The triphenylphosphonium bromide salts (147a,b) of ethyl 2-
bromopropionates (145a,b) were formed in good yields by the treatment of 
either ethyl [1-12c] or [1.13C]-2-bromopropionate (145a,b) with one equivalent 
of triphenylphosphine in refluxing acetonitrile31. 
The triphenylphosphonium bromide salts were converted to the 
phosphorus ylides32 by treatment with one equivalent of triethylamine in 
refluxing methylene dichloride, and Wittig olefination33 was achieved in situ 
by the reaction of the ylides with two equivalents of 2-methylbutyraldehyde 
(133). The formed ethyl [1.13c]-2,4-dimethylhex-2-enoate was shown to possess 
theE configuration exclusively, by measurement of the 13c.13c coupling 
constant (5.6Hz) between C-1 and the methine carbon position34. In Z olefins 
this coupling is of the order 1-2Hz, in E olefins it is approximately 7Hz. This 
conclusion was further bolstered by the results from two NOE experiments 
which showed that the alkenic methyl group was closer to the methine attached 
methyl group than to the alkenic hydrogen, and that the methine hydrogen was 
judged to be relatively close to the alkenic methyl group (fig 5.11). 
The exclusive formation of the E-configuration contrasts with the results 
of Handa35 et al. who obtained a mixture of E (30%) and Z (70%) isomers of 
ethyl 2,4-dimethylhex-2-enoate (148) when the Wadsworth-Emmons reagent 
ethyl a-diethylphosphonopropionate was condensed with 2-
methylbutyraldehyde (133) during the synthesis of the ant pheremone 
Manicone. 
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Fig 5.11. Results of two NOE experiments showing peak enhancements 
observed when the indicated resonances were irradiated. 
[1-12c] And [1-13c] ethyl2,4-dimethylhe>c-2-enoates were hydrolysed to 
their corresponding acids by treatment with refluxing dilute aqueous base. The 
acids were then converted in good yields to their N-propionylcysteamyl 
thiolesters by DCC coupling with N-propionylcysteamine (122), with DMAP in 
ether. The compounds were purified by flash chromatography over silica 
eluting with ether. 
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Chapter 6 
Experimental. 
6.1 General. 
6.2 Experimental. 
6.3 References. 
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6.1 General. 
1H n.m.r. spectra were recorded on either a Varian Gemini 200 instrument 
operating at 199.975MHz, a Brucker AC 250 instrument operating at 250.13 
MHz or a Varian 400S instrument operating at 399.952 MHz. 13c n.m.r. 
spectra were recorded on a Varian Gemini 200 instrument operating at 50.3 
MHz or a Varian VXR 400S instrument operating at 100.577 MHz. Chemical 
shifts are quoted in ppm relative to TMS in CDCl3 and H20 in D20, to two 
decimal places for 1 H and one decimal place for 13c, all coupling constants 
are in Hz Ugem, Jvic and Jav refer to geminal, vicinal and averaged 
coupling where resolution is poor, respectively). IR spectra were recorded 
on Perkin Elmer 577 and 377 grating spectrophotometers, samples being 
embedded in a KBr disc for solids or neat between KBr plates for liquids. 
Mass spectra were obtained using a VG Analytical 7070E mass spectrometer 
operating at 70 eV in the indicated mode. Melting points were determined 
using a Gallenkamp melting point aparatus and are uncorrected. Specific 
optical rotations were measured using an Optical Activity AA-10 automatic 
polarimeter. A Beckman J2-21M/E centrifuge was used for all 
centrifugations. 
All solvents were distilled and dried before uset. Reagents and starting 
materials were used without prior purification unless otherwise indicated. 
Silica gel 60 (particle size 0.035-0.070mm, Brockmann activity 2-3) was used 
for all chomatographic separations under 'flash' chromatography 
conditions2. Commercial silica gel-60 coated plates, coated to a thickness of 
0.2mm and impregnated with fluorescent indicator (F-254), were used for 
t.l.c. analyses, using the solvent systems described, and samples were 
visualised by irradiation with ultra-violet light (254 nm) unless otherwise 
indicated. Specific activities for 14c compounds were obtained from 
samples dissolved in 'Ecoscint A' or Packard 'Ultima Gold' scintillation 
solutions using a Packard 2000CA liquid scintillation analyser. Physical and 
spectrometric properties of 14C-labelled compounds were identical to the 
unlabelled materials. Properties of 13c and 2H labelled compounds differed 
from the unlabelled compounds where indicated. 
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6.2 Experimental. 
Benzyl cyanide (lOla). 
To a solution of benzyl chloride (100) (distilled, b.p. 22-24°C, 0.005 mbar, 
1.94g, 15.3mmol) and 18-crown-6 (0.3g, 1.1 mmol) in acetonitrile (6ml) was 
added potassium cyanide (l.Og, 15.4mmol). After stirring for 18h at room 
temperature, methylene dichloride (50ml) was added, and the suspension 
filtered. Organic washings were washed with water (2x50ml), dried (MgS04), 
evaporated in vacuo, and distilled (b.p. 46°C, 0.1 mbar) to yield benzyl 
cyanide as a clear colourless oil (1.68g, 14.4mmol, 93.8%). 8H(CDC13) 7.30 
(5H, m), 3.66 (2H, s). Oc(CDC13) 23.0 (CH2), l17.7 (Ph), 127.5 (Ph), 126.7 (Ph), 
129.7 (Ph). VmaxOiq. film)/cm-1 3100, 3078, 3042, 2975, 2925, 2250, 1605, 1500, 
1456 and 1418. 
[t-l3C]-Benzyl cyanide (lOlb). 
K13CN (l.Og, 15.2mmol, 99 atom% 13C) was used to synthesize [1-13C]-
benzyl cyanide by the method described above for (lOla). (1.62g, 13.7mmol, 
90.3%). OH(CDC13) 7.30 (5H, m), 3.66 (2H, d, J10.0). 
[t-14c]-Benzyl cyanide (101c). 
14c-Labelled KCN (l.Og, 15.4 mmol) of specific activity 9.47JJ.Ci/mmol was 
used to make [1-14C]-benzyl cyanide (1.48g, 12.6 mmol, 83.7%) by the method 
described above for (lOla). 
Methyl phenylcyanoacetate (102a). 
A solution of benzyl cyanide (lOla) (1.68g, 14.4mmol) in tetrahydrofuran 
(20ml) was stirred under dry N2 and cooled to -78°C . tBuLi in pentane 
(1.7M, 10ml, 17mmol) was added via dry N2 flushed syringe and the yellow 
solution was stirred for Smin, then added to an excess of solid C02 in 
tetrahydrofuran (50ml). The white suspension thus formed was acidified 
with dilute aqueous H2S04 and extracted into methylene dichloride 
(3x50ml). The organic fractions were dried (MgS04) and treated with an 
excess of an ethereal solution of diazomethane. The solvent was removed 
by evaporation in vacuo and the oil distilled (bp 78-80°C, 0.08 mbar) to 
afford (102a) as a clear yellow oil (1.07g, 6.11mmol, 42.5%). 8H(CDC13) 7.37 
(5H, m), 4.78 (lH, s), 3.71 (3H, s). Vmax(liq. film)/cm-1 3080-3020, 2962, 2260, 
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1755, 1600, 1500, 1458 and 1438. 
[3-l3C]-Methyl phenylcyanoacetate (102b). 
[1-13c]-Benzyl cyanide (101b) (1.62g, 13.7mmol,) was used without further 
purification to prepare [3-13c]-methyl phenylcyanoacetate (102b) (0.92g, 
5.2mmol, 38.2%) by the method described above for (102a). 
[3-14c]-Methyl phenylcyanoacetate (102c). 
[1-14c]-Benzyl cyanide (101c) (1.48g, 12.6 mmol) was used without further 
purification to give [3-14c]-methyl phe~ylcyanoacetate (102c) (0.84g, 
4.8mmol, 38.1%) by the method described above for (102a). 
Methyl 3-amino-2-phenylpropionate hydrochloride (103a). 
A solution of methyl phenylcyanoacetate (102a) (1.07g, 6.11mmol), in 
ethanol (50ml) and chloroform (5ml) was shaken under 2.5 atm H2 with 
Pt02 (Adam's catalyst, 200mg) for 18 h. The catalyst was removed by 
filtration and the solvent evaporated in vacuo to afford a cream solid, 
which was washed with ethyl acetate, collected by filtration and air dried to 
afford methyl 3-amino-2-phenylpropionate hydrochloride (103a) (1.12g, 5.20 
mmol, 85.1 %) as a white crystalline solid . OH(D20) 7.34-7.22 (5H, m), 4.02 
(1H, t, Jav7.6), 3.59 (3H, s), 3.53 (1H, dd, Jvic7.2, Jgem13.2), 3.29 (1H, dd, 
Jvic7.2, Jgem13.2). Vmax(KBr disc)/cm-1 3450(br), 3300-2500 (br), 1734, 1605, 
1590,1495,1460,1440 and 1410. m/z(CD 180.18 (35.29%). 
Methyl [3-13C]-3-amino-2-phenylpropionate hydrochloride (103b). 
[3-13c]-Methyl phenylcyanoacetate (102b) (0.92g, 5.2mmol) prepared as above 
was used to afford methyl [3-13c]-3-amino-2-phenylpropionate 
hydrochloride (103b) (450mg, 2.08 mmol, 40.0%) by the method described for 
(103a). 
Methyl [3-14c]-3-amino-2-phenylpropionate hydrochloride (103c). 
Methyl [3-14c]-phenylcyanoacetate (102c) (0.84g, 4.8mmol) prepared as above 
was used to afford the methylated amino acid hydrochloride (103c) (900mg, 
4.18 mmol, 87.0%) by the method described for (103a). 
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3-Amino-2-phenylpropionic add (104a) 
A solution of methyl 3-amino-2-phenylpropionate hydrochloride (103a) 
(1.12g, 5.2 mmol) in aqueous potassium hydroxide (1.2M, 50ml) was stirred 
for 12h at RT. The solution was acidified to pH 7 and purified by ion 
exchange chromatography (DOWEX 50X8-200 resin). Aqueous washings 
containing the amino acid (ninhydrin test) were evaporated in vacuo to 
afford 3-amino-2-phenylpropionic acid (104a) as white crystals after 
recrystallisation from ethanol/water. (500mg, 3.03mmol, 58.3%). m.p. 223.7-
223.90C (ethanol/water, lit3., 222-224°C). 6H(D20) 2.99 (1H, dd, Jvict7.6, 
Jgem12.8), 3.19 (1H, dd, Jvic27.6, Jgem12.4), 3.56 (1H, t, Jav7.6), 7.26 (5H, m). 
O(:(D20) 40.9 (CH2), 48.4 (CH), 128.2 (Ph), 128.8 (2Ph), 129.5 (2Ph), 134.2 (Ph), 
174.5 (CO). Vmax(KBr disc)/cm-1 3420, 320Q-2400 (br), 2200, 166Q-1490 (br), 
1452 and 1400. m/z(CI) 166.23 (74.65%) (C9H11N02 requires C65.44%, 
N8.48%, H6.71 %, found: C65.05%, N8.33%, H7.02%). 
[3-13C]-3-Amino-2-phenylpropionic add (104b). 
Methyl [3-13c]-3-amino-2-phenylpropionate hydrochloride (103b) (450mg, 
2.08 mmol) prepared as above was used to generate [3-13C]-3-amino-2-
phenylpropionic acid (104b) (200mg, 1.2mmol, 57.7%). 6H(D20) 7.25 (5H, m), 
3.65 (1H, dt, Jav7.3, JH13c6.4), 3.32 (1H, ddd, Jvict7.3, Jgem12.8, JH13c145.7), 
3.14 (1H, ddd, Jvic27.3, Jgem12.8, JH13c145.7), 6c(D20) 42.3 (CH2, 99% 
enriched), 51.4 (CH, d, Jcc37Hz), 127.9 (Ph), 128.1 (2Ph), 129.2 (2Ph), 137.2 
(Ph), 178.3 (CO). m/z(O) 166.86 (46.33%). 
[3-14c]-3-amino-2-phenylpropionic acid (104c). 
[3-14c]-Methyl 3-amino-2-phenylpropionate hydrochloride (103c) (900mg, 
4.18 mmol) prepared as above was used to generate [3-14c]-3-amino-2-
phenylpropionic acid (104c) (475mg, 2.88 mmol, 68.9%), s.a. 7.97J.1.0/mmol. 
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Diethyl 2-ethyl-2-methylmalonate (106a). 
To a suspension of sodium hydride (940mg, 36 mmol) in tetrahydrofuran 
(20ml) was added diethyl ethylmalonate (105) (3.76g, 20mmol) and 
methyliodide (2.84g, 20mmol) at 0°C. The solution was heated under reflux 
for two hours, cooled to RT and quenched with ethanol (lOml). The clear 
brown solution was added to water (20ml) and extracted into methylene 
dichloride (2x25ml). The organic extracts were combined, dried (MgS04) and 
evaporated in vacuo to yield an orange oil. Diethyl 2-ethyl-2-
methylmalonate (106a) was distilled under vacuum as a clear pale orange 
oil (b.p. 26°C, 0.02 mbar, 2.21g, 10.9mmol, 54.7%). OH(CDC13) 0.83 (3H, t, J6.0), 
1.25 (6H, t, J7.0), 1.37 (3H, s), 1.90 (2H, q ,J6), 4.12 (4H, q, J7.0). oc(CDCL3) 8.6 
(CH3), 14.0 (2xCH3), 19.2 (CH3), 28.6 (CH2), 53.9 (C-2), 60.9 (2xCH2), 172.0 
(CO). Vmax(liq. film)/cm-1 2980,2935, 1738, 1465, 1380, and 1310. m/z (CI) 220 
(M+18, 26.4%), 203 (M+1, 100%). 
Diethyl [2-methyl .13C]-2-ethyl-2-methylmalonate (106c). 
Sodium hydride (1.44g, 60 mmol), diethyl ethylmalonate (105) (6.6g, 
35mmol) and [13C]-methyliodide (5.0g, 35mmol) were used to prepare 
diethyl [2-methyl _13c]-2-ethyl-2-methylmalonate (106c) by the method 
described above. The title compound was distilled under vacuum as a clear 
pale orange oil (b.p. 26°C, 0.02 mbar, 6.27g, 30.9mmol, 88.3%). 
Diethyl [2-methyl .13c2H31-2-ethyl-2-methylmalonate (106d). 
To sodium hydride (0.34g, 7mmol) in tetrahydrofuran (25ml) stirred at 0°C 
under dry N2 was added diethyl ethylmalonate (105) (1.32g, 7mmol) and 
[13c2H3]-methyliodide (lg, 6.85mmol). The suspension was heated to reflux 
for 2h and then quenched with ethanol (lOml) and water (50ml). The clear 
solution was extracted into methylene dichloride (4x50ml) and the organic 
layers combined, dried (MgS04) and evaporated in vacuo to yield the title 
compound as a pale yellow oil which was used without further purification 
(1.15g, 5.58mmol, 81.5%). OH(CDC13) 0.87 (3H, t, J7.52), 1.25 (6H, t, J7.14), 1.90 
(2H, m), 4.17 (4H, q, J7.16), 4.18 (2H, q, J7.12). oc(CDCL3) 8.7 (CH3), 14.1 
(2CH3), 18.6 (sep, Jco19.67, 13co3), 28.6 (CH2), 53.9 (d, J34.5, C-2), 61.0 (2CH2), 
172.2 (CO). VmaxOiq. film)/cm-1 2980, 2950, 2230, 1740, 1465, 1380, 1365 and 
1290. m/z (CI) 207.07 (100%). 
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2-Ethyl-2-methylmalonic acid (107a). 
A solution of diethyl 2-ethyl-2-methylmalonate (106a) (2.12g, 10.9mmol) in 
aqueous potassium hydroxide (12.5M, 10ml) was heated under reflux for 
24h. The cooled solution was acidified with dilute aqueous sulphuric acid 
and the white suspension formed was added to water (50ml) and extracted 
into diethyl ether (4x50ml). The ethereal solution was dried (MgS04) and 
evaporated in vacuo to afford brown crystals of (107a) which were washed 
with pentane and obtained by filtration as a beige solid (1.04g, 7.13 mmol, 
65.4%). BH(D20) 0.73 (3H, t, J6.0), 1.23 (3H, s), 2.73 (2H, q, J6.0). 
[2-methyl .13c]-2-Ethyl-2-methylmalonic acid (107c). 
Diethyl [2-methyl .13c]-2-ethyl-2-methylmalonate (106c) (6.27g, 30.9 mmol) 
was used to make (107c) by the method described for (107a) above, as brown 
crystals which were washed with pentane and obtained by filtration as a 
beige solid (3.15g, 21.4 mmol, 69.3%). BH(D20) 0.64 (3H, t, J7.8), 1.15 (3H, d, 
J132.5), 1.64 (2H, m). 
[2-methyz-13c2H31-2-Ethyl-2-methylmalonic acid (107d). 
A solution of diethyl [2-methyJ-13c2H3]-2-ethyl-2-methylmalonate (106d) 
(1.15g, 5.58mmol) in aqueous KOH (2M, 20ml), was heated under reflux for 
24h. The solution was acidified with dilute aqueous HCl and extracted into 
diethyl ether (5x50ml). The organic washings were combined, dried 
(MgS04) and evaporated in vacuo to afford the title compound as a white 
solid (600mg, 4.0mmol, 71.7%). BH(D20) 0.72 (3H, t, J7.56), 1.72 (2H, dq, 
Jvic7.54, JH13c4.3). Bc(D20) 10.9 (CH3), 21.1 (sep, J19.41, 13CD3), 57.0 (d, J34.4, 
C-2), 179.9 (CO). m/z (Cl) 168 (M+18, 75%), 106 (25%). 
[dimethyl .13C2]-2,2-Dimethylmalonic acid (117). 
To sodium hydride (432mg, 18mmol) in diethyl ether (50ml) stirred under 
dry N2 and cooled in an icebath was added a solution of diethyl malonate 
(113) (960mg, 6mmol) in diethyl ether (10ml) dropwise over 10 minutes. 
[13c]-Methyliodide (1.72g, 753~1, 12mmol) was added and the supension 
heated under reflux for 1h. Ethanol (10ml) was added, followed by water 
(50ml). The solution was extracted into diethyl ether (5x50ml) and the 
ethereal solution was dried (MgS04) and evaporated in vacuo to yield 
diethyl [dimethyl .13C2]-2,2dimethylmalonate (116) as a colourless oil (0.75g, 
D 155-
3.95mmol, 65.8%). 
A solution of diethyl [dimethyl .13C2]-2,2-dimethylmalonate (116) 
(0.75g, 3.95mmol) in aqueous sodium hydroxide (1M, 20ml) was heated 
under reflux for 24h. The solution was then acidified with dilute aqueous 
hydrochloric acid and extracted with diethyl ether (5x50ml). The ethereal 
solution was dried (MgS04) and evaporated in vacuo to afford the title 
compound as white crystals (500mg, 3.73mmol, 94.5%). BH(D20) 1.26 (6H, 
dd, J130.5, J4.58). Vmax(KBr disc)/ cm-1 3410 (br.) 2985, 2900, 1705, 1455, 1395, 
1365, 1285 and 1260. 
Sodium [methyl .13c]-2-methylmalonate (115). 
To sodium hydride (120mg, 5mmol) in tetrahydrofuran (30ml) was added a 
solution of diethyl malonate (113) (900mg, 5.6mmol) in tetrahydrofuran 
(10ml) dropwise while stirring under dry N2 at RT. [13c]-Methyliodide 
(314Jll, 0.715g, 5mmol) was then added and the solution heated under reflux 
for 2h and then quenched with ethanol (10ml) and water (50ml). The clear 
solution was extracted into methylene dichloride (4x50ml) and the organic 
layers combined, dried (MgS04) and evaporated in vacuo to yield diethyl [3-
methyl _13c]-2-methylmalonate (114) as a pale yellow oil, which was used 
without further purification. 
A solution of diethyl [methyl _13c]-2-methylmalonate (114) in aqueous 
potassium hydroxide (2M, 20ml) was heated under reflux for 24h. The 
solution was acidified and extracted into diethyl ether (4x50ml). The 
ethereal extracts were dried (MgS04), and evaporated in vacuo to afford 
[methyl .13c]-2-methylmalonic acid. The acid was neutralised with dilute 
aqueous sodium hydroxide and the sodium salt obtained by evaporation of 
solvent in vacuo (390mg, 2.4mmol, 35.0%). BH(D20) 1.30 (3H, dd, Jvic5.48, 
JH13c131.0), 3.51 (lH, m). Bc(D20) 16.2 (13CH3 enriched), 48.87 (d, J33.80, C-
2), 177.268 (CO). 
2-Methylbutyric acid (108a). 
A solution of 2-ethyl-2-methylmalonic acid (107a) (1.04g, 7.13 mmol) in 
water (20ml) was sealed in an evacuated Carius tube and heated to 180°C for 
3h. The tube was cooled to -78°C and then opened and the contents acidified 
with dilute aqueous HCl and extracted into diethyl ether (3x25ml) after 
warming to RT. The ethereal extracts were combined, dried (MgS04), and 
evaporated in vacuo to afford crude (108a) as a clear pale brown oil (670mg, 
6.57mmol, 92.1 %). 
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An alternative synthesis was achieved as follows. To magnesium 
turnings (5.4g, 222mmol) stirred under dry N2 in diethyl ether (100ml) was 
added 2-bromobutane (142) (22.3ml, 27.4g, 200mmol) dropwise until 
reaction was initiated. 2-Bromobutane was added at such a rate so as to 
preserve gentle reflux of the diethyl ether. The solution was heated in the 
final stages of reaction under reflux for 35min. The black solution was 
cooled to 0°C and added to a suspension of solid C02 (approx. 100g) in 
diethyl ether (100ml). The suspension was allowed to warm to RT then 
acidified with dilute aqueous HCl (100ml). The ethereal layer was separated, 
and the aqueous layer extracted further into diethyl ether (2x100ml). The 
combined ethereal layers were dried (MgS04), and evaporated in vacuo to 
yield the crude title compound as a pale brown oil (12.12g) which furnished 
pure (108a) as a clear colourless oil upon distillation. (5.6g, 55mmol, 27.5%, 
b.p. 22°C, 0.005mbar). BH(COC13) 0.95 (3H, t, J7.50), 1.18 (3H, d, }6.89), 1.50 (lH, 
m, }6.94), 1.72 (1H, m, J8.47), 2.40 (1H, m, }6.85). Bc(DMSO D6) 11.4 (CH3), 16.5 
(CH3), 26.2 (CH2), 40.2 (CH), 177.3 (CO). 
[2.2H]-2-Methylbutyric acid (108b). 
A solution of 2-ethyl-2-methylmalonic acid (107a) (1.04g, 7.13 mmol) in D20 
(15ml) was sealed in an evacuated Carius tube and heated to 180°C for 3h. 
The tube was cooled to -78°C before opening and the contents acidified with 
dilute aqueous HCl and extracted into diethyl ether (3x25ml) after warming 
toRT. The ethereal extracts were combined, dried (MgS04), and evaporated 
in vacuo to afford crude (108b) as a clear pale brown oil (0.51g, 4.90mmol, 
68.7%). BH(CDC13) 0.95 (3H, dt, J2.0, J7.6), 1.17 (3H, s), 1.50 (1H, dq, J7.2, }13.8), 
1.71 (1H, dq, }14.0, J6.8), 11.65 (0.5H, s(br)). Bc(COC13) 11.6 (CH3), 16.351 (CH3, 
B shifted from 16.435, 92%D), 26.607 (CH2, B shifted from 26.687, 92%D), 40.7 
(t, C-D, a shifted from 41.081), 183.5 (CO). 
[5-methyl .13c, 2.2H]-2-Methylbutyric acid (lOSe). 
A solution of [2-methyz-13c]-2-ethyl-2-methylmalonic acid (107c) (3.15g, 21.4 
mmol) in D20 (35ml) was treated as above for (108a) to yield (lOBe) as a dear 
pale brown oil (1.7g, 16.19 mmol, 75.6%). BH(CDC13) 0.95 (3H, t, J7.2), 1.17 
(3H, d, JCH128.0), 1.50 (lH, m), 1.70 (lH, m). Bc(CDC13) 11.29 (CH3), 16.071 
(13CH3, 99% enriched), 26.335 (CH2, B shifted from 26.414, 98%D from peak 
area), 40.8 (d, JC-CH34.1 due to undeuterated C-2), 40.41 (dt, Jc-c34.2, Jc-
D19.7 due to deuterated material a shift of 0.384ppm), 183.299 (CO). 
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[5-methyl .13c2H3]-2-Methylbutyric acid (108d). 
A solution of [2-methyl _13c2H3]-2-ethyl-2-methylmalonic acid (107d) 
(600mg, 4.0mmol) in water (lOml) was heated to 175°C for 4h in a sealed 
evacuated Carius tube. The tube was cooled to -78°C before opening and the 
contents acidified with dilute aqueous HCl and extracted into diethyl ether 
(5x50ml) after warming to RT. The ethereal extracts were combined, dried 
(MgS04) and evaporated in vacuo (cold water bath) to afford the title acid as 
a pale brown aromatic oil (420mg, 3.96mmol, 99.1 %). BH(CDC13) 0.95 (3H, t, 
J7.56), 1.75 (1H, m), 1.69 (1H, m), 2.37 (1H, m). 12.05 (1H, s(Br)). Bc(CDC13) 
11.8 (CH3), 15.8 (sep, J19.5, 13CD3), 26.8 (CH2), 41.1 (d, J33.95), 184.1 (CO). 
Vmax(liq. film)/cm-12960, 2940,2220, 1710 and 1420. m/z (EI) 107 (31%), 89 
(16.68%), 78 (100%), 61 (72%). 
Sodium [5-methyz-13c2H3]-2-methylbutyrate (109d). 
This material was generated by the base hydrolysis of appropriately labelled 
esters and thiolesters (110-112) (recovered from feeding experiments) of [5-
methyl _13c2H3]-2-methylbutyric acid (108d), followed by acidification, 
lyophillisation and neutralisation. Bc(D20) 14.5 (CH3), 19.5 (sep, J19.14, 
13CD3), 30.1 (CH2), 47.6 (d, J40.59, CH), 174.037 (CO). 
Sodium [dimethyl-13C2]-isobutyrate (118). 
A solution of [dimethyl _13C2]-2,2-dimethylmalonic acid (117) (500mg, 
3.73mmol) in water (lOml) was heated to 180°C in a sealed evacuated Carius 
tube for 3h. Upon cooling, the contents of the tube were acidified with 
dilute aqueous hydrochloric acid and lyophilised. The lyophilisate was 
carefully neutralised with dilute aqueous sodium hydroxide and the title 
compound obtained as an amorphous white solid by freeze drying. (330mg, 
2.95mmol, 79.0%). BH (D20) 0.86 (6H, ddd, J126.5, J5.54, J6.82), 2.32 (lH, m), 
Bc(D20) 22.4 (2x13CH3 99% enriched), 39.8 (t, J33.5, C-2), 204.5 (CO). 
Vmax(KBr disc)/cm-1 3425 (br.), 2965,1560, 1475, 1420,1370 and 1260. 
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(Napropionyl)Cysteamyl 2amethylbutyrate (llOa). 
To 2-methylbutyric acid (108a) (1.02g, 10mmol) was added a solution of DCC 
(2.06g, 10mmol), DMAP (1.08g, 10mmol) and N-propionylcysteamine (122) 
(2.66g, 20mmol) in diethyl ether (20ml). The suspension was stirred 
overnight at RT. Methylene dichloride (SOml) was added and the 
suspension filtered. The organic washings were combined and washed with 
dilute aqueous HCl (50ml). The acidic aqueous layer was washed with 
methylene dichloride (2x50ml) and the combined organic layers were dried 
(MgS04) and evaporated in vacuo to yield crude (110a) which was purified 
by chromatography (Rf 0.36, diethyl ether) on silica, eluting with diethyl 
ether, to afford the title compound as a clear pale yellow oil after 
evaporation of product containing fractions (1.26g, 5.1mmol, 51.0%). 
OH(CDC13) 0.89 (3H, t, J7.08), 0.95 (3H, t, }8.06), 1.20 (3H, d, J6.44), 1.51 (1H, m), 
1.77 (1H, m), 2.25 (2H, q, J7.67), 260 (1H, m), 3.07 (2H, t, J6.47), 3.46 (2H, dt, 
J6.12), 6.75 (1H, s(br)). VmaxOiq. film)/cm-1 3310 (br), 3090, 2980, 2940, 2885, 
1695, 1655, 1550, 1465, 1408, 1378 and 1230. 
(N-propionyl)Cysteamyl [2.28]-2-methylbutyrate (llOb). 
To [2-2H]-2-methylbutyric acid (108b) (700mg, 6.8mmol) was added a 
solution of DCC (1.44g, 7.0mmol), DMAP (0.85g, 7.0mmol) and N-
propionylcysteamine (122) (950mg, 7.14mmol) in diethyl ether (20ml). The 
suspension was stirred overnight at RT. Methylene dichloride (50ml) was 
added and the suspension filtered. The organic washings were combined 
and washed with dilute aqueous HCl (50ml). The acidic aqueous layer was 
re-extracted into methylene dichloride (2x50ml) and the combined organic 
layers were dried (MgS04) and evaporated in vacuo to yield crude (110b) 
which was purified by chromatography (Rf 0.36, diethyl ether) over silica 
eluting with diethyl ether to afford the title compound as a pale yellow oil 
(1.1g, 5.05mmol, 74.2%). 8H(COC13) 0.91 (3H, t, J7.2), 1.14 (3H, t, J7.6), 1.16 (3H, 
s), 1.47 (1H, m), 1.72 (1H, m), 221 (2H, q, J7.6), 3.03 (2H, t, J6.4), 3.43 (2H, dt, 
J6.4, J6.0), 6.41 (1H, s(br)). 8c(CDC13) 9.8 (CH3), 11.6 (CH3), 17.091 (CH3, B-
shifted from 17.190), 27.074 (CH2, B shifted from 27.173), 28.1 (CH2), 29.6 
(CH2), 39.7 (CH2), 49.709 (CH, t, }19.8, a-shifted from 50.157), 174.1 (CON), 
204.3 (COS). 
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(N-propionyl)Cysteamyl [5-methyl a13c, 2..2H]-2-methylbutyrate (110c) 
To a solution of [5-methyl .13c, 2.2H]-2-methylbutyric acid (lOSe) (525mg, 5.0 
mmol) in diethyl ether (15ml) was added DCC (1.03g, 5 mmol), DMAP 
(0.61g, 5.0 mmol) and N-propionylcysteamine (122) (665mg, 5.0 mmol). The 
solution was stirred for 12h at RT. A fine white precipitate appeared within 
30 min. The suspension was filtered and evaporated to yield a pale yellow 
oil containing white crystals. The oil was purified by chromatography (Rf 
0.36, diethyl ether) over silica eluted with diethyl ether (400ml). Product 
containing fractions were combined and evaporated to afford the thiolester 
as a clear colourless oil (0.69g, 3.15 mmol, 63%). 8H(CDC13) 0.91 (3H, t, J7.2), 
1.14 (3H, t, J7.6), 1.15 (3H, d, J128), 1.48 (1H, m), 1.71 (lH, m), 2.21 (2H, q, J7.6), 
3.04 (2H, t, J6.4), 3.43 (2H, dt, J6.4, J6.0), 6.50 (lH, s(br)). 8c(CDC13) 9.8 (CH3), 
11.6 (CH3), 17.1 (13CH3, 99% enriched), 27.1 (CH2), 28.1 (CH2), 29.6 (CH2), 
39.6 (CH2), 49.715 (C-D, dt, JC-C33.8, JC-019.7, alpha shift of 0.444ppm), 50.2 
(d, JC-CH33.8 due to non deuterated material), 174.2 (CON), 204.3 (COS). m/z 
(CI) 220 (100%), 134 (37%). 
(N-propionyl)Cysteamyl [5-methyJ-13c2H3]·2-methylbutyrate (llOd). 
To [5-methyl .13c2H3]-2-methylbutyric acid (108d) (210mg, 2.0mmol) was 
added a solution of DCC (410mg, 2.0mmol), DMAP (245mg, 2.0mmol) and 
N-propionylcysteamine (122) (270mg, 2.0mmol) in diethyl ether (20ml). The 
suspension was stirred overnight at RT. Methylene dichloride (50ml) was 
added and the suspension filtered. The organic washings were combined 
and washed with dilute aqueous HCl (50ml). The acidic aqueous layer was 
washed with methylene dichloride (2x50ml) and the combined organic 
layers were dried (MgS04) and evaporated in vacuo to yield crude (llOd) 
which was purified by chromatography (Rf 0.36, diethyl ether) over silica 
eluting with diethyl ether. (155mg, 0.70mmol, 70.0%). 8H(CDC13) 0.90 (3H, t, 
J7.52), 1.14 (3H, t, J7.76), 1.45 (lH, m), 1.70 (lH, m), 2.24 (2H, q, J7.68), 2.55 (1H, 
m), 3.03 (2H, t, J7.74), 3.40 (2H, dt, J7.74), 7.45 (lH, t(Br)). 8c(CDC13) 9.2 (CH3), 
10.7 (CH3), 15.5 (13CD3, sep. }19.44), 26.3 (CH2), 27.3 (CH2), 28.6 (CH2), 38.6 
(CH2), 49.1 (CH, d, J33.9), 173.7 (CON), 202.7 (COS). m/z (CD 222 (14.5%), 134 
(4.8%). 
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Octyl [5-methyl -13c2H31-2-methylbutyrate (112d). 
To [5-methyl _13c2H31-2-methylbutyric acid (108d) (210mg, 1.98mmol) was 
added a solution of DCC (410mg, 2.0mmol), DMAP (244mg, 20mmol) and 1-
octanol (520mg, 4mmol) in diethyl ether (20ml). The suspension was stirred 
overnight at RT. Methylene dichloride (50ml) was added and the 
suspension filtered. The organic washings were combined and washed with 
dilute aqueous HCl (50ml). The acidic aqueous layer was re-extracted into 
methylene dichloride (2x50ml) and the combined organic layers were dried 
(Mg504) and evaporated in vacuo to yield a mixture of 1-octanol and the 
title compound which was used without further purification. 8H(CDC13) 
0.90 (2xCH3), 1.30 (6xCH2), 1.75 (CH), 1.90 (CH), 3.20 (CH), 4.05 (OCH2). 
oc(CDC13) 11.5 (CH3), 12.2 (CH3), 15.7 (13CD3, sep. J19.36), 27.5 (CH2), 28.2 
(CH2), 30.0 (CH2), 30.4 (CH2), 31.1 (CH2), 32.0 (CH2), 33.2 (CH2), 41.5 (CH, d, 
J37.4), 63.2 (OCH2), 154.6 (CO). 
Thiooctyl [5-methyl .13c2H31-2-methylbutyrate (111d). 
To [5-methyl .13c2H3]-2-methylbutyric acid (108d) (210mg, 1.98mmol) was 
added a solution of DCC (410mg, 20mmol), DMAP (245mg, 2mmol) and 1-
octanethiol (580mg, 4mmol) in diethyl ether (20ml). The suspension was 
stirred overnight at RT. Methylene dichloride (50ml) was added and the 
suspension filtered. The organic washings were combined and washed with 
dilute aqueous HCl (50ml). The acidic aqueous layer was re-extracted into 
methylene dichloride (2x50ml) and the combined organic layers were dried 
(MgS04) and evaporated in vacuo to yield a mixture of 1-octanethiol and 
the title compound which were separated by flash chromatography (Rf 0.46, 
methylene dichloride/hexane 25/75) on silica eluting with methylene 
dichloride/hexane 25/75. The title compound was obtained as a colourless 
oil (80mg, 0.34mmol, 17.2%). 8H(CDC13) 0.85 (3H, t, J7.2), 0.89 (3H, t, J7.6), 
1.24 (12H, m(Br)), 1.45 (1H, m), 1.60 (1H, m), 2.50 (1H, m), 2.83 (2H, t, J8.3). 
8c(CDC13) 11.6 (CH3), 14.08 (CH3), 16.40 (13cD3, sep, J19.41), 22.6 (CH2), 27.1 
(CH2), 28.5 (CH2), 28.8 (CH2), 29.1 (CH2), 29.14 (CH2), 29.6 (CH2), 31.8 (CH2), 
50.0 (CH, d, J33.6), 204.1 (COS). 
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Sodium amalgam (-3%) (119). 
Clean, dry sodium pellets (13g) were placed in a 250ml 3 necked round 
bottomed flask though which dry N2 was passed. From 430g of distilled 
mercury, an aliquot (approx. 50g) was run into the flask. Reaction was 
initiated by gentle heating with a Bunsen flame. Reaction was maintained 
by the addition of further mercury, and in the later stages of reaction by 
strongly heating with a Bunsen. When visible signs of reaction had ceased 
(approx. 20min), the molten compound was poured into a glass crystallising 
dish to cool, and cut up before fully solid. The solidified material was 
roughly ground with a mortar and pestle and stored in a stoppered bottle. 
N,N'-Dipropionylcystamine (121). 
To a solution of cystamine dihydrochloride (120) (22.5g, 100mmol) in water 
(20ml) was added aqueous sodium hydroxide solution (12.5M) until the pH 
was 8.2. Propionyl chloride (20g, 216 mmol) was added dropwise and the pH 
was maintained above 8.0 by the addition of further base as required. When 
about half of the propionyl chloride had been added a white precipitate 
started to appear. The precipitate was collected by Buchner filtration. 
Further material was precipitated on standing at 4°C overnight. Combined 
solids were washed with cold water and dried under reduced pressure in a 
dessicator to afford N,N'-dipropionylcystamine (121) as a cream solid 
(18.16g, 68.8mmol, 68.8%). mp 93.9-95.3°C. aH(CDC13) 1.16 (6H, t, J8.0), 2.26 
(4H, q, J7.8), 2.84 (4H, t, J6.8), 3.56 (4H, dt, J6.4, J6.0), 6.91 (2H, t, J6.0). 
ac(CDC13) 10.3 (CHJ), 30.0 (CH2), 38.3 (CH2), 38.9 (CH2), 175.1 (CON). 
Vmax(I<Br disc)/an-13285, 3070,2980,2950,2885, 1660,1640, 1630, 1550,1470, 
1430 and 1410. m/z (CI) 265.19 (6.79%). 
N-Propionylcysteamine (122). 
To a solution of N,N'-dipropionylcystamine (121) (2.64g 10mmol) in 
methanol (50ml) under dry nitrogen was added 3% sodium amalgam (119) 
(26g). The suspension was stirred for 90min at RT, then filtered to remove 
mercury. The methanolic solution was poured into a separatory funnel 
containing dilute aqueous HCl (50ml) and methylene dichloride (50ml). 
The acidified solution was immediately extracted with further methylene 
dichloride (2x50ml). Organic washings were dried and evaporated in vacuo 
to afford N-propionylcysteamine (122) as a pale yellow oil (227g, 17.1mmol, 
85.3%). 
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An alternative method of reduction is as follows. A solution of N,N'-
dipropionylcystamine (121) (1.55g, 5.87mmol) in tetrahydrofuran (50ml) 
containing methanol (10ml) was stirred under reflux with powdered zinc 
(l.Sg, 22.9mmol) overnight. After this time excess zinc was removed by 
filtration and the solution acidified with concentrated aqueous HCl (10ml). 
The solution was concentrated in vacuo to a volume of approx. 10ml and 
then extracted into methylene dichloride (3x25ml). Organic washings were 
combined, dried (MgS04) and evaporated in vacuo to afford (122) as a clear 
pale yellow oil (950mg, 7.14mmol~ 60.8%). aH(CDC13) 1.16 (3H, t, J7.6), 1.49 
(lH, t, J8.4), 2.26 (2H, q, J7.6), 2.67 (2H, dt, J6.8, }8.4),3.42 (2H, dt, J6.0, J6.8), 7.06 
(lH, s(br)). ac(CDC13) 9.2 (CH3), 23.3 (CH2), 28.5 (CH2), 41.8 (CH2), 174.0 
(CON). VmaxOiq. film)/cm-1 3290,3075,2975,.2938,2880,2540, 1710, 1650 and 
1545. m/z (EI) 134 (56.4%), 74 (22.5%), 57 (21.1 %). 
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(L)-N-Benzyloxycarbonyl phenylalanine (123a). 
To a solution of L-phenylalanine (99) (6.6g, 40 mmol) in aqueous sodium 
hydroxide (2M, 20ml), cooled and stirred at -5°C, was added 
benzyloxycarbonyl chloride (6ml, 7.17g, 42.0mmol) and aqueous sodium 
hydroxide (2M, 24ml) in 6x1ml and 6x4ml portions respectively, over a 
period of 30 min. The solution was acidified with concentrated aqueous HCl 
(lOml) and extracted into methylene dichloride (3x50ml). Organic washings 
were combined, dried (MgS04), and evaporated in vacuo to give (123a) as a 
clear glassy solid. (9.3Sg, 31.27 mmol, 78%). m.p. 84.4-85.7°C. l>H(CDC13) 3.14 
(2H, m), 4.65 (lH, m), 4.82 (2H, s), 5.28 (1H, d, J8.08, NH) 7.25 (m, 10H), 10.40 
(s, 1H). l)c(CDCL3) 37.7 (CHz), 54.6 (CH), 67.2 (OCH2), 127.2 (Ph), 128.1 (Ph), 
128.2 (Ph), 128.5 (Ph), 128.6 (Ph), 129.3 (Ph), 135.5 (Ph), 136.0 (Ph), 156.0 (CO), 
176.3 (CO). [a]o22 +2.46° (c 8.1, EtOH). vmax (KBr disc)/cm-1 3340, 3075, 
3040, 2940, 1715, 1695, 1610, 1590, 1540, 1530, 1500, 1460, 1420 and 1300. 
(L)-[UL-14c]-N-Benzyloxycarbonyl phenylalanine (123b ). 
To a solution of L-phenylalanine (99) (3.3g, 20mmol) in aqueous sodium 
hydroxide (lOml, 2M) was added L-[UL-14c]-phenylalanine (20j..LCi). The 
solution was treated with benzyloxycarbonyl chloride (3.Sml, 4.18g, 
24.Smmol) as described above to give a clear pale yellow oil. The oil 
crystallised under pentane after two days to form (123b) as a white solid 
(5.90g, 19.7mmol, 98.5%), s.a. 1.0j..LCimmol-1. 
N-(benzyloxycarbonyl)-3-Amino-2-phenylpropionic acid (126). 
A solution of 3-amino-2-phenylpropionic acid (104) (O.Sg, 3.03mmol) in 
aqueous sodium hydroxide (2M, 10ml) was treated with benzyloxycarbonyl 
chloride (lml, 1.2g, 7.0mmol) and aqueous sodium hydroxide solution (2M, 
Sml) as described above to afford the title compound as a white solid after 
washing with pentane. (710mg, 2.37mmol, 78.4%). m.p. 109.4-114.0°C. 
BH(CDC13) 3.59 (2H, m), 3.90 (1H, m), 5.07 (2H, s), 5.23 (1H, t(br), NH), 7.32 
(lOH, m) 9.75 (lH, s, OH). l)c(CDCl3) 43.94 (CH2), 51.99 (CH), 67.46 (OCH2), 
128.48 (Ph), 128.56 (Ph), 128.65 (Ph), 128.83 (Ph), 129.05 (Ph), 129.48 (Ph), 
136.16 (Ph), 137.0 (Ph), 156.89 (CO), 178.0 (CO). Vmax(KBr disc)/cm-1 3375, 
3075, 3045, 2940, 1705, 1690, 1605, 1555, 1500, 1455, 1425 and 1365. m/z(CI) 300 
(1.1 %). 
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(L)-N-Benzyloxycarbonyl phenylalanine (N-propionylcysfeamine) 
thiolester (124a). 
To a solution of (L)-N-benzyloxycarbonyl phenylalanine (123a) (2.99g, 
10mmol) in diethyl ether (25ml) was added DCC (2.06g, 10mmol), DMAP 
(1.22g, 10mmol) and an excess of N-propionylcysteamine (122) (2.0g, 
15.0mmol). The solution was stirred under dry N2 for 12h, methylene 
dichloride (50ml) was added and the white suspension filtered and the 
organic solution was evaporated in vacuo to afford a thick oil containing 
white crystals. This was chromatographed on silica eluting with acetonitrile 
(700ml). Product containing fractions were combined and evaporated in 
vacuo to give the title compound as a white solid. m.p. 86.5-90.2°C, (3.63g, 
8.44mmol, 84.4%). 8H(CDC13) 1.07 (3H, t, J7.6), 2.12 (2H, q, J7.6) 2.96 (2H, m, 
CH2S), 3.17 (2H, m, CH2Ph), 3.32 (2H, m, CH2N), 4.625 (lH, m, CHN), 5.01 
(2H, s, CH20), 6.44 (1H, d, J8.4, NH), 6.64 (1H, t, J5.6, NH), 7.20 (10H, m, 2Ph). 
8c(CDCL3) 9.6 {Cfl3), 28.4 (CH2), 29.3 (CH2), 37.9 (CH2), 38.8 (CH2), 61.7 (CH), 
67.0 (OCH2), 127.0 (Ph), 127.8 (Ph), 128.0 (Ph), 128.3 (Ph), 128.5 (Ph), 129.1 (Ph), 
135.5 (Ph), 135.9 (Ph), 155.7 (CO), 174.0 (CO), 200.8 (COS). [a]0 22 -9.62° (c 6.2, 
EtOH). vmax(KBr disc)/cm-13410, 3245, 3070, 3045, 2980, 2940, 1720, 1705, 
1545, 1500, 1415, 1378 and 1250. m/z (CI) 415.17 (6.87%). 
(L)-N-Benzyloxycarbonl-[UL-14c]-phenylalanine 
(N-propionylcysteamine) thiolester (124b). 
A solution of (L)-N-benzyloxycarbonyl-[UL-14c]-phenylalanine (123b) (5.90g, 
19.7mmol) in diethyl ether (100ml) was treated with DCC (4.12g, 20mmol), 
DMAP (2.44g, 20mmol) and an excess of N-propionylcysteamine (122) (3.33g, 
25mmol) as described above for (124a) to afford (124b) as a white solid after 
evaporation. The solid was washed with pentane and collected by filtration. 
(5.42g, 13.1mmol, 65.5%, s.a. 0.985JJ.Ci/mmol). 
N-(benzyloxycarbonyl) 3-amino-2-phenylpropionic acid (N-
propionylcysteamine) thiolester (127). 
A solution of N-(benzyloxycarbonyl) 3-amino-2-phenylpropionic acid (126) 
(650mg, 2.17mmol) in diethyl ether (50ml) was treated with N-
propionylcysteamine (122) (2.46g, 20mmol), DCC (2.06g, 10mmol) and 
DMAP (1.22g, 10mmol) as described above for (124a) to afford (127) as a 
white solid after chromatography (Rf 0.82, acetonitrile) on silica eluting 
with acetonitrile. (750mg, 1.81mmol, 83.4%). 8H(CDC13) 1.03 (3H, t, J7.6), 2.06 
(2H, q, J7.6), 2.95 (2H, t, J5.6, CH2S), 3.30 (2H, m, CH2N), 3.50 (1H, m), 3.75 
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(1H, m), 4.1 (lH, m), 5.05 (2H, s), 5.65 (1H, t (br), NH), 6.40 (1H, t (br), NH), 
7.27 (10H, m, 2Ph). 
(L)-Phenylalanine (N-propionylcysteamine) thiolester hydrochloride 
(125a). 
A solution of (L)-N-benzyloxycarbonyl phenylalanine (N-
propionylcysteamine) thiolester (124a) (500mg, 1.16mmol) in methylene 
dichloride (25ml) was cooled to -10°C. To this solution under dry nitrogen 
was added boron tribromide (1M in CH2Cl2, 6ml, 6mmol). After 1h stirring 
at -10°C the solution was warmed toRT. After 90min at RT a hard yellow 
solid had formed. The addition of 20ml of water decomposed this solid with 
effervescence. The aqueous layer was washed with methylene dichloride 
(2x50ml) and evaporated to yield a cream solid. The solid was dissolved in 
water (50ml) and the solution basified to pH 8 with dilute aqueous NaOH 
then extracted into diethyl ether (3x50ml). The combined ethereal extracts 
containing the free amine were then extracted into dilute aqueous HCl 
(2x50ml). The aqueous acid washings were evaporated in vacuo to afford 
(125a) as a pale brown sticky solid (150mg, 0.47mmol, 40.8%). m.p. 108.4-
119.60C. 8H(D20) 0.93 (3H, t, J6.8, CH3), 2.07 (2H, q, J6.8, CH2), 2.94 (2H, m, 
CH2), 3.05 (2H, m, CH2), 3.24 (2H, m, CH2), 4.45 (lH, m, CH), 7.22 (5H, m, 
Ph). ac<D20) 8.3 (CH3), 27.3 (CH2), 27.9 (CH2), 35.8 (CH2), 36.8 (CH2), 58.8 
(CH), 126.9 (Ph), 128.0 (Ph), 128.3 (Ph), 132.2 (Ph), 177.0 (CON), 196.3 (COS). 
m/z Cl) 281 (67%), 134 (100%) 
(L)-[Ut-14c]-Phenylalanine (N-propionylcysteamine) thiolester 
hydrochloride (12Sb). 
(L)-Benzyloxycarbonyl-[UL-14c]-phenylalanine (N-propionylcysteamine) 
thiolester (124b) (500mg, 1.2mmol) was treated with boron tribromide (1M 
in CH2Cl2, 7ml, 7mmol) for lh at -10°C under dry N2. The solution was 
warmed to RT and water (lOml) added and stirred vigorously until 
effervescence had stopped. The aqueous layer was washed with methylene 
dichloride (3x15ml) and then basified with dilute aqueous KOH and 
extracted into methylene dichloride (3x50ml). The combined organic 
extracts containing the free amine were extracted into dilute aqueous HCl 
(5x50ml). The aqueous acid layer was evaporated in vacuo to afford a 
colourless oil which crystallised overnight, giving (125b) as white crystals 
(254mg, 0.803mmol, 66.4%). s.a 1.02J,LCi/mmol, m/z (CD 281.11 (6.52%), 
134.05 (62.23%). 
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3-Amino-2-phenylpropionate (N-propionylcysteamine) thiolester 
hydrochloride (128). 
A solution of N-(benzyloxycarbonyl) 3-amino-2-phenylpropionic acid (N-
propionylcysteamine) thiolester (127) (750mg, 1.81mmol) in methylene 
dichloride (50ml) was stirred at -10°C. Boron tribromide (1M in CH2Cl2, 
5ml, 5mmol) was added and stirring continued for 90min. The solution 
became very pale yellow and a solid appeared. The solution was warmed to 
RT and stirred for 30min. Water (25ml) was added and stirring continued 
for 20min. The separated aqueous solution was washed with methylene 
dichloride (3x25ml) and then basified with dilute aqueous NaOH to pH 8 
and extracted into methylene dichloride (3x25ml). The combined organic 
layers containing the free amine were extracted into dilute aqueous HCl 
(3x50ml). The acid aqueous washi~gs were combined and evaporated in 
vacuo to afford (128) as a sticky thick yellow oil (200mg, 0.63mmol, 34.8%). 
BH(D20) 0.80 (3H, t, J7.6), 1.89 (2H, q, J7.6), 2.78 (lH, dt, Jgem14.0, Jvict6.0), 
2.90 (lH, dt, Jgem14.0, Jvict6.0), 3.12 (2H, t, Jvict6.0), 3.26 (1H, dd, Jgeml3.2, 
Jvic27.6), 3.521 (1H, dd, Jgem13.2, Jvic27 .2), 4.169 (1H, t, Jvia7.6), 7.24 (5H, m). 
Bc(D20) 12.4 (CH3), 31.3 (CH2), 31.9 (CH2), 41.0 (CH2), 43.5 (CH2), 59.2 (CH), 
131.5 (2Ph), 1321 (Ph), 1325 (2Ph), 136.7 (Ph), 180.8 (CON), 203.2 (COS). 
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(L)-N-(acetoacetyl)-Phenylalanine methyl ester (130a). 
A solution of L-phenylalanine methyl ester (99a) (3.58g, 20mmol) in toluene 
(20ml) was heated under reflux with freshly distilled 2,2,6-trimethyl-1,3-
dioxin-4-one (129, acetone diketene adduct) (3.5g, 25mmol, b.p. 36°C, 0.03 
mbar) for 2h. The resultant red solution was evaporated in vacuo to give a 
viscous red oil which was pumped free of solvent residues under vacuum. 
The oil was purified by chromatography (Rf 0.36, diethyl ether) on silica 
eluting with 50/50 hexane/ethyl acetate. Product containing fractions were 
combined and evaporated to yield (130a) as a yellow oil (3.95g, 15.0mmol, 
75.0%). OH(CDC13) 2.32 (3H, s, CH3), 3.04 (2H, m, CH2), 3.31 (2H, s, CH2), 3.67 
(3H, s, OCH3), 4.90 (1H, m, CH.), 7.20 (5H, m, Ph), 7.26 (1H, d(br), NH). 
S(S)-3--Acetyl-5-benzyl-2,4,-dioxopyrrolidine (131a). 
A solution of (L)-N-(acetoacetyl)-phenylalanine methyl ester (130a) (3.95g, 
15mmol) in methanol (50ml) was heated under reflux with a solution of 
sodium methoxide in methanol (2M, 10ml, 20mmol) for 1h. The solution 
was acidified with dilute aqueous HCl and extracted into diethyl ether 
(3x50ml). The ethereal washings were combined, dried (MgS04) and 
evaporated in vacuo to afford a yellow solid which was collected by 
filtration and washed with water (20ml). The solid was recrystallised from 
acetone/water to give the title compound as pale cream fine crystals. (1.92g, 
8.3mmol, 55.4%). m.p. 134-135°C (decomp, lit' 133-134°C). OH(CDC13) 2.47 
(3H, s, Me), 2.65 (1H, dd, Jgem 13.9, Jvic210.4, CH), 3.31 (1H, dd, Jvic13.6, 
Jgem13.9, CH), 4.02 (1H, dd, JvicJ3.6, Jvic210.3, CH), 6.15 (lH, s(br), NH or 
OH), 7.26 (5H, m, Ph). oc(CDC13) 19.6 (CH3), 38.2 (CH2), 63.7 (CH), 101.5 (C), 
127.2 (Ph), 128.9 (Ph), 129.1 (Ph), 136.5 (Ph), 174.83 (CON), 185.43 (COH), 
194.33 (COMe). [a]o22 -134.83. (c 0.445, EtOH.). m/z (CD 232 (89.7%), 142 
(3.96%). 
S(RS)-3-Acetyl-5-(p-hydroxybenzyl)-2,4,-dioxopyrrolidine (131b). 
To a solution of tyrosine methyl ester (98a) (3.9g, 20mmol) in toluene (25ml) 
was added 2,2,6-trimethyl-1,3-dioxin-4-one (129, acetone diketene adduct) 
(4.26g, 30mmol). The red suspension was heated under reflux for 30min 
giving a red solution. The solution was evaporated in vacuo to afford a red 
oil which was dissolved in diethyl ether (50ml) and washed with dilute 
aqueous HCl (3x50ml). The ethereal layer was dried (MgS04) and 
evaporated in vacuo to afford crude (L)-N-(acetoacetyl)-tyrosine methyl 
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ester (130b) as a red oil which was not purified further. OH(CDC13) 1.99 (3H, 
s, Me), 2.97 (1H, m, CH2), 3.06 (1H, m, CH2), 3.72 (3H, s, OMe), 4.83 (1H, m, 
CH), 5.25 (2H, s, CH2), 6.75 (2H, d, J8.3, Ph), 6.97(2H, d, J8.3, Ph), 7.45 (1H, d, 
NH) (OH off scale). 
To a solution of the crude (L)-N-(acetoacetyl)-tyrosine methyl ester 
(130b) in methanol (50ml) was added sodium methoxide (1.35g, 25mmol). 
The solution was heated under reflux for 1h, then acidified with dilute 
aqueous HCl (50ml) and extracted into diethyl ether (5x50ml). The ethereal 
extracts were dried (MgS04) and evaporated in vacuo to yield crude (131 b) as 
a brown solid. The tetramic acid was afforded as beige crystals by 
recrystallisation from acetone/methylene dichloride (528.5mg, 2.14mmol, 
10.7%). mp. 199.5-200.3°C (decomp., acetone/methylene dichloride). 
OH(CDC13/DMSO-D6) 2.35 (3H, s), 2.79 (1H, dd, Jgem14.1, Jvic16.8), 2.99 (1H, 
dd, Jgem14.1, Jvic24.5), 3.97 (1H, t(br), Jav6.0), 6.69 (2H, d, J8.4), 6.98 (2H, d, 
J8.5), 8.35 (1H, s), 9.30 (2H, s(br)). Oc(CDC}3/DMSO-D6) 19.4 (CHJ), 36.1 (CH2), 
62.8 (CH), 101.0 (C), 114.8 (Ph), 125.8 (Ph), 130.0 (Ph), 155.6 (PhOH), 174.8 
(COH), 184.5 (CO), 194.5 (CO). [a]o22 0.00° (c 0.55 EtOH). Vmax(KBr disc)/cm-
1 3410, 3215, 3060, 2920, 1705, 1650, 1610, 1520, 1460 and 1450. m/z (CD 248 
(100%), 107 (15%). 
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(1,1-dimethyl-N-propylidine)Ethylamine (132). 
To t'butylamine (36.5g, 0.5mol) stirred at 0°C was added propionaldehyde 
(29g, 0.5mol) dropwise over the course of two hours. When addition was 
complete stirring was stopped and KOH pellets (20g) were added, and the 
solution was left to separate at 0°C overnight. The yellow upper layer was 
carefully decanted, triply distilled over KOH at atmospheric pressure and 
collected under dry N2 to yield the title compound as a clear colourless oil 
(21.4g, 189mmol, 37.8%, b.p. 103-105°C 1atm). SH(CDC13) 1.07 (3H, t, J7.6), 1.17 
(9H, s), 2.24 (2H, dq, J4.98, J7.6), 7.60 1H, t, J4.98). Sc(CDC13) 10.37 (CHJ), 29.38 
(3CH3), 56.0 (CH2), 102.1 (C), 159.6 (CHN). Vmax(liq. film)/cm-1 2970, 2940, 
2870, 1675, 1460, 1365, 1230 and 1220. 
E-2,4-Dimethyl-2-hexenal (134). 
To a solution of freshly distilled (1,1-dimethyl-N-propylidine)ethylamine 
(132) (5.65g, 50mmol) in tetrahydrofuran (30ml) stirred under dry N2 and 
cooled to -78°C was added butyllithium (1.8M in hexanes, 30.5ml, 
55.0mmol), via dry N2 flushed syringe dropwise over ten minutes. The 
solution was warmed to 0°C and stirred for 20 min. then cooled to -78°C. 2-
Methylbutyraldehyde (133) (3.87g, 45mmol, distilled b.p. 92°C, 1atm) was 
added dropwise via dry N2 flushed syringe and then the solution was 
allowed to warm to 0°C and stirred for 4h at this temperature. An aqueous 
slurry of oxalic acid (=30ml) was added and the biphasic mixture was 
vigorously stirred for 72h. The mixture was added to water (50ml) and 
extracted into methylene dichloride (3x50ml). The combined organic layers 
were dried (MgS04) and evaporated in vacuo to yield the crude aldehyde as 
a pale yellow powerfully aromatic oil (5.3g, 42.1mmol, 93.6%) which was 
stored at -20°C under dry N2. The aldehyde was purified when required by 
flash chromatography (R£ 0.75, methylene dichloride) over silica eluting 
with methylene dichloride. SH(CDC13) 0.88 (3H, t, J7.4), 1.07 (3H, d, J6.6), 1.50 
(2H, m), 1.76 (3H, s), 2.62 (1H, m), 6.26 (1H, d, J10.1), 9.40 (lH, s). 8(:(CDCl3) 
9.2 (CHJ), 11.9 (CHJ), 19.6 (CHJ), 29.6 (CH2), 35.3 (CH), 138.0 (C), 160.4 (CH), 
195.6 (CO)~ Vmax(liq. film)/cm-1 2975, 2940, 2880, 2710, 1695, 1645, 1460 and 
1380. m/z (CD 127 (46.42%). 
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2,2-Dimethyl-6--chloromethyl-1,3-dioxin-4-one (135). 
To a solution of LDA (50mmol) stirred at a78°C in tetrahydrofuran (30ml) 
under dry N2 was added freshly distilled 2,2,6-trimethyl-1,3-dioxina4-one 
(129, acetone diketene adduct) (7.1g, 50 mmol, b.p. 36°C, 0.03 mbar} dropwise 
via dry N2 flushed syringe, giving a bright yellow suspension which was 
stirred for 15min. The thick suspension was carefully transferred dropwise 
via dry N2 flushed teflon tubing to a stirred solution of hexachloroethane 
(17.7g, 75mmol) in tetrahydrofuran (30ml) cooled to -50°C under dry N2 
over a period of 30min. 
The red solution thus formed was allowed to warm to -20°C over 30 
min. before being quenched by addition to ice cold dilute aqueous HCI 
(150ml). The acidic solution was shaken to dispel colour and extracted into 
diethyl ether (3x50ml). The combined ethereal layers were washed with a 
saturated aqueous solution of NaHC03 (2x50ml), dried (MgS04), and 
evaporated to afford a yellow oil containing crystalline hexachloroethane 
which was removed by trituration with hexane (2x50ml). The crude title 
compound could be purified by flash chromatography {Rf 0.28, methylene 
dichloride) on silica eluting with methylene dichloride, but was routinely 
used without further purification. SH(CDC13) 1.73 (s, 6H), 4.05 (s, 2H), 5.57 (s, 
lH). 5c(CDC13) 24.8 (2xCH3), 41.1 (0120), 95.6 (CH), 107.6 (C), 160.0 (C), 164.6 
(CO). Vmax(liq. film)/cm-1 3010,2960,1730, 1645,1400,1280,1205 and 1020. 
2,2aDimethyl-6-(diethylphosphonomethyl)-1,3-dioxin-4-one (136). 
Diethylphosphite (20.7g, 150mmol, distilled b.p. 2~C, 0.001 mbar) was added 
dropwise to a solution of potassium tbutoxide (16.8g, 150mmol) in 
dimethylformamide (30ml, distilled from CaH) cooled to 0°C under dry N2. 
After 30min stirring 2,2dimethyl-6-chloromethyl-1,3-dioxin-4-one (135) (as 
prepared above) was added dropwise generating a deep purple solution 
which was stirred at 0°C for a further 30min. The colour was discharged by 
the dropwise addition of concentrated aqueous HCl (approx 10ml) and the 
pale yellow solution was filtered though celite. The celite pad was washed 
with diethyl ether (lOOml) and the combined organic washings were 
evaporated in vacuo (bath temperature below 40°C) to afford a yellow oil. 
Excess dimethylformamide and diethyl phosphite were removed by 
vacuum distillation (0.02 mbar, bath temperature below 45°C) to afford 
crude title compound as a thick brown oil. Purification was effected by flash 
chromatography (Rf 0.19, ethyl acetate) on silica eluting with ethyl acetate to 
afford the title compound as a pale yellow oil (6.6g, 23.7 mmol, 47.48% from 
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(129)). OH(CDC13) 1.35 (6H, t, }7.06), 1.72 (6H, s,), 283 (2H, d, J22.14), 4.16 (4H, 
m), 5.41 (1H, d, J3.68), O(:(CDC}3) 16.8 (d, JPC6.1, 2xCH3), 25.3 (2xCH3), 327 (d, 
Jpc136.9, CH2), 63.0 (d, Jpc6.4, 2xCH2), 96.5 (d, Jpc8.00, CH), 107.5 (C), 160.9 
(C), 163.4 (CO). VmaxOiq. film)/cm-1 3400(br), 2995, 2940, 2920, 1730, 1635, 
1445,1375 and 1255(br). m/z (CD 279 (7.02%). 
2,2-Dimethyl-6-(E,E-3,5-dimethylhepta-1,3-dienyl)-1,3-dioxin-4-one 
(137). 
To a solution of LHMDS (2.75mmol) in tetrahydrofuran (30ml) cooled to 
0°C and stirred under dry N2 was added a solution of 2,2-dimethyl-6-
(diethylphosphonomethyl)-1,3-dioxin-4-one (136) (760mg, 2.73mmol) in 
tetrahydrofuran (5ml) via dry N2 flushed syringe. The red anion formed 
was stirred for 20min before cooling to -78°C and the addition of freshly 
prepared and purified E-2,4-dimethyl-2-hexenal (134) (340mg, 2.70mmol). 
The solution was allowed to warm to RT over a period of 4h, then stirred at 
this temperature for a further 8h. Solvent was removed by evaporation in 
vacuo (bath temperature below 40°C) and the resulting red solid dissolved 
in methylene dichloride (15ml). Colloidal inorganics were removed by 
vacuum filtration though glass wool and the methylene dichloride solution 
concentrated to 5ml in vacuo before purification by chromatography (R£ 
0.21, methylene dichloride) on silica, eluting with methylene dichloride. 
The title compound was obtained as a yellow oil (290mg, 1.16mmol, 42.5%). 
OH(CDC13) 0.85 (3H, t, }7.6), 1.00 (3H, d, J6.4), 1.32 (1H, m), 1.41 (1H, m), 1.72 
(6H, s), 1.81 (3H, s), 2.46 (1H, m), 5.31 (lH, s), 5.66 (1H, d, J9.6), 5.90 (1H, d, 
J15.6), 6.98 (1H, d, }15.6). O(:(CDCl3) 12.0 (CH3), 12.4 (CH3), 20.3 (CH3), 25.1 
(2xCH3), 30.1 (CH2), 35.0 (CH), 93.7 (CH), 106.1 (C), 117.1 (CH), 131.8 (C), 143.4 
(CH), 148.1 (CH), 162.1 (C), 164.2 (CO). Vmax(liq. film)/cm-1 2970, 2880, 1730, 
1660, 1625, 1595, 1580, 1460, 1380, 1375, 1270, 1205 and 1020. m/z (CI) 251 
(4.3%). 
E,E-5,7-Dimethylnona-3,5-dien-2-one (140). 
When crude 2,2-dimethyl-6-(E,E-3,5-dimethylhepta-1,3dienyl)-1,3-dioxin-4-
one (137) was purified using activated silica (heat treated at 180°C for 3h) a 
mixture of two products was obtained which was inseparable by 
chromatography. After toluene reflux in the presence of phenylalanine 
methyl ester (98a) the title compound was separated from ~e formed amide 
by chromatography (Rf 0.52, chloroform) on silica, eluting with chloroform, 
as a yellow oil. OH(CDC13) 0.85 (3H,t, }7.38), 1.00 (3H, d, J6.66), 1.29 (lH, m), 
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1.43 (1H, m), 1.79 (3H, s), 2.29 (3H, s), 2.46 (1H, m), 5.76 (lH, d, }9.6), 6.08 (1H, 
d, J16.0), 7.16 (lH, d, J16.0). 6cCCD03) 11.9 (CH3), 12.4 (CH3), 20.1 (CH3), 27.1 
(CH3), 29.9 (CH2), 35.0 (CH), 125.2 (CH), 131.9 (C), 149.1 (CH), 149.5 (CH), 199.0 
(CO). Vmax(liq. film)/cm-1 2940, 2910, 2870, 1710, 1638, 1610, 1580, 1450, 1380 
and 1265. m/z (0) 167 (100%). 
(L)-N-(E,E 3-oxo-6,8edimethyldeca-4,6-dienoyl) Phenylalanine methyl 
ester (138a). 
A solution of 2,2-dimethyl-6-(E,E-3,5-dimethylhepta-1,3-dienyl)-1,3-dioxin-4-
one (137) (275mg, 1.10mmol) and L-phenylalanine methyl ester (98a) 
(300mg, 1.65mmol) in toluene (10ml) was heated to reflux temperature for 
1h. After this time excess solvent was removed by evaporation in vacuo 
and the resultant red oil purified by chromatography (Rf 0.11, chloroform/ 
methylene dichloride 25/75) over silica to yield the title compound as an 
orange oil (190mg, 0.51mmol, 46.4%). 8H(CDC13) 0.85 (3H, t, J7.2), 1.00 (3H, d, 
J6.4), 1.30 (1H, m), 1.41 (1H, m), 1.79 (3H, s), 2.43 (1H, m), 3.12 (2H, m), 3.54 
(2H, s), 3.69 (3H, s), 4.87 (1H, m), 5.8 (1H, d, J10.0), 6.10 (lH, d, }16.0), 7.25 (6H, 
m), 7.60 (1H, d(br), J8.5). 8c(CDC13) 11.9 (CH3), 12.4 (CH3), 20.1 (CH3), 30.0 
(CH2), 35.2 (CH), 37.9 (OCH3), 46.7 (CH2), 52.3 (CH2), 53.5 (CH), 123.6 (CH), 
127.1 (Ph), 128.5 (Ph), 129.3 (Ph), 131.9 (C), 135.9(Ph), 150.8 (CH), 151.7 (CH), 
165.9 (CON), 171.7 (COOMe), 195.2 (CO). m/z (CD 372 (22.4%). 
(DL)-[t-13C]-N-(E,E-3-oxo-6,8-dimethyldeca-4,6-dienoyl) Phenylalanine 
methyl ester (138b). 
A solution of 2,2-dimethyl-6-(E,E-3,5-dimethylhepta-1,3-dienyl)-1,3-dioxin-4-
one (137) (290mg, 1.16mmol) and (DL)-[1-13c]-phenylalanine methyl ester 
(99a) (220mg, 1.22mmol) in toluene (4ml) was heated to reflux temperature 
for 1.5h. After this time excess solvent was removed in vacuo and the 
resultant red oil was purified by flash chromatography (Rf 0.11, chloroform/ 
methylene dichloride 25/75) to yield the title compound as an orange oil 
(380mg, 1.02mmol, 87.9%). 8H(CDC13) 0.86 (3H, t, J7.58), 1.00 (3H, d, J6.6), 1.35 
(2H, m), 1.79 (3H, s), 2.45 (1H, m), 3.12 ( 2H, m), 3.54 (2H, s), 3.70 (3H, d, }3.82), 
4.85 (1H, m), 5.81 (1H, d, J9.72), 6.098 (1H, d, J15.82), 7.25 (6H, m), 7.57 (1H, 
d(br), J7.98). 8c(CDC13) 11.9 (CH3), 12.4 (CH3), 20.0 (CH3), 29.9 (CH2), 35.2 
(CH), 37.9 (OCH3), 46.6 (CH2), 52.3 (CH2), 53.5 (CH, d, J61.91), 123.6 (CH), 127.1 
(Ph), 128.5 (Ph), 129.3 (Ph), 131.9 (C), 136.0 (Ph), 150.6 (CH), 151.4 (CH), 166.6 
(CON), 171.6 (COOMe, 99% enriched), 195.0 (CO). m/z (CD 373 (18.3%), 333 
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(12.8%), 181 (68.8%). 
5(RS)-[4-13C]-3-(E,E-4,6-d.imethylocta-2,4-dienoyl)-5-Benzyl-2,4-dioxo 
pyrrolidine (139b). 
To a stirred solution of freshly sublimed potassium tbutoxide (141mg, 
1.26mmol) in lbutanol (10ml) at RT was added a solution of {DL)-[1-13c]-N-
(E,E 3-oxo-6,8-dimethyldeca-4,6-dienoyl) phenylalanine methyl ester {138b) 
(235mg, 0.63mmol) in lbutanol (2ml). An immediate colour change from 
yellow to red occurred. After 30min dilute aqueous hydrochloric acid (10ml) 
and diethyl ether (25ml) were added. The orange organic layer was 
separated, washed with water (1x20ml), dried (Mg504) and evaporated in 
vacuo to afford the title compound as a red wax. 6H(CDC13) 0.85 (3H, t, 
J7.38), 1.00 (3H, d, J6.6), 1.27 (3H, s), 1.33 (2H, m), 2.45 (1H, m), 3.25 (2H, m), 
4.75 (1H, m), 5.81 (1H, d, J10.14), 6.08 (1H, d, J15.82), 7.26 (6H, m), 7.86 (1H, 
d(br), J6.6), 8.76 (lH, s(br)). Bc:CCDCl3) 11.8 (CH3), 12.3 {CH3), 19.9 (CH3), 29.8 
(CH2), 35.2 (CH), 46.1(CH2, d, }2.3), 53.6 (CH, d, }59.2), 109.0 (C, d, }65), 123.3 
(CH), 127.0 (Ph), 128.4 (2xPh), 129.3 (2xPh), 131.8 (C), 135.8 (Ph), 151.2 (CH), 
152.0 (CH), 166.8 (CON), 174.3 (COMe, 99% enriched), 195.3 (CO). m/z (0) 
391.3 (?) (12.3%), 341.2 (0.3%). 
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(DL)-Phenylalanine hydrochloride (99). 
To a solution of phenylacetaldehyde (141) (3g, 25mmol) in methanol (40ml) 
cooled to 0°C was added a solution of NH4Cl (1.46g, 27mmol) in water 
(50ml). After 10min stirring, -KCN (1.88g, 25mmol) was added and stirring 
was continued at RT for 24h. The methanol was removed by evaporation in 
vacuo and the aqueous solution extracted into methylene dichloride 
(3x50ml). The organic fractions were combined, dried (MgS04) and 
evaporated in vacuo to afford a brown oil which was heated under reflux 
with concentrated aqueous HCl (40ml) for 48h. After this time solvent was 
removed by evaporation in vacuo and the resulting solid washed with cold 
acetone (lOOml) to afford the title compo~d as a white amorphous solid 
(1.65g, 8.2mmol, 32.8%). 8H(D20) 3.07 (1H, dd, Jvic27.76, Jgem14.55), 3.23 (1H, 
dd, Jvic15.52, Jgem14.58), 4.16 (1H, dd, Jvic15.62, Jvic27.68), 7.26 (5H, m), 
8c(D20) 38.6 (CH2), 57.4 (CH), 130.8 (Ph), 132.1 (Ph), 132.3 (Ph), 136.8 (Ph), 
174.5 (CO). m/z (Q) 166 (100%). 
(DL)-[t-13C]-Phenylalanine hydrochloride (99). 
[13c]-KCN (2g, 30.25mmol) was used to make the title compound by the 
above method (3.95g, 19.5 mmol, 64.5%). 8H(D20) 3.08 (lH, ddd, Jgem14.6, 
Jvic7.8, JH 13c2.8), 3.22 (1H, dt, Jgem 14.8, Jav5.0), 4.18 (1H, dt, Jvic5.6, 
JH13c7.6), 7.26 (5H, m). 8c(D20) 38.5 (CH2), 57.2 (CH, d, Jcc58.77), 130.9 (Ph), 
132.1 (Ph), 132.3 (Ph), 137.0 (Ph), 174.6 (CO, 99% enriched). m/z (CD 167 
(42.5%), 120 (10.5%). 
(DL)-phenylalanine methyl ester (99a). 
To a solution of (DL)-phenylalanine hydrochloride (99) (1.65g, 8.2mmol) in 
methanol (10ml) cooled to 0°C was added thionyl chloride (l.Og, 8.2mmol). 
The suspension was stirred at RT until product formation was complete 
(approx. 48h) when observed by t.l.c. (silica plates eluted with 
nPrOH/NH3(aq con~) 7/3, developed with ninhydrin). Solvent was 
removed by evaporation in vacuo to afford a pale yellow solid which was 
dissolved in saturated aqueous NaHC03 (20ml). The aqueous solution was 
extracted into diethyl ether (5x50ml) and the organic extracts combined, 
dried (MgS04) and evaporated in vacuo to afford the title compound as a 
pale yellow oil (810mg, 4.5mmol, 54.8%). 8H(CDC13) 1.71 (2H, s), 2.85 (1H, dd, 
Jvic27.74, Jgem13.47), 3.08 (lH, dd, Jvic15.16, Jgem13.5), 3.69 (3H, s), 3.72 (lH, 
dd, Jvic15.2, Jvic27.74), 7.24(5H, m). 8c(CDC13) 41.0 (CH3), 51.9 (CH2), 55.8 
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(CH), 128.8 (Ph), 128.5 (Ph), 129.3 (Ph), 137.2 (Ph), 175.3 (CO). VmaxOiq. 
film)/ cm-1 3385, 3310, 3090,3065,3030,3000,2950,2855, 1740, 1608, 1500, 1458, 
1440 and 1200. m/z (CD 180 (45.3%), 120 (6.6%). 
(DL)-[t-13C]-PhenyWanine methyl ester (99a). 
(DL)-[1-13c]-Phenylalanine hydrochloride (99) (600mg, 3mmol) was used to 
make the title compound by the above method. (310mg, 1.72mmol, 57.4%). 
OH(CDC13) 1.50 (2H, s (br)), 2.82 (1H, ddd, Jgem14.0, Jvic8.25, JH13c3.25), 3.05 
(1H, dt, Jgem14.0, Jav5.0), 3.66 (3H, d, }3.7), 3.68 (1H, m), 7.2 (5H, m). 
Oc(CDC13) 40.8 (CH3), 51.6 (CH2}, 55.5 (CH, d, }58.74), 126.5 (Ph), 128.2 (Ph), 
129.0 (Ph), 137.0 (Ph), 175.1 (99% eruiched). · 
-176-
-------------~ 
2-Bromopropionic acid (143a). 
To propionic add (142a) (distilled, b.p. 140-142-c, 1atm (lits 141.C), l.Og, 
13.5mmol) stirred at 0°C was added triflouroacetic anhydride (3.0g, 
14.3mmol). Stirring was continued for Smin and the temperature was raised 
to 60°C. Red phosphorus (20mg, 0.65mmol) was added and after Smin 
stirring bromine (2.24g, 14mmol) was added dropwise, each drop added as 
the colour of the previous one was consumed. When all of the bromine 
had been added the solution was stirred at 60°C for 18h. Volatiles were 
removed directly by evaporation in vacuo (bath temperature 80-90°C) to 
afford the crude a-bromoadd as a pale brown oil (1.92g, 12.8mmol, 95.4%). 
OH(CDC13) 1.84 (3H, d, J6.88), 4.40 (lH, q, J6.88), 11.98 (1H, s(br)). Oc(CDC13) 
21.9 (CH3), 39.9 (CH), 177.0 (CO). 
[t-13C]-2-Bromopropionic acid (143b). 
To [t-13c]-propionic add (142b) (l.Og, 13.3mmol) stirred at 0°C was added 
triflouroacetic anhydride (3.0g, 14.3mmol). Stirring was continued for Smin 
and the temperature was raised to 60°C. Red phosphorus (20mg, 0.65mmol) 
was added and, after Smin stirring, bromine (2.24g, 14mmol) was added 
dropwise, each drop added as the colour of the previous one was consumed. 
When all of the bromine had been added the solution was stirred at 60°C for 
18h. Volatiles were removed directly by evaporation in vacuo (bath 
temperature 80-90°C) to afford the crude a-bromoadd as a pale brown oil 
(2.0g, 13.0mmol, 97.7%). OH(CDC13) 1.857 (3H, dd, J13CH3.0, J6.96), 4.43 (1H, 
dq, J13cH4.26, J6.92), 12.20 (1H, s). 8(:(CDCl3) 21.2 (CH3), 39.2 (CH, d, JCC61.9), 
176.5 (CO, 99% enriched). 
Methyl 2-bromopropionate (144a). 
The crude 2-bromopropionic add (143a) (l.Og, 6.7mmol), obtained as above, 
was treated with an ethereal solution of diazomethane (approx 0.84g, 
20mmol). After 30min, excess diazomethane was removed by bubbling with 
nitrogen, and the ethereal solution was evaporated in vacuo to afford the 
crude title compound as a brown oil. (243mg, 1.49mmol, 22.2%). 
Alternatively the title compound could be synthesised by the following 
method. A methanolic solution of the crude 2-bromopropionate (143a) 
(0.92g, 6.17mmol) was heated under reflux in the prescence of p 
-toluenesulfonic add (100mg, 0.6mmol) for 24h. The addition of saturated 
aqueous sodium bicarbonate solution (SOml) yielded a basic solution which 
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was extracted into methylene dichloride (3x50ml). The combined organic 
extracts were dried (MgS04) and evaporated in vacuo to yield the title 
compound as a pale brown oil. (196mg, 1.2mmol, 19.4%). aH(CDC13) 1.76 
(3H, d, J6.98), 3.72 (3H, s), 4.32 (lH, q, }6.88). ac<CDC13) 21.6 (CH3), 39.6 (CH), 
52.8 (OCH3), 170.6 (CO). 
Ethyl 2-bromopropionate (145a). 
To a solution of the crude 2-bromopropionic acid (143a) (1.99g, 13.35mmol), 
as obtained above, in ethanol (20ml) was added p toluenesulfonic acid 
(100mg, 0.6mmol). The solution was heated under reflux for 24h, then 
cooled and added to a saturated aqueous solution of sodium bicarbonate 
(50ml) which was extracted into methylene dichloride (3x50ml). The organic 
fractions were combined, dried (MgS04) and evaporated in vacuo to afford 
the crude title compound as a pale brown oil (1.52g, 8.39mmol, 62.8%). 
aH(CDC13) 1.18 (3H, t, }7.38), 1.70 (3H, d, }7.18), 4.11 (2H, q, }7.38), 4.25 (1H, q, 
J7.18). ac(COC13) 13.6 (CH3), 21.3 (CH3), 39.9 (CH), 61.7 (0CH2), 170.0 (CO). 
m/z (0) 183 (33%), ffin 155 (100%). 
[to13C] Ethyl2-bromopropionate (145b). 
To a solution of the crude [1-13c]-2-bromopropionic acid (143b) (2.0g, 
13.0mmol), as obtained above, in ethanol (25ml) was added p -
toluenesulfonic acid (100mg, 0.6mmol). The solution was heated under 
reflux for 48h, then cooled. A saturated aqueous solution of sodium 
bicarbonate (10ml) was added and the basic solution was extracted into 
methylene dichloride (4x25ml). The organic fractions were combined, dried 
(MgS04) and evaporated in vacuo to afford the crude title compound as a 
pale brown oil (1.49g, 8.18mmol, 62.9%). aH(CDC13) 1.28 (3H, t, }7.27), 1.80 
(3H, dd, J13CH4.40, JHH6.54), 4.20 (2H, dq, }2.65, }6.98), 4.33 (lH, dq, }4.39, 
J6.57). ac<CDC13) 13.8 (CH3),21.5 (CH3), 40.1 (d, Jcc64.5, CHBr),61.8 (OCH2), 
170.1 (CO, enriched). 
(N-propionyl)Cysteamyl 2-bromopropionate (146a). 
To a solution of the crude 2-bromopropionic acid (143a) (2.0g, 13.4mmol) in 
diethyl ether (50ml) was added DCC (2.75g, 13.5mmol), DMAP (1.65g, 
13.5mmol) and N-propionylcysteamine (122) (1.80g, 13.5mmol). The 
solution was stirred for 12h, then methylene dichloride (50ml) was added 
and the suspension filtered and washed with dilute aqueous HCl (50ml). 
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The acid layer was extracted with methylene dichloride (2x50ml) and the 
combined organic layers dried (MgS04) and evaporated in vacuo to afford 
the title compound as a pale yellow oil (2.97g, 11.1mmol, 82.8%). ~H(CDC13) 
1.15 (3H, t, }7.58), 1.85 (3H, d, J6.94), 223 (2H, q, J7.68), 3.12 (2H, t, J5.90), 3.48 
(2H, dt, J6.1), 4.54 (1H, q, J6.96), 6.90 (1H, t(br)). ~C(CDC13) 9.8 (CHJ), 21.9 
(CH3), 29.4 (CH2), 29.6 (CH2), 39.0 (CH2), 47.8 (CH), 174.2 (CON), 196.7 (COS). 
VmaxOiq. film)/an-1 3260 (br), 3060,2970,2920,2850, 1800, 1660(br), 1535(br), 
1445 and 1375. m/z (CI) 270 (78.19%), 269 (7.78%), 268 (76.59%). 
Ethoxycarbonylethyl(triphenyl)phosphonium bromide (147a). 
To a solution of ethyl 2-bromopropionate ~145a) (1.52g, 8.39mmol) in 
acetonitrile (25ml) was added triphenylphosphine (2.23g, 8.5mmol). The 
solution was heated under reflux for 12h and then the acetonitrile was 
removed by evaporation in vacuo to afford a sticky solid which was 
triturated with refluxing hexane (30ml). The title compound (147a) was 
collected as a fine white crystalline solid (1.65g, 3.72mmol, 44.4%) mp 156-
1570C (lit' 158°C). ~H(CDC13) 0.99 (3H, t, }7.04), 1.69 (3H, d, J5.0), 3.98 (2H, m), 
6.70 (1H, m(br)), 7.90 (15H, m). ~(CDCl3) 12.7 (CHJ), 13.4 (CH3), 36.0 (CH, 
m), 62.6 (OCH2, d, Jl.87), 128.2-134.9 (14lines, 3Cl>), 167.7 (CO, enriched). 
[t-13C]-Ethoxycarbonylethyl(triphenyl)phosphonium bromide (147b). 
To a solution of ethyl [1-13c]-2-bromopropionate (145b) (1.49g, 8.18mmol) in 
acetonitrile (25ml) was added triphenylphosphine (2.17g, 8.3mmol). The 
solution was heated under reflux for 48h and then the acetonitrile was 
removed by evaporation in vacuo to afford a sticky solid which was 
triturated twice with refluxing hexane (30ml). The title compound (147b) 
was collected as a fine white amorphous solid (3.37g, 7.6mmol, 93.0%). 
~H(CDC13) 0.99 (3H, t, }7.04), 1.69 (3H, dd, J4.94, J18.3), 3.98 (2H, m), 6.70 (1H, 
m(br)), 7.90 (15H, m). ~C(CDC13) 127 (CH3), 13.4 (CH3), 36.0 (CH, m), 62.6 
(0CH2, d, }1.87), 128.2-134.9 (14lines, 3Cl>), 167.7 (CO, 99% enriched). 
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Ethyl (E)a2,4-dimethylhex-2-enoate (148a). 
To a solution of ethoxycarbonylethyl(triphenyl)phosphonium bromide 
(147a) (1.65g, 3.72mmol) in methylene dichloride (50ml) was added 
triethylamine (376mg, 3.72mmol) and 2-methylbutyraldehyde (133) (640mg, 
7.44mmol). The solution was heated under reflux for 18h, and then washed 
with dilute aqueous HCl (2x20ml). The organic phase was dried (MgS04) 
and concentrated to a volume of 5ml, filtered to remove precipitated 
triphenylphosphine oxide, and residual solvent was removed by 
evaporation in vacuo to afford the crude title compound as a pale yellow 
fragrant oil. (226mg, 1.33mmol, 35.7%). OH(CDC13) 0.77 (3H, t, }7.34), 0.92 (3H, 
d, J6.64), 1.22 (3H, t, J7.16), 1.28 (2H, m), 1.76 (3H, d, JHMe1.44), 235 (1H, m), 
4.11 (2H, q, J7.20), 6.46 (1H, dq, JHMe1.44, JHH10.14). Oc(CDC13) 11.8 (CHJ), 
12.4 (CH3), 14.2 (CH3), 19.6 (CH3), 29.6 (CH2), 34.8 (CH), 60.3 (OCH2), 126.4 
(C), 147.8 (CH), 168.4 (CO). 
[t-13C] Ethyl (E)-2,4-dimethylhex-2-enoate (148b). 
To a solution of [1.13c]-ethoxycarbonylethyl(triphenyl)phosphonium 
bromide (147b) (3.73g, 7.6mmol) in methylene dichloride (40ml) was added 
triethylamine (808mg, 8.0mmol) and 2-methylbutyraldehyde (133) (1.38g, 
16mmol). The solution was heated under reflux for 48h, and then washed 
with dilute aqueous HCl (2x20ml). The organic phase was dried (MgS04) 
and concentrated to a volume of 5ml. The addition of hexane (30ml) 
precipitated triphenylphosphine oxide (1.75g, 6.29mmol, 83.0%, m.p. 157-
15s·c, lit5 156-158.C), as fine white crystals, which was removed by 
filtration, and residual solvent was removed by evaporation in vacuo to 
afford the pure title compound as a pale yellow fragrant oil. (670mg, 
3.92mmol, 51.6%). OH(CDC13) 0.86 (3H, t, }7.38), 1.00 (3H, d, }6.64), 1.30 (3H, t, 
J7.14), 1.38 (2H, m), 1.84 (3H, dd, JH13c4.22, JHMe1.44), 2.40 (1H, m), 4.19 (2H, 
dq, JH13c2.96, JHH7.16), 6.54 (1H, ddq, JHMe1.44, JH13c7.04, JHH9.96). 
Oc(CDC13) 11.8 (CH3), 12.4 (CHJ. d, }3.13), 14.2 (CH3), 19.6 (CH3), 29.5 (CH2), 
34.8 (CH, d, }5.16), 60.3 (OCH2), 126.4 (C, d, J37.2), 147.7 (CH, d, }1.76), 168.3 
(CO, 99% enriched). m/z (Cn 172 (78%). 
(E)-2,4-Dimethylhex-2-enoic acid (149a). 
A solution of ethyl (E)-2,4-dimethylhex-2-enoate (148a) (226g, 1.32mmol) in 
aqueous potassium hydroxide (0.24M, 1Sml) was heated under reflux for 
18h. The solution was acidified with dilute aqueous HCl and extracted into 
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methylene dichloride (4x20ml). The organic layers were combined, dried 
(MgS04) and evaporated in vacuo to afford the title compound as a waxy 
white semi-solid (160mg, 1.13mmol, 85.6%). ~H(CDCI3) 0.86 (3H, t, J7.38), 
1.01 (3H, d, J6.66), 1.40 (2H, m), 1.85 (3H, d, JHMe1.40), 2.45 (lH, m), 6.69 (1H, 
dq, JHMe1.40, JHH10.12). ~(CDCI3) 11.8 (CH3), 12.1 (CH3), 19.5 (CH3), 29.5 
(CH2), 35.1 (CH), 125.9 (C), 150.5 (CH), 173.8 (CO). m/z (EI) 142 (23%), (CD 160 
(M+18, 100%). 
[1-13C].(E)-2,4-Dimethylhex-2-enoic acid (149b). 
To an aqueous solution of potassium hydroxide (0.36M, 25ml) was added [1-
13c] ethyl (E)-2,4-dimethylhex-2-enoate (148~) (570mg, 3.33mmol), and the 
suspension was heated under reflux for 72h. The cloudy supension was 
acidified with dilute aqueous hydrochloric acid and extracted into 
methylene dichloride (4x25ml) and diethyl ether (1x25ml). The combined 
organic extracts were dried (MgS04) and evaporated in vacuo to afford the 
title compound as a clear oily wax (443mg, 3.10mmol, 93.1 %). ~H(CDC13) 
0.86 (3H, t, J7.38), 1.01 (3H, d, J6.64), 1.36 (2H, m), 1.85 (3H, dd, JH13C4.24, 
JHMe1.44), 2.43 (1H, m), 6.70 (1H, ddq, JHMe1.44, JHH10.1, JH13C7.06), 12.14 
(1H, s(br)). ~(C0Cl3) 11.9 (CH3), 12.1 (CH3), 19.6 (CH3), 29.6 (CH2), 35.2 (CH, 
d, }5.23), 126.0 (C, d, }68.80), 150.7 (CH, d, J2.11), 174.2 (CO, enriched). m/z (EI) 
143 (31.6%), (CD 161 (M+18, 75.8%). 
N-(propionyl)-S-((E)-2,4-dimethylhex-2-enoyl)-Ethanamine-2-thiol 
(150a). 
To a solution of 2,4-dimethylhex-2-enoic acid (149a) (160mg, 1.13mmol) in 
diethyl ether (15ml) was added DCC (204mg, 1.0mmol), DMAP (122mg, 
l.Ommol) and N-propionylcysteamine (122) (200mg, 1.5mmol). The 
solution was stirred overnight and filtered to remove precipitated solids. 
The solution was evaporated to a volume of 1ml and then purified by 
column chromatography (Rf 0.64, diethyl ether) over silica eluting with 
diethyl ether. The title compound was afforded as a colourless oil after 
evaporation of product containing fractions. (188mg, 0.73mmol, 64.6%). 
~H(CDC13) 0.87 (3H, t, J7.56), 1.03 (3H, d, J6.64), 1.14 (3H, t, J7.38), 1.40 (2H, m), 
1.89 (3H, s), 2.20 (2H, q, J7.56), 2.45 (1H, m), 3.08 (2H, t, J6.32), 3.47 (2H, dq, 
J6.28, J6.08), 5.97 (1H, s(br)), 6.55 (lH, d, J9.8). ~(CDCl3) 10.3 (CH3), 12.4 
(CH3), 13.2 (CH3), 20.1 (CH3), 28.9 (CH2), 30.1 (CH2), 30.2 (CH2), 35.6 (CH), 
40.2 (SCH2), 135.1 (C), 148.0 (CH), 174.5 (CON), 194.8 (COS). m/z (CI) 258 
(56%), 125 (21 %). 
-181-
N-(propionyl)-S-([t-13C]-(E)-2,4-dimethylhex-2--enoyl)-Ethanamine-2-
thiol (150b). 
To a solution of [1-13C]-2,4-dimethylhex-2-enoic acid (149b) (443mg, 
3.10mmol) in diethyl ether (25ml) was added DCC (680mg, 3.33mmol), 
DMAP (406mg, 3.33mmol) and N-propionylcysteamine (122) (530mg, 
4.0mmol). The solution was stirred overnight. Methylene dichloride (20ml) 
was added and the suspension was filtered to remove precipitated solids. 
The solution was evaporated to a volume of 4ml and then purified by 
column chromatography (Rf 0.64, diethyl ether) over silica eluting with 
diethyl ether. The title compound was afforded as viscous colourless oil 
after evaporation of product containing fractions. (493mg, 1.91mmol, 
61.6%). ~H(CDC13) 0.87 (3H, t, }7.38), 1.03 (3H, d, J6.74), 1.14 (3H, t, }7.60), 1.38 
(2H, m), 1.88 (3H, dd, JHMe1.30, JH13c4.42), 2.22 (2H, q, }7.56), 2.45 (1H, m), 
3.08 (2H, dt, J4.6, J6.46), 3.45 (2H, dt, J6.22, J5.94), 6.53 (lH, m), 6.62 (lH, t(br)). 
~(COCl3) 9.6 (CHJ), 11.6 (CHJ), 123 (CHJ, d, J2.99), 19.3 (CHJ), 28.1 (CH2), 
29.3 (CH2), 29.3 (CH2), 34.8 (CH, d, J5.46), 39.3 (CH2), 134.3 (C), 147.0 (CH, d, 
J2.77), 173.9 (CON), 193.7 (COS, enriched). m/z (CI) 259 (54%) 126 (21 %). 
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Chapter 7. 
Biological materials and methods. 
7.1 General. 
7.2 References. 
-184-
7.1 General 
An authentic culture of B. bassiana (Bals.) Vuill., strain number 110.25, was 
obtained from the CBSl culture collection (Oosterstraat, Delft, Netherlands.), 
and initiated onto agar slants. Suspension cultures were maintained in 
SOml of medium, made up as indicated below, from commercially available 
materials, in a 250ml Erlenmeyer flask, stoppered with tightly wound cotton 
wool and shaken at 200rpm on a rotary shaker (3cm eccentricity) maintained 
at 24-26°C in the dark. Growth was initiated from agar slants into a seed 
medium, which was incubated for 14 days. Production cultures were 
initiated by inoculation (2ml) from the seed medium. After seven days 
these cultures were used to inoculate another production medium. Five or 
six generations could be raised before growth became unpredictable. Seven 
day old production cultures were frozen to provide a stock of cultures which 
could be re-initiated when required by resuspension in sterile production 
medium. 
All sterilisations were performed using a portable gas heated autoclave, 
samples being heated to 121°C for 20min at 1.1 Kgcm-2. Sterile media and 
agars were handled in an ethanol sterilised laminar flow hood using sterile 
implements and containers. Supplementation of extraneous materials to 
culture broths was performed using gamma sterilised 0.2J,L filters (Sigma F-
1387). 
Cornmeal agar. 
To warm distilled water (250ml) was added cornmeal agar powder (Oxoid, 
4.25g). The powder was fully dissolved by vigorous stirring and warming as 
necessary, and the pH of the solution adjusted to 7.2 before sterilisation. The 
sterilised agar was poured into sterile petri dishes when hand-hot and 
allowed to set. 
Oatmeal agar. 
To warm distilled water (11) was added oatmeal (porridge oats, SOg). After 
2hr the thick suspension was filtered through mu~lin, and the muslin bag 
compressed to extract most of the moisture. Powdered agar (15g) was added 
to the liquor and dissolved by stirring and heating. The opaque suspension 
was divided into two batches, one adjusted to pH 6.0 and one to pH 7.0, and 
both agar solutions were sterilised before plating out into sterile petri dishes. 
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Seed medium. 
To distilled water (990ml) was added D-glucose (20g), ammonium tartrate 
(4.6g), KH2P04 (l.Og), MgS04.1H20 (O.Sg), NaCl (O.lg), CaCl2 (O.lg) and a 
mineral ion solution (lOml) containing CuS04 (39.3mgl-1 ), B(OH)3 (5.7mgl-
1), (NH4)6Mo7024-4H20 (3.68mgll), MnS04.H20 (6.1mgi-1), ZnS04.1H20 
(879mgl-1) and FeS04.1H20 (99.6mgi-1). The pH was adjusted to 7.0 before 
sterilisation. 
Production medium. 
To distilled water (990ml) was added D-mannitol (50g), KN03 (Sg), KH2P04 
(lg), MgS04.1H20 (O.Sg), NaCl (O.lg), CaCl2 (O.lg), FeS04.1H20 (20mg) and a 
mineral solution (lOml) containing Zn504.7H20 (880mgi-1), CuS04.SH20 
(40mgl-1), Mn504.4H20 (7.5mgl-1), B(OH)3 (6mgl-1), and 
(NH4)6M07024.4H20 (4mgl-1). The pH of the solution was not adjusted 
prior to sterilisation. 
Tenellin (1) production and extraction. 
B. bassiana was routinely cultured in the following manner. Cultures were 
initiated into 50ml of sterile production medium from a frozen sample of 
seven day old production medium culture by the transfer of a 2ml aliquot. 
The flask was shaken on an orbital shaker at 200rpm (3cm eccentricity) for 
seven days at 25-2~C, and the resultant culture was used to initiate a batch 
of production medium flasks (usually 8x250ml flasks each containing 50ml 
medium) by the transfer of 2ml aliquots. The cultures were incubated under 
the same conditions. The secondary cultures were supplemented with 
labelled substrates immediately prior to tenellin production, evinced by 
deep yellow colouration, usually on the second or third day after 
inoculation. Pulse fed materials were also added beginning at this time. 
Broths were incubated for a further seven to ten days before being 
harvested. Samples of unfed broth (lOml) were frozen as stock. 
The mycelia was obtained either by centrifugation (14000 rpm, 4°C, 
45min) or by vacuum filtration, and water washed before being extracted 
exhaustively with acetone in a soxhlet extractor. The acetone extract was 
evaporated in vacuo and the orange solid residue dissolved in methylene 
dichloride and repeatedly washed with brine to remove sugars and other 
water solubles. The organic phase was dried (MgS04) and evaporated in 
vacuo to afford a solid residue which was triturated with pentane to remove 
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lipids. Filtration afforded crude tenellin (1) as a tan to orange solid which 
was suitable for 13c-nmr. Yields of crude tenellin were typically 600-
800mg/l. Radioactively labelled material was recrystallised to constant 
activity from methanol and determination of label incorporation was 
calculated by two methods. 
Absolute Incorporation (A.I.) was calculated as : 
A.I. =Total gCi recovered 
Total JJ.Ci fed 
This method of calculation is subject to error caused by variable 
efficiency of recovery of labelled tenellin (1)., and thus a better measure is 
Specific Incorporation (S.I.) calculated as: 
S.I. =Specific activity of tenellin gCimmol-1 x 100% 
Specific activity of substrate J,LCimmol-1 
Feeding experiments. 
Feeding conditions with labelled substrates and the results are summarised 
in the relevent sections of chapters 2 and 3. 
NMR experiments. 
Crude tenellin (1) was dissolved in DMS0-06. Proton decoupled 13c nmr 
spectra were obtained on a Varian VXR400S spectrometer operating at 
100.577MHz. Dual proton and deuterium decoupling experiments were 
carried out by the Edinburgh Uni-versity Ultra High Field NMR Centre 
using a Varian VXR600S instrument operating at 150.9MHz. The spectra 
were referenced to internal TMS. 8c(DMSO-D6) 11.8 (CH3), 12.4 (CH3), 19.9 
(CH3), 29.4 (CH2), 34.7 (CH), 105.9 (C), 110.9 (C), 115.0 (2xPh), 122.7 (C), 123.0 
(CH), 130.3 (2xPh), 132.6 (C), 140.3 (CH), 149.9 (CH), 151.1 (CH), 156.9 (COH), 
157.5 (CO), 173.1 (COH), 193.8 (CO). See also table of peak assignments, Table 
2.513, section 2.51) 
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Tenellin degradation. 
Crude tenellin (1) (1.0g, 2.71mmol) was suspended in a biphasic mixture 
consisting of water (60ml)~ acetonitrile (20ml) and tetrachloromethane 
(20ml). To this suspension was added sodium periodate (11.76g, 55mmol) 
and ruthenium dioxide -(30mg, 0.23mmol). Vigorous stirring was 
maintained for 72h. The orange suspension became green, then black, then 
colourless. Dilute aqueous sodium hydroxide was added until the pH was 
9.0, the aqueous layer was separated, filtered through celite and the volume 
reduced to 30ml under reduced presure. The solution was acidified with 
concentrated sulphuric acid and lyophillise4. The resulting clear colourless 
solution containing the volatile carboxylic acids was adjusted to pH 8.0 and 
freeze dried to afford a mixture of sodium salts as a white powder (approx. 
80mg). The salts were treated with gaseous HCl under CDCl3 to obtain a 
solution suitable for 1H nmr examination (See Chapter 4, section 4.1). 
Biotransformation. 
S(S)-3-acetyl-5-benzyl-2,4,-dioxopyrrolidine (131a) was added to three day old 
B. bassiana (2x50ml) to a concentration of 1mM. After three days the culture 
broths were homogenised, using a Waring blender, and the supernatant, 
obtained by filtration, was acidified with dilute aqueous HCl and extracted 
into diethyl ether (SxSOml). Ethereal extracts were dried (MgS04) before 
being concentrated in vacuo to a volume of 2ml and examined by tic using 
two solvent systems (CHCl3/MeOH 9/1 and 8/2). A very faint spot 
corresponding to para-hydroxylated starting material (131b) (Rf 0.1 in 
CHCl3/MeOH 9/1, Rf 0.15 CHCl3/.MeOH 8/2) was observed in both solvent 
systems. HPLC analysis was performed using a Bakerbond standard HPLC 
column (4.6x150mm) packed with reverse phase (octadecyl, S~m) silica, 
eluting with acetonitrile/water 33/77. 
Determination of amino acid uptake. 
To a five day old production broth of B.Bassiana (1x50ml) was added equal 
quantities (Smg) of unlabelled L-phenylalanine (99) and 3-amino-2-
phenylpropionic acid (104a). After a further 3 days the mycelia was obtained 
by Buchner filtration and thoroughly washed with deionised water. The 
cells were extracted with an aqueous solution of ethanol (70%) overnight 
and removed from solution by filtration. The ethanolic solution was 
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evaporated in vacuo to a volume of 2ml and examined by tlc on silica plates 
eluting with npropanol/ con£:. ammonia 7/3. Spots corresponding to the 
supplementary materials (phenylalanine Rf 0.60, 3-amino-2-
phenylpropionic acid Rf 0.55) were detected after development by spraying 
the tlc sheets with a 0.2% ethanolic solution of ninhydrin and then heating 
with a heat gun. 3-amino-2-phenylpropionic acid (104) could not be detected 
in non-fed cultures by chromatographic methods. 
Feeding of [3-14c]-3-amino-2-phenylpropionic acid (104c) to Datura 
innoxia. 
[3-14c]-3-Amino-2-phenylpropionic acid (104c, 80mg, 1.08x105 dpm/mg, s.a. 
7.97~Ci/mmol) was administered by the wick method to 10, 3 month old, D. 
innoxia plants growing in soil in a greenhouse. After four weeks the plants 
were harvested (fresh weight 460g) and chopped up in a mixture of 
chloroform (31), diethyl ether (400ml) and concentrated aqueous ammonia 
(lOOml). The two layers obtained after filtering were assayed for 
radioactivity. The aqueous ammoniacal layer contained 46%, and the 
organic layer only 0.26%, of the original activity. The organic solvents were 
evaporated, and the tropane alkaloids purified as their hydrochloride salts 
as previously described2. The level of radioactivity in the purified salts was 
negligible. 
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7.2 References. 
1 Centraalbureau voor Schimmelcultures, Oosterstraat, Delft, Netherlands. 
2 E. Leete.,Phytochemistry, 1972, 11, 1713-1716. 
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Appendix 1. 
Lectures, colloquia and seminars attended 1989-1992. 
Part 1. Lectures and Seminars arranged within the Department of 
Chemistxy. 
* Lectures attended by the author are starred. 
* October 17 Dr. F. Palmer, University of Notingham, "Thunder and 
Lightning." 
October 25 Prof. C. Floriani, University of Lausanne, Switzerland, 
"Molecular Aggregates - A Bridge Between Homogenous and Heterogenous 
Systems." 
November 1 Dr. J.P. S. Badyal, University of Durham, "Breakthroughs in 
Heterogenous Catalysis." 
November 10 Prof. J. E. Bercaw, California Institute of Technology, 
"Synthetic and Mechanistic Approaches to Zeigler-Natta Polymerisation of 
Olefins." 
"' November 11 Prof. N. N. Greenwood, University of Leeds, ''Novel Cluster 
Geometries in Metalloborane Chemistry." 
November 13 Dr. J. Becher, Odense University, Denmark, "Synthesis of 
New Macrocyclic Systems Using Heterocyclic Building Blocks." 
"' November 16 Dr. D. Parker, University of Durham, "Macrocycles, Drugs 
and Rock 'n' Roll." 
.. November 29 Prof. D.J. Cole-Hamilton, University of St. Andrews, ''New 
Polymers from Homogenous Catalysis." 
,. November 30 Dr. M. N. Hughes, King's college London, "A Bug's Eye 
View of the Periodic Table." 
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December 4 Dr. D. Graham, B.P. Research Centre, "How Proteins Absorb to 
Interfaces." 
• December 6 Dr. R. L. Powell, ICI, "The Development of CFC 
Replacements." 
• December 7 Dr. A. Butler, St. Andrew's University, ''The Discovery of 
Penicillin, Facts and Fancies." 
December 13 Dr. J. Klinowski, University of Cambridge, "Solid State NMR 
Studies of Zeolite Catalysts." 
December 15 Prof. R. Huisgen, University of Munich, "Recent Mechanistic 
Studies of [2+2] Additions." 
• December 15 Dr. P.E. Brown, University of Newcastle, "Addition vs 
Rearrangement in Ag+ Catalysed Solvolysis in Chromenes." 
• December 15 Dr. P. Hanson, University of York, "Investigation of 
Sandmeyer Hydroxylation Reaction." 
• December 15 Dr. A. Laws, Huddersfield Poyltechnic, "!J.2, A3 lsomerisation 
of Cephalosporins." 
• December 15 Dr. D. O'Hagan, University of Durham, "Structural 
Correlations Between Polyketide Metabolites." 
• December 15 Dr. J. Fisher, University of Leeds, "Biological Applications of 
NMR Spectroscopy." 
January 24 Dr. R. N. Perutz, University of York, "P~otting the Course of C-H 
Activations with Organometallics." 
• January 31 Dr. U. Dyer, Glaxo, "Synthesis and Conformation of C-
Glycosides" 
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February 1 Prof. J. H. Holloway, University of Leicester, "Noble Gas 
Chemistry." 
.. February 5 Prof. L. Crombie, University of Nottingham, ''The Chemistry of 
Cannabis and Khat." 
February 7 Dr. D. P. Thompson, University of Newcastle upon Tyne, "The 
Role of Nitrogen in Extending Silicate Crystal Chemistry." 
.. February 8 Rev. R. Lancaster, Kimbolton Fireworks, "Fireworks Principles 
and Practice." 
February 12 Prof. L. Lunazzi, University of Bologna, "Application of 
Dynamic NMR to the Study of Conformational Enantiomerism." 
February 14 Prof. D. Sutton, Simon Fraser University, Vancouver B.C., 
"Synthesis and Applications of Dinitrogen and Diazo Compounds of 
Rhenium and Iridium." 
February 28 Dr. R. K. Thomas, University of Oxford, "Neutron 
Reflectometry from Surfaces." 
.. February 21 Dr. C. Bleasdale, University of Newcastle upon Tyne, ''The 
Mode of Action of Some Anti-Tumour Agents." 
February 22 Prof. D. T. Clark, I.C.I. Wilton, "Spatially Resolved Chemistry, 
Using Nature's Paradigm in the Advanced Materials Arena." 
.. March 1 Dr. J.F. Stoddart, University of Sheffield, ''Molecular Lego." 
March 8 Dr. A. K. Cheetham, University of Oxford, "Chemistry of Zeolite 
Cages." 
March 21 Dr. I. Powis, University of Nottingham, "Spinning off in a Huff: 
Photodissociation of Methyl Iodide." 
March 23 Prof. J. M. Bowman, Emory University, "Fitting Experiment With 
Theory in ArOH." 
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,. May 7 Dr. T. J. Simpson, University of Bristol, "Polyketide Biosynthesis, 
Past, Present and Future." 
July 9 Prof. L. S. German, U.S.S.R. Academy of Sciences, Moscow, "New 
Syntheses in Fluoroaliphatic~ Chemistry: Recent Advances in the Chemistry 
of Fluorinated Oxiranes." 
July 9 Prof. V. E. Platonov, U.S.S.R. Academy of Sciences, Novosibirsk, 
"Polyfluoroindanes: Synthesis and Transformation." 
July 9 Prof. I. N. Rozhkov, U.S.S.R. Academy of Sciences, Moscow, 
"Reactivity of Perfluoroalkyl Bromides." 
October 11 Dr. W. A. MacDonald, I.C.I. Wilton, "Materials for the Space 
Age." 
October 24 Dr. M. Bachmann, University of East Anglia, "Synthesis, 
Reactions and Catalytic activity of Cationic Titanium Alkyls." 
October 26 Prof. R. Soulen, South Western University, Texas, "Preparation 
and Reaction of Bicycloalkenes." 
,. October 31 Dr. R. Jackson, University of Newcastle upon Tyne, "New 
Synthetic Methods: a-Amino Acids and Small Rings." 
,. November 1 Dr. N. Logan, University of Nottingham, "Rocket 
Propellants." 
,. November 6 Dr. P. Kocovsky, University of Uppsala, Sweden, 
"Stereocontrolled Reactions Mediated by Transition and non Transition 
Metals." 
,. November 7 Dr. D. Jones, University of Newcastle upon Tyne, "Light and 
Airy Cheinistry." 
November 7 Dr. D. Gerrard, B.P., "Raman Spectroscopy for Industrial 
Analysis." 
November 8 Dr. S. K. Scott, University of Leeds, "Clocks, Oscillations and 
Chaos." 
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* November 14 Prof. D. T. Bell, SUNY, Stoney Brook, U.S.A., "Functional 
Molecular Architecture and Molecular Recognition." 
November 21 Prof. J. Pritchard, Queen Mary and Westfield College, London 
University, "Copper Surfaces and Catalysts." 
* November 28 Dr. B. J. Whittaker, University of Leeds, "Two Dimensional 
Velocity Imaging of State Selected Reaction Products." 
*November 29 Prof. D. Crout, University of Warwick, "Enzymes in Organic 
Synthesis." 
*December 5 Dr. P. G. Pringle, University of Bristol, "Metal Complexes with 
Functionalised Phosphines." 
* December 14 Prof. A. H. Cowley, University of Austin, Texas, U.S.A., 
"New Organometallic Routes to Electronic Materials." 
January 15 Dr. B. J. Adler, Lawrence Livermore Laboratories, California, 
"Hydrogen in all its Glory." 
January 17 Dr. P. Sarre, University of Nottingham, "Comet Chemistry." 
January 24 Dr. P. J. Sadler, Birbeck College, London, "Design of Inorganic 
Drugs: Pecious Metals, Hypertension and HIV." 
*January 30 Prof. E. Sinn, University of Hull, "Coupling of Little Electrons 
in Big Molecules. Implications for the Active Sites of (Metalloproteins and 
other) Macromolecules." 
* January 31 Dr. D. Lacey, University of Hull, "Liquid Crystals." 
* February 6 Dr. R. Bushby, University of Leeds, "Biradicals and Organic 
Magnets." 
* February 14 Dr. M. C. Petty, SEAS, University of Durham, "Molecular 
Electronics." 
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* February 20 Prof. B. L. Shaw, University of Leeds, "Syntheses with 
Coordinated, Unsaturated Phosphine Ligands." 
* February 28 Dr. J. M. Brown, University of Oxford, "Can Chemists Make 
Better Catalysts Than Enzymes?" 
March 6 Dr. C. M. Dobson, University of Oxford, "NMR Studies of Dynamics 
in Molecular Crystals." 
* March 7 Prof. K. Mullen, Max Plank Inst., "New Aromatic Compounds 
For Polymer Synthesis." 
*March 7 Dr. J. Markam, I.C.I. Pharmaceuticals, "DNA fingerprinting." 
* March 14 Prof. J. M. G. Cowie, Heriot Watt University, "Polymer 
Chemistry" 
* April 24 Prof. R. R. Schrock, MIT, "Metal Ligand Multiple Bonds and 
Metathesis Initiators." 
* April 25 Prof. T. Hudlicky, Virginia Polytechnic institute, U.S.A., 
"Biocatalysis and Symmetry Based Approaches to the Efficient Synthesis of 
Complex Natural Products." 
*May 29 Prof. H. Viehe, "Reactivity from Polar Substituent Effects." 
* June 20 Prof. M. S. Brookhart, University of North Carolina, U.S.A., 
"Olefin Polymerisations, Oligermerisations and Dimerisations Using 
Electrophillic Late Transition Metal Catalysts." 
*July 29 Dr. M. A. Brimble, Massey University, New Zealand, "Syntheteic 
Studies Towards the Antibiotic Griseusin-A." 
* September 12 Prof. D. J. Burton, University of Iowa, U.S.A., "Fluorinated 
Organometallic Reagents." 
* September 12 Prof. J. L. Adcock, University of Tenessee, Knoxville, U.S.A., 
"Aerosol Direct Fluorination." 
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* October 17 Dr. J. A. Salthouse. University of Manchester, "Son et 
Lumiere." 
November 6 Prof. B. F. G. Johnson, University of Edinburgh, "Cluster 
Surface Analogies." 
November 7 Dr. A. R. Butler, St. Andrew's University, 'Traditional Chinese 
Herbal Drugs: A Different way of Treating Disease." 
* November 13 Prof. D. Gani, St. Andrew's University, 'The Chemistry of 
PLP-Dependent Enzymes." 
*November 19 Dr. I. Flemming, University of Cambridge, "Stereocontrol in 
Organic Synthesis Using Silicon." 
,. November 20 Dr. R. More O'Ferrall, University college, Dublin, "Some 
Acid Catalysed Rearrangements in Organic Chemistry." 
November 28 Prof. I. M. Ward, IRC in Polymer Science, University of Leeds, 
"The Science and Technology of Oriented Polymers." 
* December 4 Prof. R. Grigg, University of Leeds, "Palladium Catalysed 
Cyclisation and Ion Capture Processes." 
December S Prof. A. L. Smith, ex Unilever, "Soap, Detergents and Black 
Puddings." 
December 11 Dr. W. A. Cooper, Shell Research, "Colloid Science, Theory 
and Practice." 
January 22 Dr K. D. M. Harris, St. Andrew's University, ''Understanding the 
Properties of Solid Inclusion Compounds." 
* January 29 Dr. A. Holmes, University of Cambridge, "Cycloaddition 
Reactions in the Service of the Synthesis of Piperidine and Indolizidine 
Natural Products." 
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.. January 30 Dr. M. Anderson, Sittingbourne Research Centre, Shell 
Research, "Recent Advances in the Safe and Selective Chemical Control of 
Insect Pests." 
,. February 12 Prof. D. E. Fenton, University of Sheffield, "Polynuclear 
Complexes of Molecular Clefts as Models for Copper Biosites." 
.. February 13 Dr. J. Saunders, Glaxo Group Research Limited, "Molecular 
Modelling in Drug Discovery." 
.. February 19 Prof E. J. Thomas, University of Manchester, "Applications of 
Organostannanes to Organic Synthesis." 
.. February 20 Prof E. Vogel, University of Cologne, "Poryphyrins: Molecules 
of Interdisciplinary Interest." 
.. February 25 Prof. J. F. Nixon, University of Sussex, "Phosphaalkynes: New 
Bulding Blocks in Inorganic and Organometallic Chemistry." 
February 26 Prof. M. L. Hitchman, Strathclyde University, "Chemical 
Vapour Deposition." 
March 5 Dr. N. C. Billingham, University of Sussex, "Degradable Plastics, 
Myth or Magic." 
.. March 11 Dr. S. E. Thomas, Imperial College, "Recent Advances in 
Organoiron Chemistry." 
March 12 Dr. R. A. Hann, I.C.I Imagedata, "Electronic Photography- An 
Image of the Future." 
,. March 18 Dr. H. Maskill, University of Newcastle upon Tyne, 
"Mechanistic studies of Organic Group Transfer Reactions." 
April 7 Prof. D. M. Knight, Department of Pl}ilosophy, University of 
Durham, "Interpreting Experiments: the Beginning of Electrochemistry." 
• May 6 Prof. T. B. Marder, University of Waterloo, Canada, "Transition 
Metal Catalysed Alkene Hydroboration." 
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Part 2. Other lectures and colloquia attended. 
All lectures in this section were attended by the author. 
March 7 S.C.!. Graduate symposium at the University of York. 
November 11 .. Prof T. J. Simpson, University of Bristol, "Biosynthesis of 
polyketide antibiotics" 
November 11 .. Dr. D. Rees, Parke Davis, '.'Structure activity correlation in 
K-opioids." 
November 11 .. Prof. D. Robins, University of Glasgow, "Biosynthesis of 
alkaloids from lysine and ornithine." 
November 11 .. Prof. G. Wulff, University of Dusseldorf, Germany, 
"Molecular recognition in synthetic polymers." 
December 19 I Dr. J. Huff, M.S.D., "H.I.V. protease inhibitors." 
December 19 I Dr. D. Williams, University of Cambridge, "How do 
molecules bind to each other?" 
December 19 I Dr. G. M. Blackburn, University of Sheffield, "Phosphonates 
for probing biological phosphates." 
December 19 I Prof. M. Valtier, University of Rennes, France, 
"Dichloroboranes and unctionalised boronates in organic synthesis." 
December 19 I Prof. L. Paquette, Ohio state University, U.S.A., ''Unleashing 
the synthetic potential of oxyanionic sigmatropy." 
.. Part of Irving review lectures, University of St. Andrew's. 
I Part of Sheffield Stereochemistry one day symposium. 
Aprll4 .. Dr. S. P. Stanforth, Newcastle Polytechnic, "Aspects of heterocyclic 
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chemistry" 
April 4 ,. Dr. P. Bailey, University of York, "Asymetric routes to chiral 
piperidenes." 
April 4 • Dr. 0. J. Taylor, University of Newcastle upon Tyne, "Some 
chemistry of nucleosides relevent to toxicology." 
April4 • Dr. P. G. Steele, University of Durham, "Some approaches to taxol 
C-D ring system." 
April 4 ,. Dr. D. Singh, Teeside Polytechnic, "Aspects of carbohydrate 
chemistry in the synthesis of natural products." 
April 4,. Dr. C. Rayner, University of Leeds, "Novel transformations of 2-3 
epoxy sulfides." 
April4 • Prof. 0. Meth-Cohn, Sunderland Polytechnic, "Novel aspects of the 
chemistry of thiophenes at sulphur." 
April4,. Prof. G. Stork, Columbia, "Regio and stereo control of Diels-Alder 
reactions." 
,. Part of R.S.C. Northern regional meeting at Leeds. 
July 14,. A. R. Fersht, University of Cambridge. "Protein folding and 
stability." 
July 14 ,. Prof. D. Gani, University of St. Andrews. "Amino acid metabolism: 
stereochemistry, mechanism and active site structure for key enzymes." 
July 14 • Dr. N. Turner, University of Exeter. "Novel applications of 
enzymes for organic synthesis." 
July 14 ,. Prof. J. Rebek Jr, Massachusetts Institute of Technology, U. S. A., 
"Recognition and Replication." 
July 14 ,. Dr. C. Abell, University of Cambridge, "Mechanistic studies on 
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Shikimate Enzymes." 
July 14 • Dr. P. D. Bailey, University of York, "The Synthesis of Peptidic 
'Enzymes'." 
July 15 • Prof. W. Steglich, University of Munich, Germany, "Biologically 
Active Compounds from Mushrooms and Toadstools." 
July 15 • Dr. R. L. Edwards, University of Bradford, 'New Metabolites of the 
Fungal Genus Xylaria ." 
July 15 • Prof. R. E. Moore, University of Hawaii, U. S. A., "Cyanobacterial 
Toxins." 
July 15 • Dr. D. Kelly, University of Wales, Cardiff, "Chemical 
Communication in the Natural World." 
July 15 • Prof. H. G. Floss, University of Washington, U. S. A., "Biosynthesis 
of Shikimate-derived Antibiotics." 
July 15 • Prof. G. Hofle, Gesellschaft fur Biotechnologische Forschung, 
Braunschweig, Germany, ''The biosynthesis of the Antibiotic Ambruticin." 
July 15 • Dr. R. L. Baxter, University of Edinburgh, "Biotin Biosynthesis." 
July 16 • Prof. R. M. Kellogg, University of Groningen, The Netherlands, 
"Amino Acids and Sugars as Sources of Materials and Catalysts." 
July 16 • Dr. J. K. M. Sanders, University of Cambridge, ''Towards Model 
Enzymes based on Poryphyrins and Steroids." 
July 16 • Prof. P. B. Dervan, Caltech, California, U. S. A., "Sequence Specific 
Recognition of DNA by Triple Helix Formation." 
September 2 # Prof. S. M. Roberts, University of Exeter, "Stereocontrolled 
Synthesis of Naturally Occurring Carbocyclic Nucleosides and Analogues." 
• Part of the 4th International Symposium on Progress In Natural Product 
Chemistry, held at the University of Nottingham, 14-16 July, 1992. 
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# Part of the Royal Society of Chemistry Perkin Division and the Israel 
Chemical Society, International Symposium on Structure and Reactivity in 
Organic and Bioorganic Chemistry, held at the University of Durham, 2-4 
September 1992. 
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A .I. 
atm 
av 
br 
Bu 
Bz 
C.I. 
CBZ 
d 
DCC 
DH 
DMAP 
DMF 
E.I. 
ER 
Et 
FAS 
gem 
h 
J 
KR 
KS 
LDA 
LHMDS 
m 
m.p. 
Me 
min 
nmr 
orf 
p 
Ph 
PKS 
Pr 
q 
Appendix 2. Abbreviations. 
Absolute incorporation. 
atmospheres. 
average. 
broad. 
Butyl. 
Benzyl. 
Chemical ionisation. 
Benzyloxycarbonyl. 
doublet. 
Dicyclohexylcarbodiimide. 
Dehydratase. 
4-dimethylaminopyridine. 
Dimethylformamide. 
Electric ionisation. 
Enoyl reducase. 
Ethyl. 
Fatty acid synthase. 
geminal. 
Hours. 
Coupling constant (Hz). 
Ji-Keto acyl reductase. 
J3-Keto acyl synthase. 
Lithium 
diisopropylamine. 
Lithium 
hexamethyldisilazide. 
multiplet. 
melting point. 
Methyl. 
minutes. 
Nuclear magnetic 
Resonance. 
Open reading frame. 
pentet. 
Phenyl. 
Polyketide synthase. 
Propyl. 
quartet. 
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Rf 
RT 
s 
s.a. 
5.1. 
sep 
t 
t.l.c. 
tsu 
TE 
THF 
vic 
Retention factor. 
Room temperature, 
1s-2o·c. 
singlet. 
Specific activity. 
Specific incorporation. 
septet. 
triplet. 
Thin layer 
chromatography. 
Tertiary butyl. 
Thiol esterase. 
Tetrahydrofuran. 
vicinal. 
